0001193125-13-228056.txt : 20130520 0001193125-13-228056.hdr.sgml : 20130520 20130520171656 ACCESSION NUMBER: 0001193125-13-228056 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20130331 FILED AS OF DATE: 20130520 DATE AS OF CHANGE: 20130520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: COMPREHENSIVE CARE CORP CENTRAL INDEX KEY: 0000022872 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 952594724 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09927 FILM NUMBER: 13859321 BUSINESS ADDRESS: STREET 1: 3405 W. DR. MARTIN LUTHER KING JR. BLVD. STREET 2: SUITE 101 CITY: TAMPA STATE: FL ZIP: 33607 BUSINESS PHONE: 813-288-4808 MAIL ADDRESS: STREET 1: 3405 W. DR. MARTIN LUTHER KING JR. BLVD. STREET 2: SUITE 101 CITY: TAMPA STATE: FL ZIP: 33607 FORMER COMPANY: FORMER CONFORMED NAME: NEURO PSYCHIATRIC & HEALTH SERVICES DATE OF NAME CHANGE: 19730501 FORMER COMPANY: FORMER CONFORMED NAME: NEURO PSYCHIATRIC & HEALTH SERVICES INC DATE OF NAME CHANGE: 19700402 FORMER COMPANY: FORMER CONFORMED NAME: JADE OIL CO DATE OF NAME CHANGE: 19700402 10-Q 1 d516654d10q.htm FORM 10-Q Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 10-Q

 

 

Quarterly report pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2013

Commission File Number 1-9927

 

 

COMPREHENSIVE CARE CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   95-2594724

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

3405 W. Dr. Martin Luther King Jr. Blvd, Suite 101, Tampa, FL 33607

(Address of principal executive offices and zip code)

(813) 288-4808

(Registrant’s telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer” and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated Filer   ¨    Accelerated Filer   ¨
Non-Accelerated Filer   ¨    Smaller reporting company   x

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of May 16, 2013, there were 61,247,424 shares of the registrant’s common stock, $0.01 par value, outstanding.

 

 

 


Table of Contents

TABLE OF CONTENTS

 

     PAGE  

PART I – FINANCIAL INFORMATION

  

ITEM 1 – CONSOLIDATED FINANCIAL STATEMENTS

  

Consolidated Balance Sheets as of March 31, 2013 (unaudited) and December 31, 2012

     3   

Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012 (unaudited)

     4   

Consolidated Statements of Cash Flows for the three months ended March 31, 2013 and 2012 (unaudited)

     5   

Notes to Consolidated Financial Statements

     6-13   

ITEM  2 – MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

     13-20   

ITEM  3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

     21   

ITEM 4 – CONTROLS AND PROCEDURES

     21   

PART II – OTHER INFORMATION

  

ITEM 1 – LEGAL PROCEEDINGS

     21-22   

ITEM 1A – RISK FACTORS

     22   

ITEM  2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

     22   

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

     22   

ITEM 4 – MINE SAFETY DISCLOSURES

     22   

ITEM 5 – OTHER INFORMATION

     23   

ITEM 6 – EXHIBITS

     23   

SIGNATURES

     24   

CERTIFICATIONS

  

 

2


Table of Contents

PART I – FINANCIAL INFORMATION

 

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

CONSOLIDATED BALANCE SHEETS

(Amounts in thousands)

 

     March 31,     December 31,  
     2013     2012  
     (unaudited)        

ASSETS

    

Current assets:

    

Cash

   $ 1,763      $ 920   

Accounts receivable

     1,336        4,546   

Other

     261        181   
  

 

 

   

 

 

 
     3,360        5,647   

Property and equipment, net

     132        172   

Other

     256        305   
  

 

 

   

 

 

 
   $ 3,748      $ 6,124   
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY DEFICIENCY

    

Current liabilities:

    

Notes payable:

    

Related parties

   $ 2,000      $ 2,000   

Other

     972        2,239   

Current portion of long-term debt:

    

Related parties

     1,000        1,000   

Other

     3,174        2,067   

Accounts payable

     1,197        1,110   

Accrued claims payable

     11,844        13,099   

Other accrued expenses

     6,187        5,820   
  

 

 

   

 

 

 
     26,374        27,335   

Long-term liabilities:

    

Long-term debt, net of current portion

     1,478        1,732   
  

 

 

   

 

 

 

Total liabilities

     27,852        29,067   
  

 

 

   

 

 

 

Stockholders’ equity deficiency:

    

Preferred stock, $50.00 par value, noncumulative:

    

Series C Convertible, 14,400 shares authorized; 10,434 shares issued and outstanding

     522        522   

Series D Convertible; 7,000 shares authorized; 250 shares issued and outstanding in 2012; none vested

     —          —     

Other series; 974,260 shares authorized; none issued

     —          —     

Common stock, $0.01 par value; authorized shares: 500,000,000 and 200,000,000 respectively; issued and outstanding 59,776,836

     598        594   

Additional paid-in capital

     26,224        25,982   

Deficit

     (51,448     (50,041
  

 

 

   

 

 

 

Total stockholders’ equity deficiency

     (24,104     (22,943
  

 

 

   

 

 

 
   $ 3,748      $ 6,124   
  

 

 

   

 

 

 

See accompanying notes to consolidated financial statements.

 

3


Table of Contents

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(Amounts in thousands, except per share amounts)

 

     Three Months Ended  
     March 31,  
     2013     2012  

Revenues:

    

Managed care revenues

   $ 1,217      $ 17,890   

Costs and expenses:

    

Costs of revenues

     789        16,644   

General and administrative

     1,391        515   

Depreciation and amortization

     40        96   
  

 

 

   

 

 

 
     2,220        17,255   
  

 

 

   

 

 

 

Operating (loss) income

     (1,003     635   

Other income (expense):

    

Interest expense, including amortization of debt discount of $48 and $195

     (401     (563

Other non-operating income, net

     —          11   
  

 

 

   

 

 

 

(Loss) income before income taxes

     (1,404     83   

Income taxes

     3        3   
  

 

 

   

 

 

 

Net (loss) income

   $ (1.407   $ 80   
  

 

 

   

 

 

 

Net (loss) income attributable to common stockholders

   $ (1,407   $ 80   
  

 

 

   

 

 

 

Earnings per common share:

    

Basic

   $ (0.02   $ 0.00   
  

 

 

   

 

 

 

Diluted

   $ (0.02   $ 0.00   
  

 

 

   

 

 

 

Weighted average common shares outstanding:

    

Basic

     59,745        59,252   
  

 

 

   

 

 

 

Diluted

     59,745        62,552   
  

 

 

   

 

 

 

See accompanying notes to consolidated financial statements.

 

4


Table of Contents

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(Amounts in thousands)

 

     Three Months Ended  
     March 31,  
     2013     2012  

Cash flows from operating activities:

    

Net cash provided by operating activities

   $ 1,299      $ 378   

Cash flows from investing activities:

    

Additions to property and equipment

     —          (1
  

 

 

   

 

 

 

Net cash used in investing activities

     —          (1
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Proceeds from borrowings

     —          100   

Debt issuance costs

     —          (8

Repayment of debt

     (456     (128
  

 

 

   

 

 

 

Net cash used in financing activities

     (456     (36
  

 

 

   

 

 

 

Net increase in cash

     843        341   

Cash at beginning of period

     920        832   
  

 

 

   

 

 

 

Cash at end of period

   $ 1,763      $ 1,173   
  

 

 

   

 

 

 

Supplemental disclosures of cash flow information:

    

Cash paid for:

    

Interest

     147        158   
  

 

 

   

 

 

 

Non-cash investing and financing activities:

    

Common stock and warrants issued for outside services

     135        —     
  

 

 

   

 

 

 

See accompanying notes to consolidated financial statements.

 

5


Table of Contents
COMPREHENSIVE CARE CORPORATION

NOTE 1 – DESCRIPTION OF THE COMPANYS BUSINESS AND BASIS OF PRESENTATION

The accompanying unaudited interim condensed consolidated financial statements for Comprehensive Care Corporation (referred to herein as the “Company,” or “CompCare”) and its subsidiaries have been prepared in accordance with the Securities and Exchange Commission (“SEC”) rules for interim financial information and do not include all information and notes required for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Interim results for the current period are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the consolidated financial statements and the notes thereto in our most recent annual report on Form 10-K. Certain minor reclassifications of prior period amounts have been made to conform to the current period presentation.

Our consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, each with their respective subsidiaries (collectively referred to herein as “we,” “us” or “our”). We provide managed care services in the behavioral health, substance abuse, and pharmacy management fields for commercial, Medicare, Medicaid and Children’s Health Insurance Program (“CHIP”) health plans, as well as self-insured companies, unions, and Taft-Hartley health and welfare funds. Our managed care operations include administrative service agreements, fee-for-service agreements, and capitation contracts. The customer base for our services includes both private and governmental entities. Our services are provided by unrelated vendors on a subcontract basis.

Under our at-risk contracts, we assume the financial risk for the costs of member behavioral healthcare services in exchange for a fixed, per member per month fee. Under our administrative services only (“ASO”) contracts, we may manage behavioral healthcare programs or perform various managed care functions, such as clinical care management, provider network development and claims processing without assuming financial risk for member behavioral healthcare costs. Under our pharmacy contracts, we manage behavioral pharmaceutical services for the members of health plans on an at-risk or ASO basis. In general, our contracts with our other customers have one or two year initial terms, with automatic annual extensions. Such contracts generally provide for cancellation by either party upon 60 to 90 days written notice or the right to request a renegotiation of terms under certain circumstances.

NOTE 2 – ACCOUNTS RECEIVABLE

Our trade accounts receivable at March 31, 2013 and December 31, 2012 consists primarily of receivables related to our major contract in Puerto Rico that expired December 31, 2012. During the three months ended March 31, 2013, we collected approximately $2.3 million from our Puerto Rico client. The receivable balance was further reduced by approximately $1.0 million of claims paid on our behalf by the Puerto Rico client.

Pursuant to an Assignment agreement executed April 10, 2013 and effective March 15, 2013, $1 million of the accounts receivable balance of approximately $1.3 million as of March 31, 2013 is assigned to two creditors as partial payment of their loans. See Note 3 “Notes Payable.”

NOTE 3 – NOTES PAYABLE

In January 2013, a 14%, $100,000 convertible promissory note matured and was renewed on the same terms until April 30, 2013 at which time the note was again renewed. The new note utilizes the same terms as the previous note and has a maturity date of July 31, 2013.

In February 2013, a zero coupon promissory note in the amount of $230,000 matured and was replaced by a new note of similar terms with a face value of $230,000 and a maturity date of May 31, 2012.

In March 2013, we renewed a 10% promissory note in the amount of $100,000 and a 7% promissory note in the amount of $50,000, each for additional one-year terms. One of the note holders was issued a three-year warrant to purchase 25,000 shares of our common stock at an exercise price of $0.15.

 

6


Table of Contents

On March 15, 2013, we executed an agreement with a creditor to modify the terms of a previously matured but unpaid promissory note in the amount of $1.4 million. Under the modified terms of the note, the maturity date was extended from February 28, 2013 to January 31, 2014 and the conversion price at which the note may be converted into our common stock was reduced to $0.125 from $0.25. In addition, the exercise price of a warrant to purchase our common stock issued in conjunction with the note was reset from $0.44 to $0.22. We also assigned certain receivables (see Note 2 “Accounts Receivable”) and a potential arbitration recovery to the creditor as a source of future repayment of a second loan from the creditor in the amount of $625,000 maturing May 14, 2013 and a $75,000 loan from an individual related to the creditor also due on May 14, 2013. Any proceeds remaining from the assigned receivables and potential recovery after repayment of the aforementioned loans will be used to reduce the principal of the $1.4 million loan, but not in excess of $300,000. The modification was accounted for as a troubled debt restructuring, but we recognized no gain because the effective interest rate of the modified promissory note was less than the effective interest rate of the original promissory note.

We were unable to repay our 14% senior promissory notes in the amount of approximately $1.8 million on the maturity date of April 15, 2013. We are currently in negotiations with the holders to resolve the default. We completed an agreement to extend the maturity date for approximately $1.3 million of the notes on May 13, 2013. See Note 4 “Long Term Debt.” In addition, we were not able to repay a $1 million loan due May 8, 2013.

On May 8, 2013, we executed an agreement with a creditor to modify the terms of a promissory note in the amount of $625,000. Under the modified terms of the note, the maturity date was extended from May 14, 2013 to July 15, 2013 and the conversion price at which the note may be converted into our common stock was reduced to $0.125 from $0.25. In addition, the exercise price of a warrant to purchase our common stock issued in conjunction with the note was reset from $0.44 to $0.22.

NOTE 4 LONG TERM DEBT

On May 13, 2013, we executed an agreement with a holder of approximately $1.3 million of our senior promissory notes to extend the maturity date of the notes from April 15, 2013 to April 15, 2014. We also agreed to extend the term of approximately 5.2 million warrants that had been issued at the time the notes were issued in April 2010 for an additional two years, such that the warrants will now expire in 2017. In conjunction with the renewal, we will issue 774,391 shares of our common stock to the lender relating to 50% of the interest and fees owed as of April 15, 2013.

NOTE 5 CONTINGENCIES

Economic conditions and related risks, concentrations and uncertainties:

The United States and other parts of the world have been experiencing a severe and widespread recession accompanied by, among other things, instability in the financial markets and reduced credit availability, which are likely to continue to have far reaching effects on economic activity for an indeterminate period. The probable duration and effects and probable duration of these conditions on our ability to obtain continued support from our major stockholders and lenders, success in our marketing efforts, and ultimately, profitable operations and positive cash flows, cannot be estimated at this time.

We occasionally carry cash and equivalents on deposit with financial institutions in excess of federally-insured limits, and the risk of losses related to such concentrations may be increasing as a result of recent economic developments discussed in the foregoing paragraph. The extent of a loss to be sustained as a result of uninsured deposits in the event of a future failure of a financial institution, if any, however, is not subject to estimation at this time.

Going concern uncertainty:

At March 31, 2013, we had a working capital deficiency of approximately $23.0 million and a stockholders’ equity deficiency of approximately $24.1 million resulting from a history of operating losses. Approximately $2.9 million of debt was past due and therefore in default as of March 31, 2013. As a result of these conditions, and the aforementioned economic conditions and related risks, our ability to continue as a going concern will be dependent upon the success of management’s plans, as set forth in the following paragraph, and is subject to significant uncertainty. Except for the consideration in determining the valuation allowance for deferred tax assets from net operating loss carryforwards (Note 8), the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty.

 

7


Table of Contents

Need for Additional Financing

Our existing capital may not be sufficient to meet our cash needs. We expect that with our new Senior Secured Revolving Credit Facility (see Note 10 “Subsequent Event”), existing customer contracts, the addition of new pharmacy management contracts that we are close to obtaining through our marketing efforts, the collection of receivables, and the extension of vendor payments, that we will be able to sustain current operations over the near term. However, we continue to look at various alternative sources of financing if operations cannot support our ongoing plan. Nevertheless, there can be no assurance that we will be able to find such financing in amounts or on terms acceptable to us, if at all, or that we will be able to achieve or sustain profitable operations and positive operating cash flows in the near term. Although subject to the general economic conditions, risks and uncertainties discussed in the preceding paragraphs, management believes that our current cash position will likely be sufficient to meet our current levels of operations in the short term, our ability to achieve our business objectives and continue as a going concern for a reasonable period of time is dependent upon the success of our plans to obtain sufficient debt or equity financing, and, ultimately, to achieve profitable operations and positive cash flows from operations during 2013.

Concentration, major customer contract:

We currently provide behavioral health services on an at-risk basis to approximately 37,000 members of a health plan providing Medicare benefits. The contract accounted for 43.5%, or $529,000 of our revenue for the three months ended March 31, 2013. This contract is for a three year period effective January 1, 2012 and may be terminated by either party with 90 days written notice.

Legal matters:

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. Aside from the litigation described below, as of the date of this report, we are not currently involved in any legal proceeding that we believe would have a material adverse effect on our business, financial condition or operating results.

 

  (1)

We initiated an action against Jerry Katzman, a former director, in July 2009 alleging that Mr. Katzman fraudulently induced us to enter into an employment agreement and, alternatively, that Mr. Katzman breached that alleged employment agreement and was rightfully terminated. In September 2010, the matter proceeded to a trial by jury. The jury found that Mr. Katzman did not fraudulently induce CompCare to enter into the contract but also found that Mr. Katzman was not entitled to damages. On defendant’s motion to amend the verdict due to inconsistency, the trial court set aside the jury verdict and awarded Mr. Katzman damages of approximately $1.3 million. The Company appealed the lower court’s decision and posted a collateralized appeal bond for approximately $1.3 million. On February 14, 2013, the 11th Circuit Court of Appeals of the State of Florida reversed the lower court’s judgment in favor of Katzman and remanded the case for a new trial on both liability and damages. The appellate court also taxed appellate costs in favor of CompCare against Katzman. The decision of the appellate court also reverses the lower court’s award of attorney’s fees previously awarded to Katzman against CompCare and the need for us to maintain an appeal bond for approximately $1.3 million.

 

  (2) We and a former health plan client are being sued for damages of approximately $1.7 million for allegedly unpaid claims for behavioral health professional services rendered in, 2007 and 2008. We filed a counterclaim for breach of a settlement agreement that we believed resolved many of the claims that are the subject of the complaint, which we therefore, now believe is without merit and are vigorously opposing.

 

  (3) We are in arbitration with a former health plan client in Missouri relating to its allegation that we breached our obligation to pay claims submitted to us for payment. The arbitration is underway but has not yet progressed significantly.

 

  (4) A group of health care providers in the state of Louisiana has filed suit against us claiming breach of contract in that we failed to pay claims submitted to us for payment. The litigation is currently in the discovery stage.

 

8


Table of Contents

Management believes that it has established a provision for legal expenses that it believes is adequate for the estimated probable minimum losses, including legal defense costs, to be incurred from these matters.

Other:

In connection with our former major contract to provide mental health, substance abuse and pharmacy prescription drugs management services in Puerto Rico, we obtained a letter of credit from a bank for $4,000,000 to assure the customer of our compliance with our obligations under the agreement. The letter of credit extends past the expiration date of the contract, decreasing at the rate of $666,667 monthly until the letter’s termination on June 30, 2013. Under such agreement, the customer may draw on all or part of the letter of credit under certain defined circumstances. Collateral for the letter of credit was provided by a major stockholder of the Company. If the client draws upon the letter of credit, we may become liable to our major stockholder for the amount of collateral accessed by the bank to fulfill its obligations thereunder.

NOTE 6 – FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying amounts of cash, accounts receivable and accounts payable approximate their estimated fair value due to the short-term nature of these instruments. Since our other financial liabilities are not traded in an open market, we generally use a present value technique, which is a level 3 input, as defined in generally accepted accounting principles, to measure the estimated fair value of these financial instruments, except for valuing stock options and warrants. The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk.

The carrying amounts and estimated fair values of these financial instruments (all are liabilities) at March 31, 2013, are as follows (in thousands):

 

     Carrying     Estimated  
     Amount     Fair Value  

Promissory notes

   $ 2,880      $ 2,853   

Zero-coupon promissory notes

     230        225   

Debentures

     537        534   

Senior promissory notes

     1,771        1,770   

Long-term promissory notes

     125        121   

Less: unamortized discount

     (39     —     
  

 

 

   

 

 

 

Net liabilities

   $ 5,504      $ 5,503   
  

 

 

   

 

 

 

Due to the inherent nature of related party transactions, we have not attempted to estimate the fair value of liabilities payable to related parties of the Company. As such, promissory notes payable with a carrying value of $3,000,000 are excluded from the table above.

NOTE 7 – EQUITY INSTRUMENTS

Our Series C preferred stock is currently convertible into common stock at the rate of approximately 316.28 common shares for each share of Series C preferred, adjustable for any dilutive issuances of common occurring in the future. Series C preferred shares vote with the common stockholders on an as-converted basis. The shares are nonparticipating except that dividends, when declared by our Board of Directors on the common stock, must be paid on the Series C stock on an as-converted basis before any dividends are paid on our common stock. The Series C is also cumulative with respect to dividends on common stock and junior series of preferred stock. Other significant rights and preferences of the Series C preferred include:

 

   

the right to vote as a separate class to appoint five directors of the Company, and

 

   

liquidation preferences, whereby the Series C holders have a claim against our assets senior to the claim of the holders of our common stock in the event of our liquidation, dissolution or winding-up (the value of the liquidation preference is $250 per share, or approximately $2.6 million at March 31, 2013).

 

9


Table of Contents

We also have a class of convertible preferred stock, Series D, for which 7,000 shares are authorized and 250 shares were issued and outstanding as of March 31, 2013. The shares, which were granted in January 2012, do not vest until the tenth anniversary of the grant date. Such shares were issued in exchange for the cancelation of 120 previously granted warrants to purchase Series D shares. Once vested, a Series D preferred share will be convertible at any time into 100,000 shares of common stock, subject to adjustment in the event of any common stock dividend, split, combination thereof or other similar recapitalization, without additional consideration. Prior to vesting and thereafter, each Series D convertible preferred share is entitled to all voting, dividend, liquidation and other rights accorded a share of Series D convertible preferred stock. As to dividends, the Series D stock is noncumulative. If a dividend is declared on the common stock, each share of Series D stock is entitled to receive a dividend equal to 50% of the dividend declared for the common stock as if the Series D stock had been converted. Despite their nonvested status, voting rights of each share nevertheless consist of the right to cast the number of votes equal to those of 500,000 shares of common stock. Unless otherwise required by applicable law, holders of shares of Series D have the right to vote together with holders of common stock as a single class on all matters submitted to a vote of our stockholders. At March 31, 3013, approximately $3.3 million of compensation expense remained to be recognized over the next 8.8 years related to the Series D shares.

We may periodically issue shares of common stock as payment for services, interest and debt. During the three months ended March 31, 2013, we issued 325,000 shares of common stock to consultants in lieu of cash payment.

STOCK INCENTIVE COMPENSATION PLANS

WARRANTS:

We periodically issue warrants to purchase shares of our common and preferred stock for the services of employees and non-employee directors.

During the quarter ended March 31, 2013, we issued to note holders and consultants warrants to purchase an aggregate of 1.7 million shares of our common stock. The warrants were immediately exercisable at prices ranging from $0.15 to $0.25 and had terms of from two to three years. We recognized approximately $56,000 of compensation costs related to warrants during the three months ended March 31, 2013. Total unrecognized compensation costs related to warrants as of March 31, 2013 was approximately $1,000 which is expected to be recognized over a weighted-average period of nine months. The total fair value of warrants vested during the three months ended March 31, 2013 was approximately $59,000.

A summary of our warrant activity for the three months ended March 31, 2013 and 2012 follows:

 

Warrants

   Shares     Weighted-
Average
Exercise
Price
     Weighted-Average
Remaining
Contractual Term
   Aggregate
Intrinsic Value
 

Outstanding at January 1, 2013

     35,957,583      $ 0.33       4.26 years   

Granted

     1,700,000      $ 0.25         

Forfeited or expired

     (325,000   $ 0.37         
  

 

 

         

Outstanding at March 31, 2013

     37,332,583      $ 0.33       4.00 years   
  

 

 

         

Exercisable at March 31, 2013

     37,298,583      $ 0.33       4.00 years      —     

Outstanding at January 1, 2012

     41,057,583      $ 0.35       4.86 years   

Granted

     25,000      $ 0.25         

Forfeited or expired

     (100,000   $ 0.53         
  

 

 

         

Outstanding at March 31, 2012

     40,982,583      $ 0.35       4.61 years   
  

 

 

         

Exercisable at March 31, 2012

     39,315,583      $ 0.33       4.67 years      —     

 

10


Table of Contents

OPTIONS:

From time-to-time, we grant stock options as compensation for services to our employees, non-employee directors and certain consultants (“grantees”) allowing grantees to purchase our common stock pursuant to stockholder-approved stock option plans. We currently have three active incentive qualified option plans, the 1995 Incentive Plan, the 2002 Incentive Plan and the 2009 Equity Compensation Plan (collectively, the “Plans”), that provide for the granting of stock options, stock appreciation rights, limited stock appreciation rights, restricted preferred stock, and common stock grants to grantees. Grants issued under the Plans may qualify as incentive stock options (“ISOs”) under Section 422A of the Internal Revenue Code of 1986, as amended. Options for ISOs may be granted for terms of up to ten years. The vesting of options issued under the 1995 and 2002 plans generally occurs after six months for one-half of the options and after 12 months for the remaining options. For the 2009 Equity Compensation Plan, the vesting period is determined by the Compensation Committee. The exercise price for ISOs must equal or exceed the fair market value of the shares on the date of grant. The Plans also provide for the full vesting of all outstanding options under certain change of control events. The maximum number of common shares authorized for issuance of options totals 52,000,000 under the Plans. As of March 31, 2013, there were a total of 44,668,000 options available for grant and 6,328,000 options outstanding, 6,011,334 of which were exercisable, under the Plans.

In addition, under our Non-employee Directors’ Stock Option Plan, we are authorized to issue non-qualified stock options to our non-employee directors for up to 1,000,000 common shares. Each non-qualified stock option is exercisable at a price equal to the average of the closing bid and asked prices of the common stock in the over-the-counter market for the most recent preceding day there was a sale of the stock prior to the grant date. Grants of options vest in accordance with vesting schedules established by our Board of Directors’ Compensation and Stock Option Committee. Upon joining our Board of Directors, directors receive an initial grant of 25,000 options. Annually, directors are granted 15,000 options on the date of our annual meeting. As of March 31, 2013, there were 801,668 shares available for option grants and 100,000 options outstanding under the non-qualified directors’ plan, 80,000 of which were exercisable.

A summary of our option activity for the three months ended March 31, 2013 and 2012 follows:

 

Options

   Shares     Weighted-
Average
Exercise
Price
     Weighted-Average
Remaining
Contractual Term
   Aggregate
Intrinsic Value
 

Outstanding at January 1, 2013

     6,618,000      $ 0.32       8.29 years   

Forfeited or expired

     (190,000   $ 0.79         
  

 

 

         

Outstanding at March 31, 2013

     6,428,000      $ 0.31       8.15 years      —     
  

 

 

         

Exercisable at March 31, 2013

     6,091,334      $ 0.31       8.11 years      —     

Outstanding at January 1, 2012

     8,795,400      $ 0.33       7.74 years   

Forfeited or expired

     (40,000   $ 0.38         
  

 

 

         

Outstanding at March 31, 2012

     8,755,400      $ 0.33       7.49 years      —     
  

 

 

         

Exercisable at March 31, 20112

     8,004,400      $ 0.33       7.40 years      —     

Total recognized compensation costs during the three months ended March 31, 2013 were approximately $15,000. As of March 31, 2013, there was approximately $35,000 of unrecognized compensation cost related to options expected to be recognized over a weighted-average period of 8 months. We might have recognized approximately $3,000 of tax benefits attributable to stock-based compensation expense recorded during the quarter ended March 31, 2013. However, this potential benefit was fully offset by our valuation allowance due to the aforementioned significant uncertainty of future realization. The total fair value of options vested during the three months ended March 31, 2013 was approximately $10,000.

 

11


Table of Contents

NOTE 8 – INCOME TAXES

We are subject to the income tax jurisdictions of the U.S. and multiple state tax jurisdictions. Our provision for income taxes for the three months ended March 31, 2013 and 2012 was attributable to certain states. The effective income tax rate for the three months ended March 31, 2013 and 2012 was 0.2% and 3.6%, respectively.

At March 31, 2013, we have federal net operating loss carryforwards of approximately $34.4 million, the deductibility of $29.2 million of which is presently limited under Section 382 of the Internal Revenue Code. Approximately $361,000 of any net operating losses prior to the January 2009 ownership change (“the earlier change”) can be used to offset taxable income annually. In addition, we can offset our taxable income each year by approximately $274,000 of the net operating losses which incurred between the earlier change and the August 2011 ownership change. We estimate that 59.3% of the $29.2 million pre-change losses will expire and be unavailable to offset our future taxable income.

Management has evaluated our tax positions taken or to be taken on income tax returns that remain subject to examination (i.e., tax years 2009 and thereafter federally, earlier for certain other jurisdictions), and has concluded that there are no uncertain tax positions, as defined in generally accepted accounting principles, that require recognition or disclosure in the consolidated financial statements.

NOTE 9 – PER SHARE DATA

For the periods presented, the following table sets forth the computation of basic and diluted earnings per share attributable to common stockholders (amounts in thousands, except per share data):

 

     March 31,  
     2013     2012  

Numerator:

    

Net (loss) income attributable to common stockholders

   $ (1,407   $ 80   

Denominator:

    

Weighted average common shares – basic

     59,745        59,252   

Effect of dilutive securities:

    

Series C convertible preferred stock

     —          3,300   

Stock options

     —          —     

Warrants

     —          —     
  

 

 

   

 

 

 

Weighted average common shares – diluted

     59,745        62,552   
  

 

 

   

 

 

 

Earnings per share:

    

Basic

   $ (0.02   $ 0.00   
  

 

 

   

 

 

 

Diluted

   $ (0.02   $ 0.00   
  

 

 

   

 

 

 

NOTE 10 – SUBSEQUENT EVENTS

Other than the changes in our outstanding debt instruments described in Notes 3 and 4, no events were identified that in our opinion require accounting recognition or disclosure in these financial statements, with the exception of the following:

Senior Secured Revolving Credit Facility

On May 3, 2013, we entered into a Senior Secured Revolving Credit Facility Agreement that will allow us to borrow up to $5,000,000 to fund our general working capital needs. Our initial draw on the credit facility occurred May 3, 2013 in the amount of approximately $884,000, which represents an initial draw of $1 million less transaction expenses. The credit facility is guaranteed by the current and future assets of CompCare and its subsidiaries, with the exception of our Puerto Rico subsidiary. Borrowings under the credit facility will bear interest

 

12


Table of Contents

at an annual rate of 12%, payable weekly. The credit facility will mature on November 3, 2013, at which time we may request an extension of the maturity date for an additional six month period provided that we are not in default in any respect, which may be accepted or rejected by the lender in its sole discretion.

The Agreement contains financial covenants such as, but not limited to, minimum revenues, positive earnings before interest, tax, depreciation and amortization expenses, and loan-to-value ratio. The Agreement also specifies events of default and related remedies, including acceleration and increased interest rates following an event of default. Loans under the credit facility will be evidenced by a Revolving Convertible Promissory Note. At any time while the Note remains outstanding, subject to certain limitations, the lender may convert all or any portion of the outstanding principal, accrued but unpaid interest and other sums payable under the Note into shares of our common stock at a price equal to (i) the amount to be converted, divided by (ii) 85% of the lowest daily volume weighted average price of our common stock during the five business days immediately prior to the conversion date.

As consideration for investment banking and advisory services provided to us by the lender, we paid a fee to the lender in the form of 1,470,588 shares of our common stock, issued on May 8, 2013. The shares and the Note were issued by the Company upon reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended, provided in Section 4(2) thereof.

Warrant issuance

On April 11, 2013, we issued warrants to purchase 2,000,000 shares of our common stock to a company in lieu of cash compensation for consulting and pharmacy analytical services. The warrants, which expire in April 2016, were vested in full at issuance and can be exercised at a price of $0.20 per share.

 

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In addition to historical information, the following information contains forward-looking statements as defined under federal securities laws. Such statements include, but are not limited to, the overall performance of the healthcare market, our anticipated operating results, financial resources, increases in revenues, increased profitability, interest expense, growth and expansion, anticipated favorable results from legal actions, the ability to obtain new and maintain existing behavioral healthcare contracts and the profitability, if any, of such behavioral healthcare contracts. These statements are based on current expectations, estimates and projections about the industry and markets in which we operate, the customers we serve and management’s beliefs and assumptions. Forward-looking statements are not guarantees of future performance and involve certain known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new business, the profitability of our capitated contracts, cost of care, seasonality, our ability to obtain additional financing, and other risks detailed herein and from time to time in our filings with the SEC. The following discussion should be read in conjunction with the accompanying condensed consolidated financial statements and notes thereto of CompCare and subsidiaries appearing elsewhere in this report.

OVERVIEW

We provide managed care services in the behavioral health, substance abuse, and pharmacy management fields, primarily to commercial, Medicare, Medicaid, Children’s Health Insurance Program (“CHIP”) health plans, as well as self-insured companies, unions, and Taft-Hartley health and welfare funds. Our managed care operations include administrative service agreements, fee-for-service agreements, and capitation contracts.

 

13


Table of Contents

SOURCES OF REVENUE

Our revenue can be segregated into the following significant categories (amounts in thousands):

 

     Three Months Ended  
     March 31,  
     2013      2012  

At-risk behavioral contracts

   $ 914       $ 7,476   

Administrative services only contracts

     303         817   

At-risk pharmacy contracts

     —           9,597   
  

 

 

    

 

 

 
   $ 1,217       $ 17,890   
  

 

 

    

 

 

 

Our customer base primarily includes regional health plans that do not have their own behavioral network. We provide services primarily through a network of contracted providers that includes:

 

   

psychiatrists;

 

   

psychologists;

 

   

therapists;

 

   

other licensed healthcare professionals;

 

   

psychiatric hospitals;

 

   

general medical facilities with psychiatric beds;

 

   

residential treatment centers; and

 

   

other treatment facilities.

The services provided through our provider network include outpatient programs (such as counseling or therapy), intermediate care programs (such as intensive outpatient programs and partial hospitalization services), inpatient programs and crisis intervention services. We do not directly provide treatment or own any treatment facility.

We typically enter into contracts on an annual basis to provide managed behavioral healthcare, substance abuse, and psychotropic pharmacy management services to our customers’ members. Our arrangements with our clients fall into two broad categories:

 

   

At-risk arrangements under which our clients pay us a fixed fee per member in exchange for our assumption of the financial risk of providing services; and

 

   

ASO arrangements where we manage behavioral healthcare programs or perform various managed care services, such as clinical care management, provider network development, and claims processing without assuming financial risk for member behavioral healthcare costs.

We also cover psychotropic pharmacy management services, where we receive an additional per-member per-month amount. We manage psychotropic pharmacy services through the collection and analysis of pharmacy claims data which is provided by the health plan’s pharmacy benefit manager (“PBM”), whose primary functions are claims adjudication and drug cost negotiation. Through data analysis and usage evaluation against clinically sound, evidence-based criteria, we are able to identify ineffective, inappropriate and costly drug utilization. Our approach is to address these issues in a collaborative manner with the primary care physicians and psychiatrists through the provision of useful information based on our analysis. Our goal is to produce positive outcomes for patients while controlling pharmacy costs.

Under at-risk arrangements, the number of covered members as reported to us by our clients determines the amount of premiums we receive, which is independent of the cost of services rendered to members. The amount of premiums we receive for each member is fixed by our contract at the beginning of our contract term. Under certain circumstances these premiums may be subsequently adjusted up or down, or the contract terminated, generally at the commencement of each renewal period.

Our largest expense is the cost of behavioral health services and pharmacy drugs that we provide, which is based primarily on our arrangements with healthcare providers. Since we are subject to increases in healthcare operating expenses based on an increase in the number and frequency of our members seeking behavioral care services, our profitability depends on our ability to predict and effectively manage healthcare operating expenses in relation to the fixed premiums we receive under at-risk arrangements. Providing services on an at-risk basis exposes

 

14


Table of Contents

us to the risk that our contracts may ultimately be unprofitable if we are unable to control or otherwise anticipate healthcare costs. Accrued claims payable and claims expense are our most significant critical accounting estimates. See “Critical Accounting Policies and Estimates” below.

We manage programs through which services are provided to recipients in five states. Our objective is to provide easily accessible, high quality behavioral healthcare and pharmacy services and to manage costs through measures such as the monitoring of hospital inpatient admissions and the review of authorizations for various types of outpatient therapy. Our goal is to combine access to quality behavioral healthcare services with effective management controls in order to ensure the most cost-effective use of healthcare resources.

Our programs and services include:

 

   

management of prescription drugs on an at-risk basis for health plans;

 

   

fully integrated behavioral healthcare and psychotropic pharmacy management services;

 

   

analytic services for medical and pharmacy claims for medical integration of behavioral and medical care coordination;

 

   

case management/utilization review services;

 

   

administrative services management;

 

   

preferred provider network development;

 

   

management and physician advisor reviews; and

 

   

overall care management services.

RECENT DEVELOPMENTS

Pharmaceutical Drug Management Initiative; New Business

We continue our efforts to expand our new Pharmacy Savings Management Program, marketed through our dedicated, wholly-owned subsidiary CompCare Pharmacy Solutions, Inc. For health plans, self insured entities, unions, and Taft-Hartley health and welfare funds, we will offer to manage on an at-risk basis prescription drug programs. Through the use of selected pharmacy benefits managers, pharmacy data analytics, and the development of cost-saving ancillary pharmacy programs, we believe we can materially reduce drug costs for our clients that utilize our program. Our marketing efforts of this program are receiving positive traction and, in March of 2013, we entered into an agreement with Local No. 29 of the Laborers International Union of North America to provide our Pharmacy Savings Program, and in May 2013, we signed a Pharmacy Savings Management agreement with Utica City (NY) School District. Both programs are scheduled to launch in the third quarter of this year.

Revolving Credit Facility Agreement

On May 3, 2013, we entered into a Senior Secured Revolving Credit Facility Agreement that will allow us to borrow up to $5,000,000 to fund our general working capital needs. Our initial draw on the credit facility occurred May 3, 2013 in the amount of approximately $884,000, which represents an initial draw of $1 million less transaction expenses. The credit facility is guaranteed by the current and future assets of CompCare and its subsidiaries, with the exception of our Puerto Rico subsidiary. Borrowings under the credit facility will bear interest at an annual rate of 12%, payable weekly. The credit facility will mature on November 3, 2013, at which time we may request an extension of the maturity date for an additional six month period provided that we are not in default in any respect, which may be accepted or rejected by the lender in its sole discretion.

The Agreement contains financial covenants such as, but not limited to, minimum revenues, positive earnings before interest, tax, depreciation and amortization expenses, and loan-to-value ratio. The Agreement also specifies events of default and related remedies, including acceleration and increased interest rates following an event of default. Loans under the credit facility will be evidenced by a Revolving Convertible Promissory Note. At any time while the Note remains outstanding, subject to certain limitations, the lender may convert all or any portion of the outstanding principal, accrued but unpaid interest and other sums payable under the Note into shares of our common stock at a price equal to (i) the amount to be converted, divided by (ii) 85% of the lowest daily volume weighted average price of our common stock during the five business days immediately prior to the conversion date.

 

15


Table of Contents

As consideration for investment banking and advisory services provided to us by the lender, we paid a fee to the lender in the form of 1,470,588 shares of our common stock. The shares and the Note were issued by the Company upon reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended, provided in Section 4(2) thereof.

Retirement of President

On April 22, 2013, we were notified by our President, Robert R. Kulbick, that he needed to retire for medical reasons effective May 1, 2013. We have named Ramon Martinez to direct our pharmacy management program as President of CompCare Pharmacy Solutions, Inc., the wholly-owned subsidiary dedicated to marketing our pharmacy savings program. Mr. Martinez has been working with the Company on its new, innovative pharmacy savings program as a Senior Management Advisor since August 2012.

Debt in Default

We were unable to repay our 14% senior promissory notes in the amount of approximately $1.8 million on the maturity date of April 15, 2013. On May 13, 2013, we completed an agreement to extend the maturity date for approximately $1.3 million of the notes. We are currently in discussions with the holders of the remaining $500,000 of notes and do not anticipate any difficulty in completing extension agreements. In addition, we were not able to repay a $1 million loan due May 8, 2013.

New Behavioral Health Care Business

Effective January 1, 2013, we began providing administrative behavioral health services to approximately 3,000 members of a Medicare Advantage population serviced by a health plan in the state of California.

Debt Modifications

On May 13, 2013, we executed an agreement with a holder of approximately $1.3 million of our senior promissory notes to extend the maturity date of the notes from April 15, 2013 to April 15, 2014. We also agreed to extend the term of approximately 5.2 million warrants that had been issued at the time the notes were issued in April 2010 for an additional two years, such that the warrants will now expire in 2017. In conjunction with the renewal, we will issue 774,391 shares of our common stock to the lender relating to 50% of the interest and fees owed as of April 15, 2013.

On May 8, 2013, we executed an agreement with a creditor to modify the terms of a promissory note in the amount of $625,000. Under the modified terms of the note, the maturity date was extended from May 14, 2013 to July 15, 2013 and the conversion price at which the note may be converted into our common stock was reduced to $0.125 from $0.25. In addition, the exercise price of a warrant to purchase our common stock issued in conjunction with the note was reset from $0.44 to $0.22. We have reserved funds with which to pay this obligation at maturity.

On March 15, 2013, we executed an agreement with a creditor to modify the terms of a previously matured but unpaid promissory note in the amount of $1.4 million. Under the modified terms of the note, the maturity date was extended from February 28, 2013 to January 31, 2014 and the conversion price at which the note may be converted into our common stock was reduced to $0.125 from $0.25. In addition, the exercise price of a warrant to purchase our common stock issued in conjunction with the note was reset from $0.44 to $0.22. We also assigned certain receivables and a potential arbitration recovery to the creditor as a source of future repayment of a second loan from the creditor in the amount of $625,000 maturing May 14, 2013 and a $75,000 loan from an individual related to the creditor also due on May 14, 2013. Any proceeds remaining from the assigned receivables and potential recovery after repayment of the aforementioned loans will be used to reduce the principal of the $1.4 million loan, but not in excess of $300,000.

RESULTS OF OPERATIONS

Three months ended March 31, 2013 vs. 2012

With the expiration of our at-risk Behavioral Health and Pharmacy contracts in Puerto Rico on December 31, 2012, which comprised approximately 83% of the Company’s total revenue, our operating revenues have decreased significantly. Prior to December 31, 2012, anticipating this decrease, we accelerated our efforts to advance the Company’s Pharmacy Savings Program so that we would be prepared to commence aggressively marketing this program by January 1, 2013. Simultaneously, we significantly reduced salaries, decreased our work force and generally cut back expenses. We met our Pharmacy Savings Plan launch date and commenced the marketing of that program in early January. To date, we have entered into two Pharmacy Management Agreements, with both scheduled for launch Q3 of this year. We are actively engaged in discussions with a number of other potential pharmacy accounts. The Company’s shift of focus away from the Behavioral Health/Medicare/Medicaid segments of the health care market to pharmacy savings market was occasioned by reason of the Company’s belief that significantly greater margins, less regulations and ease of closing transactions existing in the pharmacy management sector of health care. The Company believes that its focus on its Pharmacy Management Program, coupled with its decreased operating expenses, will bring the Company to profitability during the second half of 2013.

 

16


Table of Contents

Revenues:

At-risk behavioral health contracts: Operating revenues from at-risk contracts decreased by 87.8%, or approximately $6.6 million, to $0.9 million for the three months ended March 31, 2013, compared to $7.5 million for the three months ended March 31, 2012. The decrease was primarily attributable to the expiration of the Puerto Rico contract during the fourth quarter of 2012 that accounted for $4.3 million of revenue for the three months ended March 31, 2012.

ASO contracts: Revenue from ASO contracts decreased by 62.8%, or approximately $0.5 million, to $0.3 million for the three months ended March 31, 2013 due primarily to the loss of a customer during the fourth quarter of 2012 that had accounted for $0.4 million of business during the quarter ended March 31, 2012.

Pharmacy management contracts: Due to the expiration of our major contract in Puerto Rico, we did not generate any revenue for the three months ended March 31, 2013, as compared to $9.6 million for the same period in 2012.

Costs of revenues: Anticipating our decrease in revenue commencing January 1, 2013, we successfully decreased our operating expenses by 95.3%, or approximately $15.8 million for the three months ended March 31, 2013 as compared to the three months ended March 31, 2012 for reasons set forth in the following four paragraphs.

Behavioral health contracts: Claims expense on at-risk contracts decreased approximately $5.0 million due to expense reductions and cost containment measures mentioned above and a reduction to claims expense of approximately $0.7 million relating to favorable claims experience from our former major Puerto Rico contract.

Pharmacy drug costs: Pharmacy costs decreased 100%, or approximately $9.6 million, due to the expiration of our Puerto Rico pharmacy contract on December 31, 2012.

Other healthcare operating costs: Other healthcare costs, attributable to servicing both at-risk contracts and ASO contracts, decreased approximately $1.2 million from approximately $2.0 million for the three months ended March 31, 2012 to approximately $0.8 million for the three months ended March 31, 2013 due primarily to reductions in salaries and benefits attributable to workforce reductions.

General and administrative expense: General and administrative expenses decreased $0.7 million (after excluding a $1.6 million adjustment of legal expense for the three months ended March 31, 2012) for the three months ended March 31, 2013 as compared to the three months ended March 31, 2012 due primarily to a $0.4 million decrease in salaries and benefits due to workforce reductions and a $0.1 million reduction in professional fees.

Interest expense. Interest expense, excluding amortization of debt discount, decreased by approximately $15,000 for the three months ended March 31, 2013, as compared to the three months ended March 31, 2012 due to a decrease in the weighted average amount of debt outstanding to $9.0 million for the three months ended March 31, 2013 from $9.4 million for the comparable prior period net of a decline in the effective interest rate, excluding amortization of debt discount, for the three months ended March 31, 2013, to approximately 13.6% from 15.8% for the same period in 2012.

Income taxes. Our provisions for income taxes for the three months ended March 31, 2013 and 2012 represented solely income tax expenses for certain states. Our effective income tax rate for the three months ended March 31, 2013 and 2012 was 0.2% and 3.6%, respectively.

 

17


Table of Contents

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Preparation of our consolidated financial statements requires us to make significant estimates and judgments to develop the amounts reflected and disclosed in the consolidated financial statements. On an on-going basis, we evaluate the appropriateness of our estimates and we maintain a thorough process to review the application of our accounting policies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

We believe our accounting policies specific to our revenue recognition, accrued claims payable, premium deficiencies and claims expense, goodwill, and income taxes are critical to the preparation of our consolidated financial statements.

Revenue recognition. The majority of our managed care activities are performed under at-risk arrangements pursuant to terms of agreements primarily with health plans to provide contracted behavioral healthcare and pharmacy management services to subscribing members. Revenue under these agreements is earned continuously over time regardless of services actually provided and, therefore, is recognized monthly based on the number of qualified members. The information regarding qualified members is supplied by our clients, and we review member eligibility records and other reported information to verify its accuracy and determine the amount of revenue to be recognized. The remaining balance of our revenues is earned and recognized as services are delivered on a non-risk basis.

We also manage the psychotropic drug benefit under certain behavioral health contracts for certain health plans’ subscribing members and are responsible for the cost of drugs dispensed. In accordance with the contracts, the health plan’s pharmacy benefit manager (“PBM”) performs drug price negotiation and claims adjudication. As such, payment for our pharmacy management services is withheld until a monthly or quarterly comparison of our total premium to total drug cost is made, at which time we receive or pay the difference. Accordingly, similar to our other at-risk arrangements, pharmacy drug management revenue is earned at a contracted rate per eligible member and recognized monthly.

Accrued claims payable. Claims expense, a major component of cost of care, is recognized in the period in which an eligible plan member actually receives services and includes incurred but not reported (“IBNR”) claims. We contract with various healthcare providers including hospitals, physician groups and other licensed behavioral healthcare professionals either on a discounted fee-for-service or a per-case basis. We determine that a member has received services when we receive a claim within the contracted timeframe with all required billing elements correctly completed by the service provider. We then determine whether the member is eligible to receive the service, the service provided is medically necessary and is covered by the benefit plan’s certificate of coverage, and the service is authorized by one of our employees, if required. If all of these requirements are met, the claim is entered into our claims system for payment.

The accrued claims payable liability represents the estimated ultimate net amounts owed for all behavioral healthcare services provided through the respective balance sheet dates, including estimated amounts for claims IBNR. We have used the same methodology and assumptions for estimating the IBNR portion of the accrued claims liability for the last two years.

Our unpaid claims liability is estimated using an actuarial paid completion factor methodology and other statistical analyses. These estimates are subject to the effects of trends in utilization and other factors. Any significant increase in member utilization that falls outside of our estimates would increase claims expense and could adversely affect our ability to achieve and sustain improvements in profitability and positive cash flow. Although considerable variability is inherent in such estimates, we believe that our unpaid claims liability is adequate.

Whenever we believe it is probable that a future loss will be incurred under a managed care contract based on an expected premium deficiency and we are unable to cancel our obligation or renegotiate the contract, we record a loss in the amount of the expected future losses. We perform our loss accrual analysis on a contract-by-contract basis by taking into consideration various factors such as future contractual revenue, estimated future healthcare and maintenance costs, and each contract’s specific terms related to future revenue increases as compared to expected increases in healthcare costs. The estimated future healthcare and maintenance costs are based on historical trends and expected future cost increases. Our analysis at March 31, 2013 did not identify any loss contracts.

 

18


Table of Contents

Accrued claims payable consists primarily of amounts established for reported claims and IBNR claims, which are unpaid through the respective balance sheet dates. Our policy is to record management’s best estimate of IBNR. The IBNR liability is estimated monthly using an actuarial paid completion factor methodology and is continually reviewed and adjusted, if necessary, to reflect any change in the estimated liability as more information becomes available. In deriving an initial range of estimates, we use an industry accepted actuarial model that incorporates past claims payment experience, enrollment data and key assumptions such as trends in healthcare costs and seasonality. Authorization data, utilization statistics, calculated completion percentages and qualitative factors are then combined with the initial range to form the basis of management’s best estimate of the accrued claims payable balance. However, estimating IBNR claims involves a significant amount of judgment by our management. The following are the principal factors that would have an impact on our future operations and financial condition:

 

 

Changes in the number of employee plan members due to economic factors;

 

 

Other changes in utilization patterns;

 

 

Changes in healthcare costs;

 

 

Changes in claims submission timeframes by providers;

 

 

Success in renegotiating contracts with healthcare providers;

 

 

Occurrence of catastrophes;

 

 

Changes in benefit plan design; and

 

 

The impact of present or future state and federal regulations.

The accrued claims payable ranges were between $11.8 and $11.9 million at March 31, 2013 and between $12.9 and $13.1 million at December 31, 2012. Based on the information available, we determined our best estimate of the accrued claims liability to be $11.8 million at March 31, 2013 and $13.1 million at December 31, 2012. Our accrued claims liability at March 31, 2013 and December 31, 2012 includes approximately $9.4 million and $9.8 million, respectively, of submitted and approved but unpaid claims and $2.4 million and $3.3 million for IBNR claims, respectively. A 5% increase in assumed healthcare cost trends from those used in our calculations of IBNR at March 31, 2013 could increase our claims expense by approximately $24,000. Actual claims incurred could differ from estimated claims accrued.

Income taxes. Computing our provision for income taxes involves significant judgment and estimates particularly in relation to the realization of deferred tax assets from net operating loss carryforwards, uncertain income tax positions, and in estimating the probable annual effective income tax rates for interim financial reporting periods.

At March 31, 2013, we have federal net operating loss carryforwards of approximately $34.4 million, the deductibility of $29.2 million of which is presently limited under Section 382 of the Internal Revenue Code to approximately $361,000 annually due to recent changes in control of the Company. We are particularly vulnerable to additional changes in control in the near term due to probable future equity dilution or possible takeover resulting in further loss of our ability to utilize the remaining carryforwards pursuant to Section 382. In addition, as of March 31, 2013, the Company continues to be in a deficit position. Based on this evidence, and the uncertainty as to our ability to continue as a going concern and current economic conditions discussed under LIQUIDITY AND CAPITAL RESOURCES below, we concluded that at this time, it is not more likely than not that the Company’s deferred tax assets, which relate primarily to the federal net operating losses, will be realizable within the carryforward period. Accordingly, the Company continues to maintain an effective 100% valuation allowance against the balance of these deferred tax assets at this time. Our judgments regarding future taxable income may change due to many factors, including changes in operating results from changing economic or market conditions, or changes in tax laws, operating results or other factors.

RECENT ACCOUNTING PRONOUNCEMENTS

No recent accounting pronouncements have been issued that are not yet effective and have not been early adopted that we believe will have a significant effect on our consolidated financial in future periods.

 

19


Table of Contents

SEASONALITY OF BUSINESS

Historically, we have experienced increased member utilization during the months of March, April and May and consistently low utilization by members during the months of June, July, and August. Such variations in member utilization affect our costs of care during these months, having a generally positive impact on our operations during June through August and a negative impact from March through May.

LIQUIDITY AND CAPITAL RESOURCES

At March 31, 2013, we had a working capital deficiency of approximately $23.0 million and a stockholders’ equity deficiency of approximately $24.1 million resulting from a history of operating losses. Approximately $2.9 million of debt was past due as of March 31, 2013. Our ability to continue as a going concern will be dependent upon the success of management’s plans, as set forth in the following paragraphs, and is subject to significant uncertainty. In their report on our most recent audited financial statements as of and for the year ended December 31, 2012, our independent auditors expressed substantial doubt as to our ability to continue as a going concern. Except for its consideration in establishing our valuation allowance for deferred tax assets, the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty.

The United States and other parts of the world have been experiencing a severe and widespread recession accompanied by, among other things, instability in the financial markets and reduced credit availability, which are likely to continue to have far-reaching effects on economic activity for an indeterminate period. The effects and probable duration of these conditions on our ability to obtain continued support from our major stockholders and other lenders, success in our marketing efforts, and ultimately, profitable operations and positive cash flows, cannot be estimated at this time.

Need for Additional Financing

Our existing capital may not be sufficient to meet our cash needs. We expect that:

  i. with our new Senior Secured Revolving Credit Facility;
  ii. existing customer contracts;
  iii. collection of receivables;
  iv. extension of vendor payments;
  v. the addition of significant new pharmacy management contracts that we have reason to believe will be obtained through:
  (a) the expansion of our pharmacy management sales force;
  (b) our execution of a strategic consulting agreement supporting the pharmacy management program;
  (c) the integration of care management and wellness programs;
  (d) our ability to commit to saving our clients substantial sums of money on their pharmacy expenses, backed by a performance bond to be issued by a surety company;
  (e) our CEO joining the Board of Directors of “America’s Agenda: Health Care for All,”

We believe all of the above items places the Company in a position to sustain and grow current operations over the near term. We continue to look at various alternative sources of financing if operations cannot support our ongoing plan. Nevertheless, there can be no assurance that we will be able to achieve the growth anticipated from all or some of the above factors, nor find such financing in amounts or on terms acceptable to us, if at all, or that we will be able to achieve or sustain profitable operations and positive operating cash flows in the near term. Although subject to the general economic conditions, risks and uncertainties discussed in the preceding paragraph, management believes that our current cash position will likely be sufficient to meet our current levels of operations in the short term, our ability to achieve our business objectives and continue as a going concern for a reasonable period of time may be dependent upon the success of our plans to obtain sufficient debt or equity

Our primary internal source of liquidity on an on-going basis is from operations and consists of the monthly capitation payments we receive from our clients for providing managed care services. Based on historical experience, there is a high degree of certainty with respect to the reliability and timing of these payments from continuing contracts. However, the expiration or termination of existing contracts, whether expected or not, or the commencement of new contracts may cause our operational cash flow to vary significantly.

Our external sources of liquid funds consist primarily of borrowings and the use of equity instruments. Our ability to continue to borrow funds on an unsecured basis is unknown, as well as our ability to sell shares of our common stock in private placement offerings. With the exception of contracted maturities of debt, there are no other known future liquidity demands due to commitments or events. We do not have any off-balance sheet financing arrangements. The duration of our borrowings has typically ranged from one week to three years, with stated interest rates ranging from 7% to 24%. Certain of the loans have contained features such as the ability to convert all or a portion of the loan into our common stock, or have had a detachable warrant for the purchase of our common stock issued in conjunction with the loan, or both.

As evident in our statement of cash flows, during the three months ended March 31, 2013, our cash balance increased by $843,000 due primarily to collections of receivables, managing our cash outflows related to our cost of care, cost reduction initiatives, and delaying payments to vendors. We also repaid existing debt, including capitalized leases, in the amount of $456,000.

 

20


Table of Contents
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

While we currently have market risk sensitive instruments, we have no significant exposure to changing interest rates, as the interest rates on our short-term debt is fixed. Additionally, we do not use derivative financial instruments for investment or trading purposes.

 

ITEM 4. CONTROLS AND PROCEDURES

 

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer along with the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (2) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure.

 

(b) Change in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

In the ordinary conduct of our business, we are subject to periodic lawsuits and claims. Although we cannot predict with certainty the ultimate resolution of lawsuits and claims asserted against us, we do not believe that any currently pending legal proceedings to which we are a party could have a material adverse effect on our business, or our future results of operations, cash flows or financial condition except as described below:

 

  (1) We initiated an action against Jerry Katzman, a former director, in July 2009 alleging that Mr. Katzman fraudulently induced us to enter into an employment agreement and, alternatively, that Mr. Katzman breached that alleged employment agreement and was rightfully terminated. In September 2010, the matter proceeded to a trial by jury. The jury found that Mr. Katzman did not fraudulently induce CompCare to enter into the contract but also found that Mr. Katzman was not entitled to damages. On defendant’s motion to amend the verdict due to inconsistency, the trial court set aside the jury verdict and awarded Mr. Katzman damages of approximately $1.9 million. The Company appealed the lower court’s decision and posted a collateralized appeal bond for approximately $1.9 million. On February 14, 2013, the 11th Circuit Court of Appeals of the State of Florida reversed the lower court’s judgment which was in favor of Katzman. The decision of the appellate court also reverses the lower court’s award of attorney’s fees previously awarded to Katzman. As a result of the Court of Appeals reversal, the Company’s need to maintain appellate bonds in the aggregate amount of $1.9 million has been eliminated. The appellate court also taxed appellate costs in favor of CompCare against Katzman. The amount of these costs is currently pending before the court for determination. In addition, the Company holds a judgment against Katzman for approximately $1.3 million. The Company intends to pursue collection of this judgment.

 

  (2)

On January 5, 2011, a complaint entitled “Community Hospitals of Indiana, Inc. vs. Comprehensive Behavioral Care, Inc. and MDwise, Inc.” was filed against us. The complaint claims damages of approximately $1.7 million from us and MDwise, Inc., a former client, for allegedly unpaid claims for behavioral health professional services rendered between 2007 and 2008. The complaint alleges, among

 

21


Table of Contents
  other things, breach of contract and unjust enrichment, and requests recovery of alleged losses despite the absence of a contract between us and complainant. We believe the suit against the Company is without merit and are vigorously opposing the litigation.

 

  (3) We are in arbitration with a former health plan client in Missouri relating to its allegation that we breached our obligation to pay claims submitted to us for payment. The arbitration is underway but has not yet progressed significantly.

 

  (4) A number of health care providers in the state of Louisiana have filed suit against us claiming breach of contract in that we failed to pay claims submitted to us for payment. The litigation is currently in the discovery stage.

 

  (5) We are in arbitration with a former client in Puerto Rico. The Company believes that it is owed approximately $2.0 million. We have currently moved for summary judgment on approximately $1.2 million. We anticipate a favorable result on that motion and a hearing date to be scheduled shortly on remaining monies claimed by the Company to be due it.

Management believes that the Company has made adequate provision for any estimated probable losses, including legal defense costs, from the litigation described above.

 

ITEM 1A. RISK FACTORS

The risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2012 have not materially changed.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the period April 12, 2013 through May 20, 2013, we issued shares of common stock and warrants to purchase shares of our common stock in private placements not involving a public offering as follows:

 

   

On May 3, 2013, we issued a Revolving Convertible Promissory Note as part of a Senior Secured Revolving Credit Facility Agreement. At any time while the Note remains outstanding, subject to certain limitations, the lender may convert all or any portion of the outstanding principal, accrued but unpaid interest and other sums payable under the Note into shares of our common stock at a price equal to (i) the amount to be converted, divided by (ii) 85% of the lowest daily volume weighted average price of our common stock during the five business days immediately prior to the conversion date.

 

   

On May 8, 2013, we issued 1,470,588 shares of our common stock to a lender in exchange for investment banking and advisory services provided by the lender during the process of negotiating the aforementioned Senior Secured Revolving Credit Facility Agreement.

Based on certain representations and warranties of the recipients referenced above, we relied on Section 3(a)(9) and 4(2) of the Securities Act of 1933, as amended (the “Securities Act”) as applicable, for an exemption from the registration requirements of the Securities Act. The shares purchased have not been registered under the Securities Act and may not be sold in the United States absent registration or an applicable exemption from registration requirements.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

As of May 20, 2013, we were in default on approximately $4.4 million of debt. We are currently in negotiations with certain of the holders to resolve the defaults.

 

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

 

22


Table of Contents
ITEM 5. OTHER INFORMATION

Debt Modification

On May 8, 2013, we executed a Loan Extension Agreement, filed herewith as Exhibit 4.25, with a creditor to modify the terms of a previously matured but unpaid promissory note in the amount of $625,000. Under the modified terms of the note, the maturity date was extended from May 14, 2013 to July 15, 2013 and the conversion price at which the note may be converted into our common stock was reduced to $0.125 from $0.25. In addition, the exercise price of a warrant to purchase our common stock issued in conjunction with the note was reset from $0.44 to $0.22.

On May 13, 2013, we executed an agreement, filed herewith as Exhibit 4.26, with a holder of approximately $1.3 million of our senior promissory notes to extend the maturity date of the notes from April 15, 2013 to April 15, 2014. We also agreed to extend the term of approximately 5.2 million warrants that had been issued at the time the notes were issued in April 2010 for an additional two years, such that the warrants will now expire in 2017. In conjunction with the renewal, we will issue 774,391 shares of our common stock to the lender relating to 50% of the interest and fees owed as of April 15, 2013.

 

ITEM 6. EXHIBITS

 

EXHIBIT
NUMBER

 

DESCRIPTION

    4.24

  Loan Extension Agreement dated March 15, 2013 between the Company and Sherfam, Inc., incorporated by reference to Exhibit 4.24 to our Form 10-K Annual Report dated December 31, 2012 and filed April 12, 2013.

    4.25

  Loan Extension Agreement dated May 8, 2013 between the Company and Sherfam, Inc.

    4.26

  Second Note Modification Agreement dated May 13, 2013 between the Company and Lloyd I. Miller

  31.1

  Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

  31.2

  Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

  32.1

  Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

  32.2

  Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101

  The following materials from Comprehensive Care Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, formatted in eXtensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements, tagged as blocks of text. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

 

23


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

COMPREHENSIVE CARE CORPORATION

May 20, 2013

 

By  

/s/    CLARK A. MARCUS        

  Clark A. Marcus
  Chief Executive Officer and Chairman
  (Principal Executive Officer)
By  

/s/    ROBERT J. LANDIS        

  Robert J. Landis
  Chief Financial Officer and Chief Accounting Officer
  (Principal Financial and Accounting Officer)

 

24

EX-4.25 2 d516654dex425.htm LOAN EXTENSION AGREEMENT Loan Extension Agreement

Exhibit 4.25

LOAN EXTENSION AGREEMENT

This Loan Extension and Modification Agreement (the “Agreement”) is dated as of this 8th day of May, 2013, by and between Comprehensive Care Corporation, a Delaware corporation (the “Company”) and Sherfam, Inc. (“Sherfam”).

Terms not otherwise defined herein shall have the meaning ascribed to such terms in the following documents: (1) the 18 Month Convertible Promissory Note Face Value $625,000 Coupon 14% Issue Date November 14, 2011 and the Addendum thereto (the “Promissory Note”) and (2) the Subscription Agreement dated November 14, 2011 between the Company and Sherfam (“Subscription Agreement).

WITNESSETH:

WHEREAS, the Borrower obtained a loan from Sherfam in the principal amount of $625,000 (the “Loan”);

WHEREAS, the Loan is evidenced by the Promissory Note.

WHEREAS, Pursuant to the Subscription Agreement, the Promissory Note is convertible at Sherfam’s option into the Company’s Common Stock at a conversion price of $0.25 and Sherfam received one five year Warrant for every two dollars of face value of the Promissory Note convertible into the Company’s Common stock at a price of $0.44 per share;

WHEREAS, under the Promissory Note, the Maturity Date is May 14, 2013 (the “Original Maturity Date”). Upon the Original Maturity Date and, unless and to the extent that the Promissory Note is converted in accordance with the terms therein, all outstanding principal and any accrued and unpaid interest becomes due and owing under such Note and is to be immediately paid by the Company to Sherfam;

WHEREAS, the Company seeks Sherfam’s consent to modify and extend the Original Maturity Date to the date specified hereinafter and, in consideration thereof, the Company and Sherfam have agreed to modify certain terms of the Subscription Agreement as more fully set forth herein.

NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby acknowledged the Company and Sherfam agree as follows:

1. Extensions. The Promissory Note is amended to extend the Original Maturity Date from May 14, 2013 to July 15, 2013.

2. Amendment to Subscription Agreement to Adjust Conversion Price and Strike Price. The Subscription Agreement is amended as follows:

(a) The conversion price set forth in paragraph 2 (iii) of said Subscription Agreements is amended to change the conversion price from $0.25 per share to $0.125 per share.

(b) The strike price on the five year Warrant set forth in paragraph 2(iv) of said Subscription Agreement is amended to change the strike price from $0.44 per share to $0.22 per share.

(c) The aforementioned changes as set forth above are contained in Amendment No.1 to the Subscription Agreement attached hereto as Exhibit A.

3. No Defaults. The Company, by execution of this Agreement, hereby represents and warrants that as of the date hereof, no Event of Default exists or is continuing with respect to the Promissory Note or the Subscription Agreement.


4. Loan Extension Agreement. It is the intention and understanding of the parties hereto that this Agreement shall act as an extension of the Promissory Note and that this Agreement shall not act as a novation of such note.

5. Except as specifically amended hereby, the parties hereto acknowledge and confirm that the Promissory Note and Subscription Agreement remain in full force and effect and enforceable in accordance with their terms.

IN WITNESS WHEREOF, intending to be legally bound, the parties hereto have caused this Agreement to be signed by their duly authorized officers.

Dated: May 8, 2013

 

SHERFAM, INC.
By:  

/s/Alex Glasenberg

Title:  

CFO

COMPREHENSIVE CARE CORPORATION
By:  

/s/ Robert J. Landis

Title:  

CFO

EX-4.26 3 d516654dex426.htm SECOND NOTE MODIFICATION AGMT Second Note Modification Agmt

Exhibit 4.26

SECOND NOTE MODIFICATION AGREEMENT

THIS SECOND NOTE MODIFICATION AGREEMENT (this “Agreement”), entered into on the 13th day of May 2013 and made effective as of the 15th day of April 2013, is between Lloyd I. Miller III and certain of his affiliates and associates named as Holders on Exhibit A hereto (collectively, together with their successors and assigns, “Lender”), and Comprehensive Care Corporation, a Delaware corporation (“Borrower”).

WHEREAS, Lender is the owner and holder of the notes dated April 15, 2010 executed by Borrower to the order of Lender in the aggregate principal sum of $1,290,650.00 bearing interest and due and payable in cash as therein provided, as more particularly described on Exhibit A hereto (collectively, the “Note”);

WHEREAS, the original maturity date of the Note was April 15, 2012 (the “Original Maturity Date”);

WHEREAS, the Borrower failed to repay the Note on the Original Maturity Date;

WHEREAS, Lender and Borrower entered in to a Note Modification Agreement dated June 29, 2012 and made effective as of April 15, 2012, a copy of which attached hereto as Exhibit B (“First Note Modification”), wherein the maturity date of the Note was extended until April 15, 2013 and the interest rate was modified as set forth therein.

WHEREAS, the Borrower failed to repay the Note on April 15, 2013;

WHEREAS, Lender is the owner and holder of warrants (the “Warrants”) for the purchase of 5,121,100 shares of common stock of Borrower, par value $0.01 per share, pursuant to a Warrant to Purchase Shares of Common Stock issued by Borrower on April 30, 2010 (the “Warrant Agreement”);

WHEREAS, the Warrant Agreement provides that the Warrants will expire on September 15, 2015; and

WHEREAS, Lender is the owner and holder of warrants (the “Additional Warrants”) for the purchase of 41,500 shares of common stock of Borrower, par value $0.01 per share, pursuant to a Warrant to Purchase Shares of Common Stock issued by Borrower on January 19, 2011 (the “Additional Warrant Agreement”);

WHEREAS, the Additional Warrant Agreement provides that the Warrants will expire on January 19, 2015; and

WHEREAS, Lender and Borrower desire to modify the terms of the Note, Warrant Agreement and Additional Warrant Agreement as set forth below;

NOW, THEREFORE, in consideration of the mutual agreements herein expressed, the parties hereto covenant and agree as follows:

The Note is modified by changing the following terms:

 

  the maturity date is changed from “April 15, 2013”, to “April 15, 2014”; and

 

  the title of the Note is changed from “14% Senior Note, due April 15, 2013” to “14% Senior Note, due April 15, 2014”;

The Warrant Agreement is modified by changing the following term:

 

  the term for this Warrant is changed from “Warrant shall commence on April 27, 2010 and shall expire at 6:00 p.m., eastern time, on September 15, 2015”, to “Warrant shall commence on April 27, 2010 and shall expire at 6:00 p.m., eastern time, on September 15, 2017”.

The Additional Warrant Agreement is modified by changing the following term:

 

  the term for this Warrant is changed from “Warrant shall commence on January 19, 2011 and shall expire at 6:00 p.m., eastern time, on January 19, 2015”, to “Warrant shall commence on January 19, 2011 and shall expire at 6:00 p.m., eastern time, on January 19, 2017”.


As partial consideration for Lender entering into this Agreement, Borrower shall, contemporaneous with its execution of this Agreement, pay to Lender the past due interest sum of $90,345.50 (the “Past Due Interest”). The Past Due Interest sum will be paid $45,172.76 in cash and by issuing a total of 451,728 restricted shares of the Borrowers Common Stock ($0.10 per share) to Lender. All subsequent interest payments will be made in cash.

Also, as partial consideration for Lender entering into this Agreement, Borrower shall, contemporaneous with its execution of this Agreement, pay to Lender the sum of $32,266.26 in cash and shall issue to Lender a total of 322,663 restricted shares of the Borrowers Common Stock ($0.10 per share) (the “Amendment Fee”).

Borrower’s failure to pay the either the Past Due Interest or the Amendment Fee within ten days of execution of this Second Note Modification Agreement to Lender as required herein shall constitute an Event of Default under the Note.

Borrower hereby represents and warrants to Lender that (i) Borrower has the corporate power and authority necessary to enter into this Agreement and perform its obligations hereunder, and has taken all corporate action as may be necessary or appropriate to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder, (ii) this Agreement, the Note and the Warrant Agreement are obligations enforceable in accordance with their respective terms, and neither the execution and delivery of this Agreement by Borrower nor the performance of Borrower’s obligations hereunder will violate or contravene any applicable requirements of law or any of Borrower’s charter, bylaws or other material agreements applicable to Borrower, (iii) Borrower is justly indebted to Lender for the unpaid principal balance of the Note, together with any and all accrued and unpaid interest or charges thereon, (iv) after giving effect to this Agreement, Borrower is not in default of any of its obligations under the Note or the Warrant Agreement and (v) Borrower has no offsets, defenses or counterclaims or any nature with respect to the Note or the Warrant Agreement.

Borrower hereby unconditionally agrees and promises to pay to the order of Lender the outstanding principal balance under the Note, together with all interest thereon and all other amounts set forth therein, in accordance with the terms, covenants and conditions set forth in the Note, as modified hereby.

This Agreement may be executed in any number of separate counterparts, each of which, when so executed and delivered, shall be deemed an original, but all of which, collectively and separately, shall constitute one and the same agreement.

Except as modified herein, all the remaining terms, covenants and conditions of the Note and Warrants are hereby ratified, and shall continue to remain in full force and effect.

This Agreement shall be governed by and construed under the laws of the State of New York.

Time is of the essence of each and every covenant, condition and provision to be performed by Borrower under the Note, the Warrant Agreement and this Agreement.

THIS AGREEMENT REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES WITH RESPECT TO THE MATTERS SET FORTH HEREIN AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES IN REGARD TO THESE MATTERS.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]


IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement effective as of the day and year first above written.

 

LENDER:

/s/ Lloyd I. Miller

Lloyd I. Miller III, individually and in his capacity as authorized signatory for each of the Holders listed on Exhibit A hereto


COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

 

BORROWER:
COMPREHENSIVE CARE CORPORATION
By:  

/s/ Robert J. Landis

  Robert J. Landis
  Chief Financial Officer

 

30

EX-31.1 4 d516654dex311.htm CERTIFICATION Certification

Exhibit 31.1

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

Certification of Chief Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Clark A. Marcus, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Comprehensive Care Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements and other financial information included in this quarterly report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

   

/s/ CLARK A. MARCUS

May 20, 2013     Clark A. Marcus
    Chief Executive Officer and Chairman
    (Principal Executive Officer)
EX-31.2 5 d516654dex312.htm CERTIFICATION Certification

Exhibit 31.2

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

Certification of Chief Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Robert J. Landis, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Comprehensive Care Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements and other financial information included in this quarterly report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

   

/s/ ROBERT J. LANDIS

May 20, 2013     Robert J. Landis
    Chief Financial Officer and Chief Accounting Officer
    (Principal Financial and Accounting Officer)
EX-32.1 6 d516654dex321.htm CERTIFICATION Certification

Exhibit 32.1

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

Certification of CEO Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report of Comprehensive Care Corporation (the “Company”) on Form 10-Q for the quarter ending March 31, 2013 as filed with the Securities and Exchange Commission on May 20, 2013 (the “Report”), Clark A. Marcus, as Chief Executive Officer and Chairman of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ CLARK A. MARCUS

Clark A. Marcus
Chief Executive Officer and Chairman
May 20, 2013
EX-32.2 7 d516654dex322.htm CERTIFICATION Certification

Exhibit 32.2

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

Certification of CFO Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report of Comprehensive Care Corporation (the “Company”) on Form 10-Q for the quarter ending March 31, 2013 as filed with the Securities and Exchange Commission on May 20, 2013 (the “Report”), Robert J. Landis, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ ROBERT J. LANDIS

Robert J. Landis
Chief Financial Officer and Chief Accounting Officer
May 20, 2013
EX-101.INS 8 chcr-20130331.xml XBRL INSTANCE DOCUMENT 0000022872 2013-02-28 0000022872 us-gaap:CommonStockMember us-gaap:WarrantMember 2013-01-01 2013-03-31 0000022872 us-gaap:StockOptionsMember 2012-03-12 2012-12-31 0000022872 us-gaap:StockOptionsMember 2011-01-01 2011-12-31 0000022872 us-gaap:StockOptionsMember 2012-12-31 0000022872 us-gaap:StockOptionsMember 2011-12-31 0000022872 us-gaap:StockOptionsMember 2013-01-01 2013-03-31 0000022872 us-gaap:StockOptionsMember 2012-01-01 2012-03-31 0000022872 us-gaap:StockOptionsMember 2013-03-31 0000022872 us-gaap:StockOptionsMember 2012-03-31 0000022872 chcr:NonQualifiedDirectorsPlanMember 2013-03-31 0000022872 us-gaap:WarrantMember us-gaap:CommonStockMember 2012-03-12 2012-12-31 0000022872 us-gaap:WarrantMember us-gaap:CommonStockMember 2011-01-01 2011-12-31 0000022872 us-gaap:SeriesCPreferredStockMember 2013-03-31 0000022872 chcr:OtherSeriesPreferredStockMember 2013-03-31 0000022872 us-gaap:SeriesCPreferredStockMember 2012-12-31 0000022872 chcr:OtherSeriesPreferredStockMember 2012-12-31 0000022872 us-gaap:StockOptionMember 2013-01-01 2013-03-31 0000022872 us-gaap:StockOptionMember 2012-01-01 2012-03-31 0000022872 us-gaap:ConvertiblePreferredStockMember 2013-01-01 2013-03-31 0000022872 us-gaap:ConvertiblePreferredStockMember 2012-01-01 2012-03-31 0000022872 us-gaap:WarrantMember 2012-01-01 2012-03-31 0000022872 us-gaap:MinimumMember us-gaap:StockOptionMember 2013-01-01 2013-03-31 0000022872 chcr:SeriesDConvertiblePreferredStockMember 2013-01-01 2013-03-31 0000022872 chcr:FourteenPercentSeniorPromissoryNotesMember 2013-01-01 2013-03-31 0000022872 chcr:TenPercentConvertiblePromissoryNotesMember 2013-03-31 0000022872 chcr:SevenPercentConvertiblePromissoryNotesMember 2013-03-31 0000022872 chcr:ZeroCouponNotesMember 2013-03-31 0000022872 chcr:SeniorPromissoryNotesMember 2013-03-31 0000022872 chcr:PromissoryNotesMember 2013-03-31 0000022872 chcr:LongTermPromissoryNotesMember 2013-03-31 0000022872 chcr:DebenturesMember 2013-03-31 0000022872 us-gaap:ConvertibleNotesPayableMember 2013-05-08 0000022872 chcr:FourteenPercentSeniorPromissoryNotesMember 2013-03-15 0000022872 chcr:SeriesDConvertiblePreferredStockMember 2013-03-31 0000022872 us-gaap:SubsequentEventMember 2013-04-11 0000022872 us-gaap:MinimumMember 2013-03-31 0000022872 us-gaap:MaximumMember 2013-03-31 0000022872 2012-03-31 0000022872 2011-12-31 0000022872 2012-01-01 2012-03-31 0000022872 us-gaap:WarrantMember 2013-01-01 2013-03-31 0000022872 us-gaap:StockOptionMember 2013-01-01 2013-03-31 0000022872 2012-12-31 0000022872 2013-05-16 0000022872 us-gaap:WarrantMember us-gaap:MinimumMember 2013-01-01 2013-03-31 0000022872 us-gaap:MaximumMember us-gaap:WarrantMember 2013-01-01 2013-03-31 0000022872 chcr:StockIncentiveCompensationPlansMember us-gaap:MaximumMember 2013-03-31 0000022872 chcr:StockIncentiveCompensationPlansMember 2013-03-31 0000022872 us-gaap:WarrantMember us-gaap:CommonStockMember 2012-12-31 0000022872 us-gaap:WarrantMember us-gaap:CommonStockMember 2011-12-31 0000022872 us-gaap:WarrantMember us-gaap:CommonStockMember 2013-01-01 2013-03-31 0000022872 us-gaap:WarrantMember us-gaap:CommonStockMember 2012-01-01 2012-03-31 0000022872 us-gaap:WarrantMember us-gaap:CommonStockMember 2013-03-31 0000022872 us-gaap:WarrantMember us-gaap:CommonStockMember 2012-03-31 0000022872 chcr:ZeroCouponConvertiblePromissoryNotesMember 2013-02-01 2013-02-28 0000022872 us-gaap:SeriesDPreferredStockMember 2013-03-31 0000022872 us-gaap:SeriesDPreferredStockMember 2012-12-31 0000022872 us-gaap:CommonStockMember 2013-01-01 2013-03-31 0000022872 chcr:NonQualifiedDirectorsPlanMember 2013-01-01 2013-03-31 0000022872 us-gaap:ConvertiblePreferredStockMember 2013-03-31 0000022872 us-gaap:LetterOfCreditMember 2013-01-01 2013-03-31 0000022872 us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2013-01-01 2013-03-31 0000022872 us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2013-05-03 0000022872 chcr:CustomerAgreementMember 2013-03-31 0000022872 us-gaap:SubsequentEventMember 2013-05-08 0000022872 chcr:NonQualifiedDirectorsPlanMember chcr:InitialMember 2013-01-01 2013-03-31 0000022872 us-gaap:MinimumMember 2013-01-01 2013-03-31 0000022872 us-gaap:MaximumMember 2013-01-01 2013-03-31 0000022872 2013-03-31 0000022872 chcr:TenPercentConvertiblePromissoryNotesMember 2013-03-01 2013-03-31 0000022872 chcr:SevenPercentConvertiblePromissoryNotesMember 2013-03-01 2013-03-31 0000022872 chcr:ConvertiblePromissoryNotesPayableMember 2013-02-16 2013-03-15 0000022872 us-gaap:ConvertibleNotesPayableMember 2013-01-01 2013-03-31 0000022872 chcr:FourteenPercentConvertiblePromissoryNoteMember 2013-01-01 2013-01-31 0000022872 chcr:FourteenPercentSeniorPromissoryNotesMember 2013-05-13 0000022872 chcr:ConvertiblePromissoryNotesPayableMember 2013-03-15 0000022872 chcr:ConvertiblePromissoryNotesPayableMember us-gaap:MaximumMember 2013-03-15 0000022872 us-gaap:LoansPayableMember 2013-03-15 0000022872 us-gaap:ConvertibleNotesPayableMember 2013-03-15 0000022872 chcr:FourteenPercentConvertiblePromissoryNoteMember 2013-01-31 0000022872 2010-09-01 2010-09-30 0000022872 us-gaap:SubsequentEventMember 2013-03-12 2013-04-11 0000022872 chcr:FourteenPercentSeniorPromissoryNotesMember 2013-04-14 2013-05-13 0000022872 us-gaap:ConvertibleNotesPayableMember 2013-03-31 0000022872 2013-03-15 0000022872 2013-05-13 0000022872 2013-04-14 2013-05-13 0000022872 chcr:RevolvingConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2013-01-01 2013-03-31 0000022872 2013-01-01 2013-03-31 chcr:Plan chcr:Person iso4217:USD xbrli:shares iso4217:USD chcr:Unit xbrli:pure xbrli:shares iso4217:USD <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock--> <!-- xbrl,ns --> <!-- xbrl,nx --> <font style="display:none"></font> <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>N<small>OTE</small> 1 &#8211; D<small>ESCRIPTION</small> <small>OF</small> <small>THE</small> C<small>OMPANY</small>&#8217;<small>S</small> B<small>USINESS</small> <small>AND</small> B<small>ASIS</small> <small>OF</small> P<small>RESENTATION</small> </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The accompanying unaudited interim condensed consolidated financial statements for Comprehensive Care Corporation (referred to herein as the &#8220;Company,&#8221; or &#8220;CompCare&#8221;) and its subsidiaries have been prepared in accordance with the Securities and Exchange Commission (&#8220;SEC&#8221;) rules for interim financial information and do not include all information and notes required for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Interim results for the current period are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the consolidated financial statements and the notes thereto in our most recent annual report on Form 10-K. Certain minor reclassifications of prior period amounts have been made to conform to the current period presentation. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Our consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, each with their respective subsidiaries (collectively referred to herein as &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;). We provide managed care services in the behavioral health, substance abuse, and pharmacy management fields for commercial, Medicare, Medicaid and Children&#8217;s Health Insurance Program (&#8220;CHIP&#8221;) health plans, as well as self-insured companies, unions, and Taft-Hartley health and welfare funds. Our managed care operations include administrative service agreements, fee-for-service agreements, and capitation contracts. The customer base for our services includes both private and governmental entities. Our services are provided by unrelated vendors on a subcontract basis. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Under our at-risk contracts, we assume the financial risk for the costs of member behavioral healthcare services in exchange for a fixed, per member per month fee. Under our administrative services only (&#8220;ASO&#8221;) contracts, we may manage behavioral healthcare programs or perform various managed care functions, such as clinical care management, provider network development and claims processing without assuming financial risk for member behavioral healthcare costs. Under our pharmacy contracts, we manage behavioral pharmaceutical services for the members of health plans on an at-risk or ASO basis. In general, our contracts with our other customers have one or two year initial terms, with automatic annual extensions. Such contracts generally provide for cancellation by either party upon 60 to 90 days written notice or the right to request a renegotiation of terms under certain circumstances. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 2 - us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>N<small>OTE</small> 2 &#8211; A<small>CCOUNTS</small> R<small>ECEIVABLE</small> </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Our trade accounts receivable at March&#160;31, 2013 and December&#160;31, 2012 consists primarily of receivables related to our major contract in Puerto Rico that expired December&#160;31, 2012. During the three months ended March&#160;31, 2013, we collected approximately $2.3 million from our Puerto Rico client. The receivable balance was further reduced by approximately $1.0 million of claims paid on our behalf by the Puerto Rico client. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Pursuant to an Assignment agreement executed April&#160;10, 2013 and effective March&#160;15, 2013, $1 million of the accounts receivable balance of approximately $1.3 million as of March&#160;31, 2013 is assigned to two creditors as partial payment of their loans. See Note 3 &#8220;Notes Payable.&#8221; </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 3 - us-gaap:ShortTermDebtTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>N<small>OTE</small> 3 &#8211; N<small>OTES</small> P<small>AYABLE</small> </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In January 2013, a 14%, $100,000 convertible promissory note matured and was renewed on the same terms until April&#160;30, 2013 at which time the note was again renewed. The new note utilizes the same terms as the previous note and has a maturity date of July&#160;31, 2013. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2"> In February 2013, a zero coupon promissory note in the amount of $230,000 matured and was replaced by a new note of similar terms with a face value of $230,000 and a maturity date of May&#160;31, 2012. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In March 2013, we renewed a 10% promissory note in the amount of $100,000 and a 7% promissory note in the amount of $50,000, each for additional one-year terms. One of the note holders was issued a three-year warrant to purchase 25,000 shares of our common stock at an exercise price of $0.15. </font></p> <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p> <p style="margin-top:0px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">On March&#160;15, 2013, we executed an agreement with a creditor to modify the terms of a previously matured but unpaid promissory note in the amount of $1.4 million. Under the modified terms of the note, the maturity date was extended from February&#160;28, 2013 to January&#160;31, 2014 and the conversion price at which the note may be converted into our common stock was reduced to $0.125 from $0.25. In addition, the exercise price of a warrant to purchase our common stock issued in conjunction with the note was reset from $0.44 to $0.22. We also assigned certain receivables (see Note 2 &#8220;Accounts Receivable&#8221;) and a potential arbitration recovery to the creditor as a source of future repayment of a second loan from the creditor in the amount of $625,000 maturing May&#160;14, 2013 and a $75,000 loan from an individual related to the creditor also due on May&#160;14, 2013. Any proceeds remaining from the assigned receivables and potential recovery after repayment of the aforementioned loans will be used to reduce the principal of the $1.4 million loan, but not in excess of $300,000. The modification was accounted for as a troubled debt restructuring, but we recognized no gain because the effective interest rate of the modified promissory note was less than the effective interest rate of the original promissory note. <i></i> </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">We were unable to repay our 14% senior promissory notes in the amount of approximately $1.8 million on the maturity date of April&#160;15, 2013. We are currently in negotiations with the holders to resolve the default. We completed an agreement to extend the maturity date for approximately $1.3 million of the notes on May&#160;13, 2013. See Note 4 &#8220;Long Term Debt.&#8221; In addition, we were not able to repay a $1 million loan due May&#160;8, 2013. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">On May&#160;8, 2013, we executed an agreement with a creditor to modify the terms of a promissory note in the amount of $625,000. Under the modified terms of the note, the maturity date was extended from May&#160;14, 2013 to July&#160;15, 2013 and the conversion price at which the note may be converted into our common stock was reduced to $0.125 from $0.25. In addition, the exercise price of a warrant to purchase our common stock issued in conjunction with the note was reset from $0.44 to $0.22. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 4 - us-gaap:LongTermDebtTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>N<small>OTE</small> 4 L<small>ONG</small> T<small>ERM</small> D<small>EBT</small> </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">On May 13, 2013, we executed an agreement with a holder of approximately $1.3 million of our senior promissory notes to extend the maturity date of the notes from April 15, 2013 to April 15, 2014. We also agreed to extend the term of approximately 5.2 million warrants that had been issued at the time the notes were issued in April 2010 for an additional two years, such that the warrants will now expire in 2017. In conjunction with the renewal, we will issue 774,391 shares of our common stock to the lender relating to 50% of the interest and fees owed as of April 15, 2013. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 5 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>N<small>OTE</small> 5 C<small>ONTINGENCIES</small> </b></font></p> <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Economic conditions and related risks, concentrations and uncertainties: </i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The United States and other parts of the world have been experiencing a severe and widespread recession accompanied by, among other things, instability in the financial markets and reduced credit availability, which are likely to continue to have far reaching effects on economic activity for an indeterminate period. The probable duration and effects and probable duration of these conditions on our ability to obtain continued support from our major stockholders and lenders, success in our marketing efforts, and ultimately, profitable operations and positive cash flows, cannot be estimated at this time. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">We occasionally carry cash and equivalents on deposit with financial institutions in excess of federally-insured limits, and the risk of losses related to such concentrations may be increasing as a result of recent economic developments discussed in the foregoing paragraph. The extent of a loss to be sustained as a result of uninsured deposits in the event of a future failure of a financial institution, if any, however, is not subject to estimation at this time. </font></p> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Going concern uncertainty: </i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">At March&#160;31, 2013, we had a working capital deficiency of approximately $23.0 million and a stockholders&#8217; equity deficiency of approximately $24.1 million resulting from a history of operating losses. Approximately $2.9 million of debt was past due and therefore in default as of March&#160;31, 2013. As a result of these conditions, and the aforementioned economic conditions and related risks, our ability to continue as a going concern will be dependent upon the success of management&#8217;s plans, as set forth in the following paragraph, and is subject to significant uncertainty. Except for the consideration in determining the valuation allowance for deferred tax assets from net operating loss carryforwards (Note 8), the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty. </font></p> <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p> <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Need for Additional Financing </i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Our existing capital may not be sufficient to meet our cash needs. We expect that with our new Senior Secured Revolving Credit Facility (see Note 10 &#8220;Subsequent Event&#8221;), existing customer contracts, the addition of new pharmacy management contracts that we are close to obtaining through our marketing efforts, the collection of receivables, and the extension of vendor payments, that we will be able to sustain current operations over the near term. However, we continue to look at various alternative sources of financing if operations cannot support our ongoing plan. Nevertheless, there can be no assurance that we will be able to find such financing in amounts or on terms acceptable to us, if at all, or that we will be able to achieve or sustain profitable operations and positive operating cash flows in the near term. Although subject to the general economic conditions, risks and uncertainties discussed in the preceding paragraphs, management believes that our current cash position will likely be sufficient to meet our current levels of operations in the short term, our ability to achieve our business objectives and continue as a going concern for a reasonable period of time is dependent upon the success of our plans to obtain sufficient debt or equity financing, and, ultimately, to achieve profitable operations and positive cash flows from operations during 2013. </font></p> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Concentration, major customer contract: </i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">We currently provide behavioral health services on an at-risk basis to approximately 37,000 members of a health plan providing Medicare benefits. The contract accounted for 43.5%, or $529,000 of our revenue for the three months ended March&#160;31, 2013. This contract is for a three year period effective January&#160;1, 2012 and may be terminated by either party with 90 days written notice. </font></p> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Legal matters: </i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2"> From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. Aside from the litigation described below, as of the date of this report, we are not currently involved in any legal proceeding that we believe would have a material adverse effect on our business, financial condition or operating results. </font></p> <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p> <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"><font size="1">&#160;</font></td> <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">(1)</font></td> <td align="left" valign="top"> <p align="left"><font style="font-family:times new roman" size="2">We initiated an action against Jerry Katzman, a former director, in July 2009 alleging that Mr.&#160;Katzman fraudulently induced us to enter into an employment agreement and, alternatively, that Mr.&#160;Katzman breached that alleged employment agreement and was rightfully terminated. In September 2010, the matter proceeded to a trial by jury. The jury found that Mr.&#160;Katzman did not fraudulently induce CompCare to enter into the contract but also found that Mr.&#160;Katzman was not entitled to damages. On defendant&#8217;s motion to amend the verdict due to inconsistency, the trial court set aside the jury verdict and awarded Mr.&#160;Katzman damages of approximately $1.3 million. The Company appealed the lower court&#8217;s decision and posted a collateralized appeal bond for approximately $1.3 million. On February&#160;14, 2013, the 11</font><font style="font-family:times new roman" size="1"> <sup>th</sup></font><font style="font-family:times new roman" size="2"> Circuit Court of Appeals of the State of Florida reversed the lower court&#8217;s judgment in favor of Katzman and remanded the case for a new trial on both liability and damages. The appellate court also taxed appellate costs in favor of CompCare against Katzman. The decision of the appellate court also reverses the lower court&#8217;s award of attorney&#8217;s fees previously awarded to Katzman against CompCare and the need for us to maintain an appeal bond for approximately $1.3 million. </font></p> </td> </tr> </table> <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p> <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"><font size="1">&#160;</font></td> <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">(2)</font></td> <td align="left" valign="top"><font style="font-family:times new roman" size="2">We and a former health plan client are being sued for damages of approximately $1.7 million for allegedly unpaid claims for behavioral health professional services rendered in, 2007 and 2008. We filed a counterclaim for breach of a settlement agreement that we believed resolved many of the claims that are the subject of the complaint, which we therefore, now believe is without merit and are vigorously opposing. </font></td> </tr> </table> <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p> <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"><font size="1">&#160;</font></td> <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">(3)</font></td> <td align="left" valign="top"><font style="font-family:times new roman" size="2">We are in arbitration with a former health plan client in Missouri relating to its allegation that we breached our obligation to pay claims submitted to us for payment. The arbitration is underway but has not yet progressed significantly. </font></td> </tr> </table> <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p> <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"><font size="1">&#160;</font></td> <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">(4)</font></td> <td align="left" valign="top"><font style="font-family:times new roman" size="2">A group of health care providers in the state of Louisiana has filed suit against us claiming breach of contract in that we failed to pay claims submitted to us for payment. The litigation is currently in the discovery stage. </font></td> </tr> </table> <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p> <p style="margin-top:0px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Management believes that it has established a provision for legal expenses that it believes is adequate for the estimated probable minimum losses, including legal defense costs, to be incurred from these matters. </font></p> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Other: </i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In connection with our former major contract to provide mental health, substance abuse and pharmacy prescription drugs management services in Puerto Rico, we obtained a letter of credit from a bank for $4,000,000 to assure the customer of our compliance with our obligations under the agreement. The letter of credit extends past the expiration date of the contract, decreasing at the rate of $666,667 monthly until the letter&#8217;s termination on June&#160;30, 2013. Under such agreement, the customer may draw on all or part of the letter of credit under certain defined circumstances. Collateral for the letter of credit was provided by a major stockholder of the Company. If the client draws upon the letter of credit, we may become liable to our major stockholder for the amount of collateral accessed by the bank to fulfill its obligations thereunder. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 6 - us-gaap:FairValueDisclosuresTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>N<small>OTE</small> 6 &#8211; F<small>AIR</small> <small>VALUE</small> <small>OF</small> <small>FINANCIAL</small> <small>INSTRUMENTS</small> </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The carrying amounts of cash, accounts receivable and accounts payable approximate their estimated fair value due to the short-term nature of these instruments. Since our other financial liabilities are not traded in an open market, we generally use a present value technique, which is a level 3 input, as defined in generally accepted accounting principles, to measure the estimated fair value of these financial instruments, except for valuing stock options and warrants. The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The carrying amounts and estimated fair values of these financial instruments (all are liabilities) at March&#160;31, 2013, are as follows (in thousands): </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="79%">&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>Carrying</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>Estimated</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Amount</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Fair&#160;Value</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Promissory notes</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,880</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,853</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Zero-coupon promissory notes</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">230</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">225</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Debentures</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">537</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">534</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Senior promissory notes</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,771</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,770</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Long-term promissory notes</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">125</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">121</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Less: unamortized discount</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(39</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net liabilities</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,504</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,503</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Due to the inherent nature of related party transactions, we have not attempted to estimate the fair value of liabilities payable to related parties of the Company. As such, promissory notes payable with a carrying value of $3,000,000 are excluded from the table above. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 7 - us-gaap:StockholdersEquityNoteDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>N<small>OTE</small> 7 &#8211; E<small>QUITY</small> I<small>NSTRUMENTS</small> </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Our Series C preferred stock is currently convertible into common stock at the rate of approximately 316.28 common shares for each share of Series C preferred, adjustable for any dilutive issuances of common occurring in the future. Series C preferred shares vote with the common stockholders on an as-converted basis. The shares are nonparticipating except that dividends, when declared by our Board of Directors on the common stock, must be paid on the Series C stock on an as-converted basis before any dividends are paid on our common stock. The Series C is also cumulative with respect to dividends on common stock and junior series of preferred stock. Other significant rights and preferences of the Series C preferred include: </font></p> <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p> <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="8%"><font size="1">&#160;</font></td> <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">&#8226;</font></td> <td width="1%" valign="top"><font size="1">&#160;</font></td> <td align="left" valign="top"> <p align="left"><font style="font-family:times new roman" size="2">the right to vote as a separate class to appoint five directors of the Company, and </font></p> </td> </tr> </table> <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p> <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="8%"><font size="1">&#160;</font></td> <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">&#8226;</font></td> <td width="1%" valign="top"><font size="1">&#160;</font></td> <td align="left" valign="top"> <p align="left"><font style="font-family:times new roman" size="2">liquidation preferences, whereby the Series C holders have a claim against our assets senior to the claim of the holders of our common stock in the event of our liquidation, dissolution or winding-up (the value of the liquidation preference is $250 per share, or approximately $2.6 million at March&#160;31, 2013). </font></p> </td> </tr> </table> <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p> <p style="margin-top:0px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">We also have a class of convertible preferred stock, Series D, for which 7,000 shares are authorized and 250 shares were issued and outstanding as of March&#160;31, 2013. The shares, which were granted in January 2012, do not vest until the tenth anniversary of the grant date. Such shares were issued in exchange for the cancelation of 120 previously granted warrants to purchase Series D shares. Once vested, a Series D preferred share will be convertible at any time into 100,000 shares of common stock, subject to adjustment in the event of any common stock dividend, split, combination thereof or other similar recapitalization, without additional consideration. Prior to vesting and thereafter, each Series D convertible preferred share is entitled to all voting, dividend, liquidation and other rights accorded a share of Series D convertible preferred stock. As to dividends, the Series D stock is noncumulative. If a dividend is declared on the common stock, each share of Series D stock is entitled to receive a dividend equal to 50% of the dividend declared for the common stock as if the Series D stock had been converted. Despite their nonvested status, voting rights of each share nevertheless consist of the right to cast the number of votes equal to those of 500,000 shares of common stock. Unless otherwise required by applicable law, holders of shares of Series D have the right to vote together with holders of common stock as a single class on all matters submitted to a vote of our stockholders. At March&#160;31, 3013, approximately $3.3 million of compensation expense remained to be recognized over the next 8.8 years related to the Series D shares. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2"> We may periodically issue shares of common stock as payment for services, interest and debt. During the three months ended March&#160;31, 2013, we issued 325,000 shares of common stock to consultants in lieu of cash payment. </font></p> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><u>S<small>TOCK</small> I<small>NCENTIVE</small> C<small>OMPENSATION</small> P<small>LANS</small></u><small></small> </font></p> <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>WARRANTS: </i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">We periodically issue warrants to purchase shares of our common and preferred stock for the services of employees and non-employee directors. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2"> During the quarter ended March&#160;31, 2013, we issued to note holders and consultants warrants to purchase an aggregate of 1.7&#160;million shares of our common stock. The warrants were immediately exercisable at prices ranging from $0.15 to $0.25 and had terms of from two to three years. We recognized approximately $56,000 of compensation costs related to warrants during the three months ended March&#160;31, 2013. Total unrecognized compensation costs related to warrants as of March&#160;31, 2013 was approximately $1,000 which is expected to be recognized over a weighted-average period of nine months. The total fair value of warrants vested during the three months ended March&#160;31, 2013 was approximately $59,000. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">A summary of our warrant activity for the three months ended March&#160;31, 2013 and 2012 follows: </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="54%">&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> <p style="border-bottom:1px solid #000000;width:33pt"><font style="font-family:times new roman" size="1"><b>Warrants</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Shares</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted-<br />Average<br />Exercise<br />Price</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted-Average<br />Remaining<br />Contractual Term</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Aggregate<br />Intrinsic&#160;Value</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at January&#160;1, 2013</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">35,957,583</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">4.26&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,700,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.25</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Forfeited or expired</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(325,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.37</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at March&#160;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">37,332,583</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">4.00 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercisable at March&#160;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">37,298,583</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">4.00 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td height="8">&#160;</td> <td height="8" colspan="4">&#160;</td> <td height="8" colspan="4">&#160;</td> <td height="8" colspan="2">&#160;</td> <td height="8" colspan="4">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at January&#160;1, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">41,057,583</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.35</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">4.86 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">25,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.25</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Forfeited or expired</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(100,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.53</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at March&#160;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">40,982,583</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.35</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">4.61 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercisable at March&#160;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">39,315,583</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">4.67 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <!-- End Table Body --> </table> <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p> <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>OPTIONS: </i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">From time-to-time, we grant stock options as compensation for services to our employees, non-employee directors and certain consultants (&#8220;grantees&#8221;) allowing grantees to purchase our common stock pursuant to stockholder-approved stock option plans. We currently have three active incentive qualified option plans, the 1995 Incentive Plan, the 2002 Incentive Plan and the 2009 Equity Compensation Plan (collectively, the &#8220;Plans&#8221;), that provide for the granting of stock options, stock appreciation rights, limited stock appreciation rights, restricted preferred stock, and common stock grants to grantees. Grants issued under the Plans may qualify as incentive stock options (&#8220;ISOs&#8221;) under Section&#160;422A of the Internal Revenue Code of 1986, as amended. Options for ISOs may be granted for terms of up to ten years. The vesting of options issued under the 1995 and 2002 plans generally occurs after six months for one-half of the options and after 12 months for the remaining options. For the 2009 Equity Compensation Plan, the vesting period is determined by the Compensation Committee. The exercise price for ISOs must equal or exceed the fair market value of the shares on the date of grant. The Plans also provide for the full vesting of all outstanding options under certain change of control events. The maximum number of common shares authorized for issuance of options totals 52,000,000 under the Plans. As of March&#160;31, 2013, there were a total of 44,668,000 options available for grant and 6,328,000 options outstanding, 6,011,334 of which were exercisable, under the Plans. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In addition, under our Non-employee Directors&#8217; Stock Option Plan, we are authorized to issue non-qualified stock options to our non-employee directors for up to 1,000,000 common shares. Each non-qualified stock option is exercisable at a price equal to the average of the closing bid and asked prices of the common stock in the over-the-counter market for the most recent preceding day there was a sale of the stock prior to the grant date. Grants of options vest in accordance with vesting schedules established by our Board of Directors&#8217; Compensation and Stock Option Committee. Upon joining our Board of Directors, directors receive an initial grant of 25,000 options. Annually, directors are granted 15,000 options on the date of our annual meeting. As of March&#160;31, 2013, there were 801,668 shares available for option grants and 100,000 options outstanding under the non-qualified directors&#8217; plan, 80,000 of which were exercisable. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">A summary of our option activity for the three months ended March&#160;31, 2013 and 2012 follows: </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="55%">&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> <p style="border-bottom:1px solid #000000;width:27pt"><font style="font-family:times new roman" size="1"><b>Options</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Shares</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted-<br />Average<br />Exercise<br />Price</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted-Average<br />Remaining<br />Contractual Term</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Aggregate<br />Intrinsic&#160;Value</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at January&#160;1, 2013</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,618,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.32</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">8.29&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Forfeited or expired</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(190,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.79</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at March&#160;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,428,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.31</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">8.15&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercisable at March&#160;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,091,334</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.31</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">8.11&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td height="8">&#160;</td> <td height="8" colspan="4">&#160;</td> <td height="8" colspan="4">&#160;</td> <td height="8" colspan="2">&#160;</td> <td height="8" colspan="4">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at January&#160;1, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,795,400</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">7.74 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Forfeited or expired</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(40,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.38</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at March&#160;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,755,400</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">7.49&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercisable at March&#160;31, 20112</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,004,400</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">7.40&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <!-- End Table Body --> </table> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Total recognized compensation costs during the three months ended March&#160;31, 2013 were approximately $15,000. As of March&#160;31, 2013, there was approximately $35,000 of unrecognized compensation cost related to options expected to be recognized over a weighted-average period of 8 months. We might have recognized approximately $3,000 of tax benefits attributable to stock-based compensation expense recorded during the quarter ended March&#160;31, 2013. However, this potential benefit was fully offset by our valuation allowance due to the aforementioned significant uncertainty of future realization. The total fair value of options vested during the three months ended March&#160;31, 2013 was approximately $10,000. </font></p> <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 8 - us-gaap:IncomeTaxDisclosureTextBlock--> <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>N<small>OTE</small> 8 &#8211; I<small>NCOME</small> <small>TAXES</small> </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">We are subject to the income tax jurisdictions of the U.S. and multiple state tax jurisdictions. Our provision for income taxes for the three months ended March&#160;31, 2013 and 2012 was attributable to certain states. The effective income tax rate for the three months ended March&#160;31, 2013 and 2012 was 0.2% and 3.6%, respectively. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">At March&#160;31, 2013, we have federal net operating loss carryforwards of approximately $34.4 million, the deductibility of $29.2 million of which is presently limited under Section&#160;382 of the Internal Revenue Code. Approximately $361,000 of any net operating losses prior to the January 2009 ownership change (&#8220;the earlier change&#8221;) can be used to offset taxable income annually. In addition, we can offset our taxable income each year by approximately $274,000 of the net operating losses which incurred between the earlier change and the August 2011 ownership change. We estimate that 59.3% of the $29.2 million pre-change losses will expire and be unavailable to offset our future taxable income. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Management has evaluated our tax positions taken or to be taken on income tax returns that remain subject to examination (<i>i.e.,</i> tax years 2009 and thereafter federally, earlier for certain other jurisdictions), and has concluded that there are no uncertain tax positions, as defined in generally accepted accounting principles, that require recognition or disclosure in the consolidated financial statements. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 9 - us-gaap:EarningsPerShareTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>N<small>OTE</small> 9 &#8211; P<small>ER</small> <small>SHARE</small> <small>DATA</small> </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">For the periods presented, the following table sets forth the computation of basic and diluted earnings per share attributable to common stockholders (amounts in thousands, except per share data): </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="80%">&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>March&#160;31,</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Numerator:</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net (loss) income attributable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(1,407</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">80</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Denominator:</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average common shares &#8211; basic</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">59,745</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">59,252</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Effect of dilutive securities:</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Series C convertible preferred stock</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,300</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock options</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average common shares &#8211; diluted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">59,745</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">62,552</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td height="8">&#160;</td> <td height="8" colspan="4">&#160;</td> <td height="8" colspan="4">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Earnings per share:</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Basic</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.02</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.00</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Diluted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.02</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.00</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 10 - us-gaap:ScheduleOfSubsequentEventsTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>N<small>OTE</small> 10 &#8211; S<small>UBSEQUENT</small> E<small>VENTS</small> </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Other than the changes in our outstanding debt instruments described in Notes 3 and 4, no events were identified that in our opinion require accounting recognition or disclosure in these financial statements, with the exception of the following: </font></p> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Senior Secured Revolving Credit Facility </i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">On May&#160;3, 2013, we entered into a Senior Secured Revolving Credit Facility Agreement that will allow us to borrow up to $5,000,000 to fund our general working capital needs. Our initial draw on the credit facility occurred May&#160;3, 2013 in the amount of approximately $884,000, which represents an initial draw of $1 million less transaction expenses. The credit facility is guaranteed by the current and future assets of CompCare and its subsidiaries, with the exception of our Puerto Rico subsidiary. Borrowings under the credit facility will bear interest at an annual rate of 12%, payable weekly. The credit facility will mature on November&#160;3, 2013, at which time we may request an extension of the maturity date for an additional six month period provided that we are not in default in any respect, which may be accepted or rejected by the lender in its sole discretion. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2"> The Agreement contains financial covenants such as, but not limited to, minimum revenues, positive earnings before interest, tax, depreciation and amortization expenses, and loan-to-value ratio. The Agreement also specifies events of default and related remedies, including acceleration and increased interest rates following an event of default. Loans under the credit facility will be evidenced by a Revolving Convertible Promissory Note. At any time while the Note remains outstanding, subject to certain limitations, the lender may convert all or any portion of the outstanding principal, accrued but unpaid interest and other sums payable under the Note into shares of our common stock at a price equal to (i)&#160;the amount to be converted, divided by (ii)&#160;85% of the lowest daily volume weighted average price of our common stock during the five business days immediately prior to the conversion date. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">As consideration for investment banking and advisory services provided to us by the lender, we paid a fee to the lender in the form of 1,470,588 shares of our common stock, issued on May&#160;8, 2013. The shares and the Note were issued by the Company upon reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended, provided in Section&#160;4(2) thereof. </font></p> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Warrant issuance </i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2"> On April&#160;11, 2013, we issued warrants to purchase 2,000,000 shares of our common stock to a company in lieu of cash compensation for consulting and pharmacy analytical services. The warrants, which expire in April 2016, were vested in full at issuance and can be exercised at a price of $0.20 per share. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: note6_table1 - us-gaap:FairValueByBalanceSheetGroupingTextBlock--> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The carrying amounts and estimated fair values of these financial instruments (all are liabilities) at March&#160;31, 2013, are as follows (in thousands): </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="79%">&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>Carrying</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>Estimated</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Amount</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Fair&#160;Value</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Promissory notes</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,880</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,853</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Zero-coupon promissory notes</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">230</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">225</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Debentures</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">537</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">534</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Senior promissory notes</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,771</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,770</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Long-term promissory notes</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">125</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">121</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Less: unamortized discount</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(39</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net liabilities</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,504</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,503</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: note7_table1 - us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock--> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">A summary of our warrant activity for the three months ended March&#160;31, 2013 and 2012 follows: </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="54%">&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> <p style="border-bottom:1px solid #000000;width:33pt"><font style="font-family:times new roman" size="1"><b>Warrants</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Shares</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted-<br />Average<br />Exercise<br />Price</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted-Average<br />Remaining<br />Contractual Term</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Aggregate<br />Intrinsic&#160;Value</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at January&#160;1, 2013</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">35,957,583</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">4.26&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,700,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.25</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Forfeited or expired</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(325,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.37</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at March&#160;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">37,332,583</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">4.00 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercisable at March&#160;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">37,298,583</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">4.00 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td height="8">&#160;</td> <td height="8" colspan="4">&#160;</td> <td height="8" colspan="4">&#160;</td> <td height="8" colspan="2">&#160;</td> <td height="8" colspan="4">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at January&#160;1, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">41,057,583</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.35</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">4.86 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">25,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.25</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Forfeited or expired</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(100,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.53</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at March&#160;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">40,982,583</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.35</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">4.61 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercisable at March&#160;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">39,315,583</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">4.67 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: note7_table2 - us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock--> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">A summary of our option activity for the three months ended March&#160;31, 2013 and 2012 follows: </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="55%">&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> <p style="border-bottom:1px solid #000000;width:27pt"><font style="font-family:times new roman" size="1"><b>Options</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Shares</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted-<br />Average<br />Exercise<br />Price</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted-Average<br />Remaining<br />Contractual Term</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Aggregate<br />Intrinsic&#160;Value</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at January&#160;1, 2013</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,618,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.32</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">8.29&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Forfeited or expired</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(190,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.79</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at March&#160;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,428,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.31</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">8.15&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercisable at March&#160;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,091,334</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.31</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">8.11&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td height="8">&#160;</td> <td height="8" colspan="4">&#160;</td> <td height="8" colspan="4">&#160;</td> <td height="8" colspan="2">&#160;</td> <td height="8" colspan="4">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at January&#160;1, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,795,400</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">7.74 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Forfeited or expired</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(40,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.38</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at March&#160;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,755,400</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">7.49&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercisable at March&#160;31, 20112</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,004,400</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.33</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">7.40&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: note9_table1 - us-gaap:ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock--> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">For the periods presented, the following table sets forth the computation of basic and diluted earnings per share attributable to common stockholders (amounts in thousands, except per share data): </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="80%">&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>March&#160;31,</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Numerator:</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net (loss) income attributable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(1,407</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">80</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Denominator:</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average common shares &#8211; basic</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">59,745</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">59,252</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Effect of dilutive securities:</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Series C convertible preferred stock</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,300</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock options</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average common shares &#8211; diluted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">59,745</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">62,552</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td height="8">&#160;</td> <td height="8" colspan="4">&#160;</td> <td height="8" colspan="4">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Earnings per share:</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Basic</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.02</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.00</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Diluted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.02</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.00</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> P5D 0.85 P2Y 5200000 0.44 0.44 2017 2016-04 1300000 774391 1000 At any time while the Note remains outstanding, subject to certain limitations, the lender may convert all or any portion of the outstanding principal, accrued but unpaid interest and other sums payable under the Note into shares of our common stock at a price equal to (i) the amount to be converted, divided by (ii) 85% of the lowest daily volume weighted average price of our common stock during the five business days immediately prior to the conversion date. 100000 625000 75000 300000 0.25 0.25 1300000 2013-04-30 2013-05-14 2013-02-28 2013-04-15 P1Y P1Y 1000000 2900000 135000 P90D P60D P2Y P1Y 25000 1470588 4000000 29200000 1000000 P6M 666667 250 2600000 P3Y 37000 5504000 5503000 361000 274000 1000000 3 5 120 Tax years 2009 and thereafter federally, earlier for certain states 15000 P10Y 0.50 0.50 0.593 0.435 316.28 P90D 230000 529000 0 39315583 37298583 0.33 0.33 P4Y8M1D P4Y 0.53 0.37 0.25 0.25 0.35 0.35 0.33 0.33 6328000 52000000 24100000 P3Y P2Y 1700000 P3Y 23000000 false --12-31 Q1 2013 2013-03-31 10-Q 0000022872 61247424 Smaller Reporting Company COMPREHENSIVE CARE CORP 1110000 1197000 4546000 1336000 25982000 26224000 15000 56000 195000 48000 6124000 3748000 5647000 3360000 920000 1763000 832000 1173000 920000 1763000 341000 843000 0.22 0.15 0.22 0.25 0.15 0.20 25000 2000000 0.01 0.01 200000000 500000000 59776836 59776836 59776836 59776836 594000 598000 100000 16644000 789000 17255000 2220000 1400000 1800000 1000000 625000 537000 125000 2880000 1771000 230000 0.125 0.125 1400000 50000 100000 534000 121000 2853000 1770000 225000 0.14 0.14 0.07 0.10 2013-07-31 2013-05-08 2013-04-15 2013-07-15 2012-05-31 2014-01-31 2014-04-15 39000 34400000 96000 40000 1000000 1000000 0.00 -0.02 0.00 -0.02 0.036 0.002 35000 P8Y9M18D P8M P9M 3300000 3000 515000 1391000 17890000 1217000 83000 -1404000 3000 3000 1000000 3300000 563000 401000 158000 147000 29067000 27852000 6124000 3748000 27335000 26374000 0 13099000 11844000 884000 2013-06-30 2013-11-03 0.12 5000000 1732000 1478000 1300000 -36000 -456000 -1000 378000 1299000 80000 -1407000 80000 -1407000 2000000 2000000 3000000 2008 635000 -1003000 5820000 6187000 181000 261000 305000 256000 2067000 3174000 11000 2239000 972000 8000 1000 50.00 50.00 50.00 50.00 50.00 50.00 974260 14400 7000 974260 7000 14400 7000 10434 250 250 10434 250 10434 250 10434 250 522000 522000 Equal to 500,000 shares of common stock 2300000 100000 172000 132000 128000 456000 -50041000 -51448000 P10Y plans generally occurs after six months for one-half of the options and after 12 months for the remaining options. 100000 325000 25000 1700000 41057583 40982583 35957583 37332583 P4Y10M10D P4Y7M10D P4Y3M4D P4Y 801668 44668000 8004400 6091334 0.33 0.31 P7Y4M24D P8Y1M10D 40000 190000 0.38 0.79 1700000 8795400 8755400 6618000 100000 6428000 0.33 0.33 0.32 0.31 P7Y8M27D P7Y5M27D P8Y3M15D P8Y1M24D 10000 59000 80000 6011334 230000 -22943000 -24104000 325000 0 62552000 59745000 59252000 59745000 59252000 59745000 EX-101.SCH 9 chcr-20130331.xsd XBRL TAXONOMY EXTENSION SCHEMA 0604 - Disclosure - Long Term Debt (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0204 - Disclosure - Long Term Debt link:presentationLink link:calculationLink link:definitionLink 0610 - Disclosure - Subsequent Events (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06061 - Disclosure - Fair Value of Financial Instruments (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0602 - Disclosure - Accounts Receivable (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0210 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0202 - Disclosure - Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 0609 - Disclosure - Per Share Data (Details) link:presentationLink link:calculationLink link:definitionLink 0606 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0605 - Disclosure - Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0509 - Disclosure - Per Share Data (Tables) link:presentationLink link:calculationLink link:definitionLink 0506 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0209 - Disclosure - Per Share Data link:presentationLink link:calculationLink link:definitionLink 0206 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0205 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 0608 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0603 - Disclosure - Notes Payable (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0601 - Disclosure - Description of the Company's Business and Basis of Presentation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0121 - Statement - Consolidated Statements of Operations (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0130 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0120 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0111 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0110 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 06071 - Disclosure - Equity Instruments (Details 1) link:presentationLink link:calculationLink link:definitionLink 0607 - Disclosure - Equity Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 06072 - Disclosure - Equity Instruments (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0507 - Disclosure - Equity Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0201 - Disclosure - Description of the Company's Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0203 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 0207 - Disclosure - Equity Instruments link:presentationLink link:calculationLink link:definitionLink 0208 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 chcr-20130331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 chcr-20130331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 chcr-20130331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 13 chcr-20130331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 15 0001193125-13-228056-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-13-228056-xbrl.zip M4$L#!!0````(`"J*M$+/77,SQ64``+#B!``1`!P`8VACE`,8HDZ/.\7*>KPG[=]G]T(;:0*/FPYQ?(6$X&K/!ET/VQ%IL"-*^76/W_^ MW_\Y_%NAP'X_NCIEOXA`:!X*CPUEV*-K9UQ_974U&&G9[87LI_H_6'O$KJY8 M0P6!\'TQ8H5"`N2(&WA6!19:I>B,[YT)W85[,C`A#US!/.5&?1&$!ZQ^\*41 M_S",!QYKBC`$+,V70;F\]W;O2T.8KZ$:?*E?G%U>'7\Z/F^>_'K,ZK4K^-_% MU>7%5:UUVYNE`I M.]5RM>H4@4;-@V. M;^`,E4+9*8SG0'CR&_B"=[WQ`]G!;TOV9CK4R%D<@9%.Z?>STZ;;$WU>F)S` M$Q/0C7"+7753@AM9_$&RC!TB8P\,0;H2'4:,/@A'`_%AR\C^P$>P=*VG1>?# MUH0J&6^+E2P@M(6Z"D)Q&X(VNR&8H+4$N.?&UZ7W8>N(^XAMS5QTKBO['T4; MH5ED8"08A`Q'\2_X+3V\TI%",T)2Y!B24%8_^??6SV7\KU+9WZLEF*1I^EK`*'$&%WKF./"$ M=UUUP)^X/81\75?]O@JNFZ%ROUZ?B7Y;Z.O?N-8P3?QSX9P`4$9TT?.D%^"2 M5;P#<3OPI2M#BPOS)(RSSC0V@(-F"+X2GS[^;P3X`4$#%:`;J]U*L_5S,LP2 M2G1:6(>EF5,\#8>ZSPWH$4V3GS]FZL/F/BSE.7*?LH!:Z+`!.,3JXL`_@)%> M30>*P,L,JX+5(6@O,^C!6C44_HU5JT2K&L)%:XZ5Z6*`%F=61(MJ0ZZ]%GB9 MO-2(E)B2%Q!=!67B5.X3707&+$)TSD9TCQ:=\S"K+V399?:&?]3:;0ID%A#M,-:X-G.25.XD9:A M%.8)G8MG[II\<]=FM@(K4'O5DFO4FDV M71%P8,1$1D#4U5/:%BC316=JU>N+L`?&'PMLK<1%:0&19ZE;97FES;>-8:U" M8ZZR,:LEE=:#.W=)6E19&3'-3STR)>SWU\5;-6M;%C&^3#_OGOT"P8W0H6S[ M8M5]Z%UU04KD2[C293/5C8S7W8XG^UAK(,^7VU_SZM*K7I_)0/:C?I(0K6!L MO>)!=Z*K'Q.UP$[0W3O$OK.4+&T)-=;;X5-Q9$EM?->!O7K]444Z%"*XOA0: M"L@0-""02H/,55\:H_3HFO9KKXC0L;]\`B6GIFWK&6DG=,9D6BK'1!*-:R/Q M>5W$5D;.>0-?+V&W4CGGK/L%A+WX3G!3W'PG4B1*UU:._R>T`O%%D'>LE+@^ M$.$O&DB10;LK$VEQ`M&WUE=1FE214)%L2_5*2V^U MH^039?B"P7/QDOP^1;@FPCM501>R&MW_3L6(]"/Y:R).2`4`!:#V.Q'?F-Y5 MDEAY_XR/ICK_UNHN^8CCK]40WZS4T6RH]^LS,K*&=W4^>_ M7JKB[#Y_TKEISJW@OB#'J0VT%6#4-N*_$9K?\8U8G:66%&W">L;F^_R`EQ#. M3L%Y]O0COX2R[%)YZG+)I;=WNNC`B_O\T%,[=9O[I'6LPV"\ M7?XF^#^J&+1Q_R3`+IZ\$?CB MZP#8Q2D/P#?&3>J'5JILO+?SA;]3LK-4$]$OXYQ6N8[]!M79Z,H2R6]SG,*K MQ).%O_"^Z,/5-OJRMOJRR//?-FJS7FJS7#7/)HRMM7Z][BEZ&]5:+]5:_$%_ M&XU96XUYXDKI19"+8.G'#G+O)ZS!6R;-GM(A;I5%Y1GO8)EX)^&E7S.93%HJ M#TM:[*"5NE'\C@VXBQH0UZ:$VJ[E__BXYIS3G!RV@;%V*3?RO M[._+U>35M8VNK;VN3;U45WWNC0;UR(2J#\I2ZX);ZZ^.EIPJ8R`5P*^YBL"% M@NMH=,[Q150(..GE428M3"A-"5WV?&'V"ZLK:M1+:D^+^?SH`XJLZY-`AI+[ MJR*^Q=9A?E\C1.ENSMAV=< M#-L::V'5Q6OT'?+>'+/W?$3G?M6EEXJ"CN9:] M5()WGBG]=-(^[N9O-J<+W,%??NL=+*D#/&MGRNGC?)3C/\_G.@MSDNJ^0Z^:%Z3QC?['< M%`.`6G[U%FHNG2\7RN\>D,[3L&KYN?HPFT,R%]-0N__;]>EIFL\CR$UI]FJ? M%@(Q[CQ`VK:&6]SNV4WJL'1;8#)9WJL'FP7EL=6E/8WMT0V3>:[UU4E\!8'E!ZC`KLO.=;Q#18,67B^E12Z(%7\K M%#X',F1-X>(Q4X6"O1SA-60/[EI+>=$7'+]]$G]Q".XS[)G] M/(%MB``,+Y@'&-5?'I@>U\+,@SP-XK"4H6`^P9^7D&"2&VK,UZ=`S.5D%@)8$3OV:4MH8DDL,26\=R2Z,F!'OG*_ MLA;O=H7'T(VG8Q(G>Z&[/)!_T8EOX/R-\J5'/VJ!=PDT`'SZ>='Y""P.7,G] M="^J&7^+;?U*=.[P=#_ZX7O`LG%1;_UQ>Z66E>E6X3E MX,/QGX4P\V31"[TMX,&/W?`]<3U&9"Z['%9@BV+5##10>[8#,PM#>^MV\E8' MV,U,./(A*GC2#'P^.@A4(+9P%`XHX8C<(X-D?)]KH+H0JL%!>7#[/O[95F&H M^G@EA9&=!/\N='A?^J.#$**Z88$8,L@5P&LS(_^"(97TP3;^<8Y_F3[W??QU MT3HFM-(+P.,?>7_P_N_[%<=YSQJYTODXGSBH3S,CW?=;7V:F)$X M4<]#.+NLG?^1'Y9BM?<^-[8Y,=E1[N[GYLGY<7-R3&Y([;QQ)XA:\^3.YZ?( MOD`%F&P?[/SQ-9UH]P;CK MJOZ`!R-(1UD4\,B3(9BC!+>B91_]"TQEX(J;VB#\Z"0F!W,F-L8V5A8KUA!;@"KAA(2"3Z$"E_+YNL=I.+X&R M`OR)$3A!9L0_&`\`=\#%0#8K/9!)03J(95%FZ'$]#14SQP010V.,AH#Z""1F4 M'Q!U8_IQ$.;6&CE@7"!_)+@NLBEUGLU\TU.1[R%4+3AI`O#@SRBP43U5A?OU M'<6#(ZV(0E1ET&B`IR+-^LJ$,`'V%V%@$,&CH'M*APPF^0C($/5.N?#O(JM# M#89L) M[O92F4MDOD%-`W4D/N3D[X%N9:*V89]H M7O`(D'C1M)=:=37OYWQF_=/)9#@7Z*/#APN^`4F$6YS%K MUB2S"/V:L=2T>"C!!)>!Q@=Y%(G"CSPB:A3.>ZI@="Q=26:Q#VP M/VE";;U1S%_&DQ:N^B46V2-]I5, MUN9&$+-1.3-R)#P,`\/JH<'?@+(3R*ZZ$3K`.4"XU%4`/EBBTJ>1J%A/P+>- M@$E:^&0^-R+PE#;H=SBJ1((5HB'-\OJ!SP#&LHB'!2W-US$_MT&^H"$&*ES2 M_;&'H'%I"`(?3$ZA;]MB4R8R94@B"?AQ!)2WPMLF3H"^)&#H3^QKHCX460;/ MF1J$G`=_D;6!6O,B9P)YPC#F666=@_'`FI5A-B20Q[_!DYDBD]?R3AS5#/H" M<'1@5*X/*&+,I`'9S"#6'@WR"(=*?V6>`$>G!GT;PJS=0VB2,#&,Q3".01:= MIXI"*XY\U$V%<2?_24I9-J8>:I(MDRR)!XHH)(I2?B?RM].2!F2=#%E"D&H5 M#`9Y)-8`V5-7!.`

$^M>@X%$,AB-"`>Y21@$+1NYI@ M%;J/-.##/((G0#_<)"L`B[&]6IB\B4(:SQ8C`LJ31`#RT.A:?=^Z&+!T(0D7 MR&M#,/L!7'Q;QJ#TKLP\/@*<(:&%*3!-07\6\T;+;B_$89A:"LA5./P5B"X, MLI!5AV@GW,&;H'#<.$]QI7:CO@TM=SF0P]*BBOE,5P;\X_R^R[?T9F@_&"T7 MMC2D4X#9!3+V"G(X<,5MR.S7OP%3R31@'L6/B;EFQH[]5^Q^5'+=CUIN=+U^ M\?F\-=D+N,IW2.K')[_6CDXGX2Y]K8_)0HAR'&?+.I4D^$)&:W.6.<[;\ONJ ML\U0>2D!:Q*NLH6?E#Q4<$[?^HB:T"M#@$'W5F(BXTV*AM(D3`)FD,0Q9(XDX=1 M?`"^]190#S&I?U,I5J$,\WWT@!U@(Z&;10[B)XC#)G09!K;MPC8;0HCM1)H\ M,J`?N92-V40Q/Q-:>3(3<"P)K)AD*UM"8J3S.^CBD<)92"QKZG89:1/Q@.(+ M1-H:9`K=P.812;9,.(I;X48HA1IHCS^6E5/.*)_H=&S1-2E19S>1Z!LGR\I< M23A#1C!D2A9CJ7/*%^99@S28Z``U5IDQU+MT-@]FV-Q0%,:0/^`CHM>B`X6E MC]X4(CQH*7G:JA72."1!#-;PI=TRA9S43)V00O M>QBLYL+@U.C)&)CO>-?^6,4`"(D]:%Z$[4WK-#AS=GY`WU$N;Y?+9=319#,& MYMOQ;@SJ[D'`"JD+0:T%;BA5'@KRU.AM#,="-,Z40^D3K1,^K9KZM)`->Q(2 M?40W;2`26-[%]#H&;F,,4D/WH7T-CPI(IG4EYQ3\PV2I'J-Y6JE?*T M)*$FM%$:8*;,!.2@BK-LML4;Z\!8J+7]2.2@(K09O#[CTZRN%%.6+B.[ M@=,4^\:Y4J+K8"_E'Q[`Z<2>+$_V'O+(+CUA&RW4D:7VB^?%#AH+ZP)5U"2+ M(KL(TM4"@MA3OH=5.`H49HH(6TH)[6-#^VD!C-B#"(C#_EMEE["T>P<0FHIL M]Q.7"/"\)S14CBTA;(<:M#!IDX#44U>:! MNC%S2?F92XA@1@9&2*6ZDB9TV%])4KW$=I)$"<705Y[LV,36VAI MG;:C$'PJI<4/4+WB3I+')0TEZ@/A9!(SMF2J1'.V[?VZXCAD%V'5M%I:KV5+ M"[B/VEC9M8C"WY5=ZF$EQF,)G-9A/M,FIN:*C6G>&AFB3?1;G(P(4SQV=F+D M*A5:P^"^4>/4.>DD9>I$]I-)EBB@10:#9!KN=&)4-DP%HS3=K@OKHQC.UX8,M@W51M5;%)D#=HNC]K$ MR2I)O$!,T@VUBH`JCWF0F*-RACIRK5#L'!3:7-4-P,7A.CNCY*LM7`Z(6[-) M*T]:SL]:MV/6!">>$6/F(?-CCP4.@*2W!>6/IF(=D`XU,@XP3K-M#^?JM+WQV5^,,-SPR.3 MC83=Q"#0!>ET11S`P6R9=K<9.[4DF2#5$ MA/[(R9DBN9@<$OO+7BQ9A5T^>(?N8'4$`SWPEEZCZ M[*3J;>0(2]B;B,;G@:Y=UB)<4X=E+Q%L0>]^(]CW%G(;1@LMT[ M8X/JV'%9C/"E>QOU@VP[(]D@8+;C36;DDV.XZ>241@=J&"^%(52`MT?.=J9? MI$8-[EO`&(\/$SIL;V]GN_K.N:O3$1<8OJ"2F?UD:OUB`9[WZ412(7<,V@8.T:6-]M)6(FA?2>F/.Y3,-M[% MG<3)ED4<`>9OFRBX&?"`C6O#)0TN6+?C>V5`%&WML52H=.]2FAD/E?:]S-YF MW/NM):HIN"3LRMR@JZ7^O?2$&=`N;DW;RFG]UDVVBF)/?QL3='B.YHE3?!5A(@J;^=H2@?$;+OWXP>TXH<;*TI=?,8[83=A@ M6!&55D1&AZ-3Y2[.'+O6T['Q"RVE2V M>9$>OR20P*0&SM2(9"=7#]+EK)[%VPP2)F#FW[;[NV("<+/T@/:LIULA[,X- MBAI)G8R3VLAAMQE2RR;9!4]\C,D&0/$>6:BCX[A+VPX[,B2,,YMR;2L*O1[P MS^6FQSJ^&J(E\`!+5WPGP/Q_>]_:W+B1J_U75/,FIR95LD?WR^QNJCR^)#YG M9NRU/*BI9;-1"(57NSQ_OH70'>338J4*(J22+GS(6/+(AN-1@-H-/"` MOT189-,EDUS>LRDX)?8(ID)Z'"1E!(;^E<^-UO!OWWPVII3<#BLS9C1];MW5 M0@:8M>?+S&4E0C9A8YXL&*1,3TW0]H+C/.4/LQVY,("N=ZFN)(@PNB+W4-4S MXGQH6B#[!F5[4FB-5VC(/!]@12#(2LJH6QN#3?%=ESM$M+]LASW:^!K8\."; M&?,G+M7DG8FH*U*&],"XKN^B/'(G0QW6M^0HE2A:_4*91.!J8P1.;%^'X?9!.1>1R.692C!.=,_$U7^H%V*!?+;HDG`. M++HE,?,1&#[:KH\1&927`K!A&0ITR M!<,0T2E\9J:K;EV\[:`K`QPXW`['6.+'YIY2,L#+X?@N-WG%HC3&,MD0[_^% M&L#!*:D,7S`.2H*,[WC#@AX$280%5$<%@6M_>`B.>V.W]IY\]<%/]2!Y+2AB M6UT*%:TDK%'EDU+A%]31"5D([H!LWX-QQ`G;="-\62]'(?V&>XF2*^2&NR!] M^96)JZ.3\)0N,M&MQY`795:;F.#+OH/B4=4B+KMPEUQ_PG4:[8<90Y'$.`#Z M'Q9>$U+8A!=:Q/J%SE-AOJ)46(,5,C MD!GU(K>N4"\+I90"$-H78G%08I&FI%*VL'J"ST%<^\">8Z&'RS>R8_N/3VEN M*E<&O-Z/CZCX#=<$U%M)?,_Z46<#*D`Y:6+<&Z"&DW%^<5K5QY: MDCDOQ[5?I5M"VKD\(@A#8O"^Y,I MECB!K"@&!;Y"LQF2'P5C"(]K'!->DVSP6GZOFN+NLPXNJV`H>$ MW]6K?%D=MU!?J)9@JB5_5.M'ZQ[QQ=M]GKL3E@T::N&@&(>R>D1E-+'A`50` M2(VL\I55+=&7EA"F?_,'LD3PO;L M50B4TO@7Y*33%9--_P:5P12/0>>+6P_0R>:CS'8+[VU$.1$X!12VP0)=(6Z+ MFMY":(PIIE([+IT&I#[',R15G7::T7")WC3MJW.0+$PA'?U_&ARGE&@0@0<@8$=RY?7VHJ>>)2>598<>;G?$RQ]L!XZA1^B" M&G.7?90_"%DSIG"@_0C,FGCO:OR[_WK7>%?#RN`Y^LG68_"[.S=&\O<7<^P] M_>M=L]'@4EH+1W=BOX_EESMQ@29A;29-*,(V;[SDC7B(ABG\ZQTP[%U-_$S3 MV6CSO&_^E(D0=<`(*;&E+HRPWYDH!Y=WZ?Q<014?KE?[;X;!X/\QO/_,,`?2 M0$4^(R1/WET8[RLHX0=T=6.([C#>]XG-\<4Y#M=!O`,VK>&/_:G<9/P.PR>K MQ_`FE^?Z&%QYL]E\:K]&*_2XHZ2<)\A72AWO@6XX,/CQQ/UUAG>0:2_F^3M8 M@S[Q,1@>6ARZW[Z%0P#'#,`K]"!/"LD6FH$'K3'-$_>56V#\"?CG M6^,EY(Y-PE;B$>%%5M4DNE2,7YYJX3&+E/(,5@V&DT6M1]@=4T[ZV)B!1 MY(M\`85!,?@D\E>3F<1I7)[@P9D>8.[,Y^`Q,4XM&`9R*X&6R,S&;&2Z,A@+ MGC7M"3INHSHWII21R]\$RLT:K\B<)!XN)NG+7#G.EV9S03&LN9&;4>4`9V;\ MW7OBE\W\MTW'X,JB=HH("Z8'7,5EI/P*9$9@8ND&%7^YF-J..3;(B71T" MN2+.^C_],0'VHCZ9&,\V9>_(]>8A7OAI+-XTDD@UO#2*RQ;"3B!$S=249T+" M,Y/RC-*`:T>+*021=HEG?!?+*O_D\HN;@(Y@TTFU*`CC+PVD1B:@)PTB&.$& M!_0T&23A)\D&"^U8[#7R5\IO4RX8,\8R^1\/Q=:KU#F" M:N[C.$P$I7A44'X%BP-PS\OLD!<6WM_5*:-/'F5,-X!/`IZ;PBK#:Y_-1]LA MSZHD]HC*/*Y@D$W4J`: MG?"Z17KTGVT?O%S#,DA^N3US\2P@_4W?Y3L$]UAHU50P);G/,/6);Y_EVXH7 MZ8BM1=M*"?1A@%DMFJ,(G^F*VE`@^S$QZ)MY$]66[:)J%\Q_6;R_$YF8L#XF M5U`,LU"GIOM$;@N)A2M])AX*Q2MYRY57?Z9R%XA@1&/VMX^2$P`C!UF102(H M9J[,_)E(0*J+1!'*1*$!*/K@BO-87>3>P9=\RF61P5]71F#R0H9N,\9/:$<5 MB.WST@V+)Q6(8FF19"&L:PP:#?>N1/_E^*\IX+Y1;%]$>AXYYIR'ZAW_T54O MDU7$4P56C`+T_":5A''**."&RH7G=XCLM@?#XK">/W0(M@/OLCR;YP%PCSBX M40R+3>93,X1:E\":H>V7$)-TKI<^N=!%<3)X+8_(D.-)&'-3^`!JR9!D8ATC M!T$"*W]$5E[_T.OUZKU>G]^WT>G$,Z>B&@;'C40%9)125"#_MV^Q18`?B3S! M$5?E7.I1QN!-SM@Q7C@;*)&,T%P-)SA'+,P["L*)*8H$I1`%XSP-@FB!2EAX M$:47*EC!QF):=PQ*^[AV*<\__'8=2'?#:_GX",IE%6688:2(YVD$.>2\\DD9 M4%(;%M2&\4!*"R'G38#AD0AB9HD_G5"E$Z:1*,)$YRWB5Z92I/4*8[91HW1A MF,YO""L4CN<>:DE23RE)6CKOLE<@]2(H:A>1;Y]?OR5!J&5L MLG)Q^?7DZ^GER>?HE\+8M/SD\NOMW+N*;T:YFK42F9`K-D26W/`H1_ M3+ZI)Z.88O1$?C[G2(IJ7`K5@NDH+A)UN.!H7OQ")2C:I^RG(RH5M0B)*$RA M-H.6?HCG:!*B9(`('5XSR^BX*<#9\21*`*SBIANOGBV1>4CZ,D1[)G,NNS4( M^CPV>K+,OWTFHTKH_/$$KEH;WCCW/;J#EV;!M)07\JPZ%G"'$LTX%`ME,XJ) MB^Y7,3]285+`@V@-A>!&G:I11#(U/D"A0BHPM>=A)I4LY;2;[E]'$\QPH8=YKK-X@?L*/TI\;4R[4S[`Y\I;'I0H[E08 ME+`2[HJEH-F\IUXO#E-%\:.BFGWJV]I^.>[;M`AOO3QUSYX*T" MXR#QR$4\LB%""?W>CY$`2([PB3C]C^CF]UV*9;LCHG[%\L.8I4H/G/2'/R;- M-B$<(2,0G$W!Y'H9G]_QERI`;CP6L33.%9M.4<&NW;P6/6?8)Q:JE@11SJ&B MFE''Z%3HJ64^Q-YF7U6FGDL]OS>NZAT"BQDS%\)*->??:U2&5?M_U/6W4="B MGY"AU_MH#ZS'HV9KQ/V13_;X==$?J3T\`M]M<(C^ M'YP%V&02O^H9+\N"C'K$Z")];!XW&FP6=8&/^(>;^<%A(W2.K+/*Z2S+!EES MFC_DVCOB5TJ%U9-_\<<^R@9JN^U^!:1:+V_NY>U48'FKZ&G=)H/%:GVU78%NUOO]Q3*I\HFT7N`-%K@* M?O1A.%J(<,QS"+0BV[&<5^(XH9495O-QRWS..-U[":$=X15B+)/@PQV9S4>PO"TEXWP2U MJH=FJQ8LR>(I:@X;#F4&A2=A8>B)2Y6N]<7.?O(ELL6J+&X):HE^:`?UPUAY MPKY3`X.PY+S&RSZ,!_MY&;!L6,>YM)IP&V6;MTH;D7-"FL:O'7Y7N;Y2PIF9 M!V4OY^Q'RCG/(]_^][?+NS]BW[^,?*.ZA9;8.>(66ZRYM5.L.A1-3&0O7@7^ M0S0*-G%7$AQFI(MDK+0^AJW=[!VW!N(!FK'H1XE5>P1B0K_C@XNTU$61'ZD# MWB/MM38VISYOI^ZZ/E6_\Z)QHL@>(=6BT0#I.^H&=9PX44[(,[45ELTTU9G) M3F<"1-P]"ALF$Y(XKV04K^&UGA:I2VQU+VH9J3`2$3QH[F,3B^^M,:KK)X;% M_*.IX?#Z=BPF_60+<,(S@?_JRH[G*EWUV@R8@F@=A*@FOA',4)1>IA`-CU%# M(IG%N]M0AJ_K@,S2G_?)?"12D25=C\>0L_$'W<6:2LJ*V&R[!EB$?0A*YL M:F"#=JY-<$N.0P42<=QX"YN,(:!4GUICH>D]5*4]-#7!01US`!_%=I`5=I@` MEPDLB+3[HM<`!Q.5,&S4$X?W>!.MS24\.'U-[+;`=4CHNLT]$YIFT+82OZ00 M6>^K)?P0OX?""L1_Z\]EZVH@L`CY)GAX;ZAU:W@:U`N)-";4CB#0V/ M>V&+Q%2(@)^*A"4^8.0WV8`^E!R78S)PI+[`B8YY.W4I>V=UU"SVU5_8]1(8:B]:MR]I%ABYLB%L++WM$K`Z.)R(Z MQU"WF+KL.OB,'>%#T"SLXXK];"T38;@-1P+GTN3I7031!7ZX+UW^*-6\I^V3 M83V&F'8C].ZGLIEQK=EJJ-#(J`5_?9#88P1OA=I"PLZX)L@D=9D6G?_,_PC](?&%C;"Q8:3'Y7'M MVA'*"[E"@B(;CAH3#SO.T>DL8%2*^!+33#?2X@!.P#1U<%:H\U8X)U53A6W` MI6,_&MD$MFXLG`E3A^=GA1,WI>FARL2->PKRP+R[U M2P_.><>U,SB*F0'ND85_(*03'C&P?9MXEP,!FL*!T!< M^*GQ4E=-:_B^@"FD>1==9L]^9"1K=%157A%G,L@>L&8JW6H!T2<0,*,@J@9_ M-;?>/+2A1`U`*A/-:9LC[D2M<#ML`""(0NQ/OD\$#B@U:""()P[4">)EP]D8 MC8'2-_*[5QL<#Z@%6*3+=U1PA$[,$Y?:10R<"/B=(PGR/F:P_HAG1;8B18IJ MU#N9MYR9\-`"@5TB[BFL'9HK:E?!'CS8(+Q;WWIMURC$+LQ5N]5=(M&B*3(V MEB++)/H)3TWF2R2S$'?[V[_"T>53V- M1EV_7)]_O3VYN[SZ&OO>=>1[GT^^QN*H])LO?XI^O`B`5TB8=7,^$A;M[R-^.(HT M'(FKHD1P@S=SOWLV8V.3[`^WVM^9,S)=0SB\#(;X5R\!(X:%JN.0HGJ6$L2U+[?Z7>O'GR[BQDH3A8 ME-<<;S3[TE1=MKOU8;=?[PZJ4+E1M57>=T5.X[BMES6/:[#1A#O'K5Y('47V M2C3S3$?`[3Z4ZQRY9W/U"T^BT.9HZ_A+_`I]%NLG>U:D2[T:CI M0/;;\C0/%?^J/.S7#Y7CH<.(-YY'ZQ*T][DO[[,U'&CO4WN?;VI9WZ;W67EM M]5\2S^\@,?<72'VB'-Q_O1MD="#"[X=YKIT]/9O(D,W'/8`X6TKJ:$N[.MM5 M'IUFO:%31P_7U=').GMP=0:]&]W!&MQC]XFSWF!A\U M__$3]L2R7S"<)_\:Z5:RT/$2_H*MNJD=E](CZXBZ3#P'W6+X!&OSJ6'QIB%A M!W+1U@M[-U!+!VS$AUH5?\)V8^;$Q"MFY06\"5QS..S6+H.O7L-?^!]:C48K M]@?9``__-B0^\+;VU#HWX#9]\SWV36!$R/25OU!A&7XEPJ\Z=0"OX63-<=C? MD)B'7,169NH2U\6OR!\V,OG`O%L;]M";F5[`L\2O8+ M(A]M*U0;G5;K1':\`\YPT*M3P[89=?$XKEV)(9&[ M.!21^!!VLB2NRU8U_IR:U#!+MJC!MBJR$2+V$!$OX[,G1H0<(*'BG4%`B$C: M:H_,8@[U3:(6]$`7-E&$'?Y=-AO!\6V+'3T9TXF<7K"EX67\@69+_3XULI,H MVO+;Q[4+\2<4U%0AY6(IYR2ZR5"70^0"=9(3C6\CC\(OU.*.$4]HYJ(U$.-- M@10&8Q=ZWNV/DCM&C/$-1)UI0%_^Q3PTA&&G6MFBB/=7'(MN1K1"?`FX<%$/ MU?ANF?C3J;I$V)=/[7,J>IM*RM'N?%6MW9FT=H&'U_]'[984%-<68J.` MH8WUUP7EP/N?H?4,#4Q$N1$+A+U-,;*X1ES5-`/1B$C8<>T<6V^FC\)[1T5B M&H;8ATJ?3?A<=(T2&VTTM;&/9>W!Y`V!#?QW(0SV^5M;;&[J84F#?ZE[3Z4V]\=/;&Q/X6YP`?`%]-]XNH,U^*3;3C4-RMQ^2/* M#ED3D0=%^WV;P^]_VD+U*N^E^0?OKBO+';1\A66S0#1A>?@\@1C1,#+0X2>6 MY:.]4)\WE,;+S6YT-T=5)G4AIS?49HPA3]91,8-&$Q5+T%LZHE.$W`FW`#DD MVQVKVX04,V?4M61A5J-2;XI3N-E;'36%=W&GLKY%:` M)[DN5%)BB\FJ(%NGL5:_L$YCXM1%DWK($E[98W2V+$U]=*.QO;%>-QHK[CIC M3RNG&XWI1F,K[CETHS'=:&Q'=X>]>J\Y*$6Q52E-R$8S*D&B0T*FD%[6[28Z M#(Y;PY"Z4F8\Z+0\709`Z]>J>E`Q:'ZA6VFWI9=Q^P:'9+'K"HO-8ZO!*-@W+$ M=4VT?NAM/%3%X*MNH5,&$]:K-X:4@E\!8U6U1=:.=UF7="C;JZS'W4RJ/>'W7I'1Q\/TPG2N#`[=X+ZQ_U..7%A]$%=9TF5 MWR*][^@DJ<,U2(.]KVMYEU4G2;V)NQF=)*4?>@L/'62<0N/7[L5S&-3[71VF M.%BO4(F'WL9#58R]9DJ2TI[W]CWO M1J.C/6_M>;^I9=VRY]W0GK?VO-?SO(/?-^P@L6-TUCN"SG;8R'ZT",@YTBEA M9+N>6QO[#D;7DC%:4_%9.38W-BSX;LX,CTU?:S]PC%Z!O$MS7X6^B]#(T7>T MNQ()U[>6T0V3FAH>AZ:6H,#L^YR-Q&&@!`P^C#<2T MJ='"#+_&FRPH+XE3*@GUC.\PG,4FIN@18'B>8S[X'#96]G@X>C#<^$208,OE M@SC(;64M_O8-!Q&GER[#<>U7^X7!9)"CIEN;VQ[V'8`U%P01BQ$J'O%Y)R[S M)"HT;"=?@#XCOBYA2H]]%N!G3VR'S?!=-B+CN[#US(DY0O!FWQ)@\AYA_DY\ MSW0YC2,^_\C/3\4RH3^@A4RN,C MS!F?`)T2?H/#M*5_1PY^:8%PL3OC>\)X!/_;=AW3>:]\C)>^#P M?9O__.YGH>#.KD[O_K@^KSUYLVGM^MNGSY>GM7=''S[\WC[]\.'L[JSVO[_> M??E<@V-&[.4+PP_"WJ[MS MDIK@`YA&8"F;_ZA=1K[]]?3J2_S[D2_TQ(8+/_*EGSJ<(H8_([PL/ M'->N0+=1JPQ7]`*B&8<#,'<)(OEJ-')2/#'U+GMK$$VBDP:;3%C0F$?.S4&: M-QV]<=SZD3YI'_=^I-XV<]EYI\0H\:EE5M1M@BSMA(VQ90R\P@,C`3]2:P/8 MT&YM9#C.*S#NQ7#&)!1Q4]PY[H#1GDZI^P4U!F!C'[CR8$Y-;J9^:`V/6\0' M\;T0;!_M)K"1=U:2[812FO&T!ZVEO7C`^8F1UFM*/\&P7A,FQ]QH)PB1BLV; MV=@O%EB2)W,N&[>H#83PVW!\F9K8WX7^'/P1VPF!L48OR'>%D\3-/\@ARJVZ M*PS1>N&X%FDB`NN"KQ#/H<\@GI7/,6S5@0(_8H\=C#PML(8<-^R',2/-@`VFNL/C]H^2A$4! M@$4_$@-(BN`O(M&0QD3V66$[B)"+R`WN^,284MXM^,6PP.-%EPZV&V@<[@"B M;^QS'8D::FYSD^S";W_!6G"Q?&#R5RNBSA@P`+^*O.9MF53%SKX#51;W,=\C MV=1NSCQFQW5B"_U*+Z)#.!=XL=+@25+[)Z$3L"V(%`G4GU+CVOC5J`7XB;?T M>J*N<-9HZH^I"1-0R(\<:'TL.W1BH].N<_\=NT)-J"44?"%L966,1FR.+,,^ M+#[O509[UQJA27+KDA'@]SG!P8&F#R2/`^=$]I;!+G.8$$2+`*.!"XZ..UF1 M&>_)E"I+H<>YS/O9AI-Y;CB(+.U>,X=PVP_5PQPJ'F;JG#.XE\L.$UOW+X<1 M__(Z\NWSFV7.Y>VO)S=+O<^SD[N3JCF?LD\T3-P?'SA/\`1WIS1/IF;$Y]W,=,B`J.P?L)+;J+2I\I<52LO3=F MJ%!*A:ID2WBH?WN*J[KE)10!3LH_U?N.,;Y5FHZ5<3;V%IA^A M(^S/,+A@.Q^S.Z%ONL3G;X_QJ9^">-WJ`T7)93\O+_:=L?.^ M6>\T^IF(T+6QE5K90142[):F@U?/:)\QRZ8(L3;;VFSOR6RWMR7ELC]CT(D^ MTN<^$I>E*&+)Q7Y[2FU'"KX[K/<[W0HH>;W"^5>XU:U"@[J=FO&M*;ASRG#! M6Q"Z^\!4%Y>-?,?T3.9^++DZTU;\H*QX=UM"?LLB\FVG%GU[R@ZUF,MY&O?_MT M>_[O;^=?[V(/G4>^]1M\H7+8KE>$QN<]&0+?CJ`5"=(*X1)MI9/?F#UX\+GK M.3XAW<$'[L@Q'SC@'@J%6^.PIYTZHO4Q$@"..6XBK>;$%+!^-&DYQ-RT$)E+ M0O`I,'VKT/A`O_""`"EL#CVL'(DJPBK<,&,%A'6^Q M*`>8=<.>[>DS\N(4?C6]VH4QXNBH1+!99L&R:E^,UU#9MQ7H6()_(;GQ[)I1 MXQ-?/6F:TLFCPS@B)B$W$OHGH:&#-B+<2]MQ\)#?#@:$MEH7D*H.$\AV+NRAV/"3V@]-FKQ$09TR%R:+^ML8J:#T`L@X M3JCIUAY]`S,I&6*VOO+9(.U`&>Y8`8MJN`2=!^.=VK/YJ2$054WXS`7%;HY- M`TMKTC88LO;:9PZP^L8$SK\=@N7%9Z!*%H_0F,906\P'!:4V2$)=K"@.) M%(BW'(\9!FNV?JS7YL8K^04OC/V%6+A)DZ>7`M-Q@C8JJFV!.@F2B.-%: MH&"CG,Z,5])+0`A2`+L#F*QH$WHKCC&6(-%&",:+.LG\SL&B:1JB;P$!70<` MIR\2W11U*R*8&OZ4?D3@88$3+44$R7E@(:(IC.>P/WGW!+&H4T;,A>=IT6S@ M#:I-AW%\_UPZ;PMXHCM"L,&,6TPDU!PJ8$NK/:40)@%3?`GAU%;"DD][0E7@<%$6<6!E'&.:Y^! MX`R;#YY$:SWB,F6HVE@II[N&131=UW9>R?(?UTYP)EQ#\]WS9"+0#8Q#[B)' M&G95AZ*NX@Y+8%]:1X/#^JH"C:(OROE0V]=HJ[W"PCJJ=5?=%8'Q:TSKR$+' MQ_GXV`AC;I@*ZY"C')'8]6=NH%!"-A'Y9*A$.II0="J`#VDHOL<=2M!YJN?+JD!,"CP:# M(S<+ZF/3PI8EM!,?#.LOOCF`6^-GDX379_T&_7N8+!$9F"/NRY*I1USE`:R2PSJ0_&\Q%(G8>0> M-7]8T(GF&O>#/R=/>FI2:QCAMK#O;,9M]`381A\Y<*H#1Y[S27C>,ZF9\`NW M055X[807C#>';3210,N,&A_40Y:9EG1:H[C[G?>MGSB"MSW)*3?;]+=%<0FQ MDOA5>I^:Q@?'^@1VZ#3D$`_^?5,T?H!8D]QB5:$B:< M&IJ20.\WQ^1#T(FCA4@C\TCEN- M,&LG$SA[AF!&$2$D"FA]1.>%]>XIA-6,1Y4N#-/Y#=V+3Z^?C"G.^?:),>\7 MQ_;AT/QXJ*&E!,XHL::L3,D2<-I%,ST6E34<[X1^ZX&`H>.4:F#PND'F`R?M# M#4R^)W)S7>7O\KYT%TC*.554#"'Y5.BI94'KDEQ"5X>IYU+/[XVK>H?L'&O\ MA`R]WD=[8#WZA^%4R%,LSU MU[7;KL"Z5C&Q]O^88\/YD6*G\[>AIDI3AMQJ:VUUR,O;J@*(P-+B>.$7M[M^K/F6 MR&=F8\H*#^ZHM,K:7EUY>[AWF3[`JO+2K&]0-*CAD\M8>7Z8L+^:C]N'@:E. M"QAL-JWD@AZH1=_W#6RWWFU4(2ZHUW7]=:WZS7KES?2APIIH3I87("9K(Y`I&R^G$'-JE-CXM:_\?Q)./ M[?8\MQ\>2^"/]/Q["#15*4^TI:EZ((B[I2PKR>GP\%@ONU<=T2=.[0,9=0[' MH7YT+FK4U<^NL5#]3:U:_!!=BI5+6*T;`JP1Q9#RPU,8P@&W#-%=[I@S*^7* ME69CG#P^.NS1\")\O00.FA8VEM`U6F5+;+E2X),,KP8'1Q^.)2$+Q<&BO.9X MH]F7YDJQW:T/N_UZ=U"%L&355GG?X>;&<5LO:Q[78*,)=XY;O9"Z5V8X"==D M^Q7HG86/BSM'[ME<_4*`IH?:$*,TYJA9[W/0,*VV#M`:Z8S:HM5KF6C9B7VH MS@'GPG8FS!30R1QT4)N/K2?`MKJEL!X'F`6[?_.A*V&U^=C4?%0]>>DPJF*,(!;23DF5T3[@EB/:_7J[W=(1[4-U`O6R)C-YJQ'M1J.F`]EO MR],\U.3N\K!?/U2.APXCWBA2OB@Y1'N?>_0^6\.!]CZU]_FFEO5M>I^5UU:< MD$,%E%@@]8ERWJ;%=Y=)KU MADX=/5Q71R?K[,'5&?3*Z>KH$[K.(:V(72I)"E`IE5?%;9).("U:VY:)EC>= M/*#317>O4-XW2U)LH--%MV`L*M'#K%(*NDRTZ$M\G2ZZ?^;KA\KQT&$$"#(E MD.JX]K;CVHWZ<*`32`_5+=1Q[10F;S6NW6OJN/8;\SUU`JE^Z&T\5,5X8Z9T M4>UK;CM==%AO-[O:USQ47U,OZSY\S7XY?#WW)T=$$]$+@%[U=OH\M)+[/*S!HK(V M>;#G2+/N\5#*'@]=W>/AK9!;`9[D.LJF>'7)JB!;CX=6O[`>#U>D_72+!]WB MH1*LURT>BCM(ZA8/![0Q=(N'::73&72+AW5V77%1FUZ]UQR4(LVUE"9DHQF5 M(,2<<$>CEW6[(>;!<6L84E?*6+.^$-4%&.4W3>^;0UV`<;"FJ3_<^[J6=UEU M`<:;2(+3!1CZH;?PT-)-7-6(A<90W(OGT*MW6CI@<:A>8;NIEW7W`8MFM^0! MB\IKK<-+CCLH1UQ7H^B'WL9#50R^:O#R,IBP7KTQ;-;;[4X%C%75%ED[WF5= MUBT[WDWM>&O'.[_CO4"J!C%_&\%'#6N^'W4RJ/>'W7I'1Q\/TPG2%;D[=X+Z MQ_U..2MR]4%=9TF5WR*][^@DJ<,U2(.]KVMYEU4G2;V)NQF=)*4?>@L/'62< M0B.'[<5S&-3[71VF.%BO4(F'WL9# M58R]9DJ2TI[W]CWO1J.C/6_M>;^I9=VRY]W0GK?VO-?SO(/?B\#N70/E=7W@ MWM::P+W#&-[O(KVGQG3D3XG(J\E7?\89> M,XZ,D1"+OO$2\0*_C!<,T1P?R.S:F/E_Q,L`''J+G("/`\ M/<=\\/G[/!O?,8/'707]NO;>F-F^!4/!2GE/MN_".]UZC7T?L;FGO&ML>,9/ ME8$1[O?*"R,\:&@8X3V1F^LHN4N790M0D+V"_+\8Q./BD98H>PAHW!T?WN*J M[AG@,RCQVL=ZOW'&MTJST5+<^K<`F!HL2."6?ERV+*4*ZY4\!GR0LZYB$/LK M\VKOI[;K_@2'`S@[9#I0E%SV\_)BW]'.]\UZI]'/1(3.*Z[4R@ZJ<#EQ&.EP M@=%6XD?:;&NSO1>SW=Z6E,O>%C6#][8(K#0UBJD%MPO-?_`H8LG%?GM*;4<* MOCNL]SNZD_UAKW"K6P5P_YV:\:TIN//)A(T\O`6ANP_S&2]+1KYC>B9S/Y9< MG6DK?E!6O+LM(;]E#DAS[12O?L&.>R8>N><.FS#'`=M.1^Z2BWKE]7KU$S'T MTNP/*W8 MM'1KQ::7/H]7E]`4U)_?B59?$')\==.AKWWI;&^0# M75AMD+49T0:Y).-F-LC![P7`7A6!A;0&'%8F',U^>2[IL5<]\QX=2.P57=/#F-?X(,G%T9GX_MVDS!$",?JACW;TV>@ M_/XT3'>^OP8E9+JN[;S>(WWW7QB.<7_K/[CL;Q]\DOOS9_P___S=S]?=LW]^ MR$5IQDD"6Q'UP7AD)_/YU&3C.SM@/WSG-V/JLQU/NN9;)A_KVG?8N]J8CPZG=,6=V3?!6$0Y<69'Y-]M? MC%<.5W;=^D/2MN*%:XQ]0FA6$0H^&5/#&K$3>$P9/N3;M]LSE6U'W7<_=UND M'3*2Q\=,)?+*N4$'0$#",N)X\$=7_-6%CVWGAH'I-:;IY'<#Z8E.X/SZV\+2 M=SJ)]*]/SBYFINX+=3?@%G#OKXU7U$:+,K__J<]-AS;)'\QP,@G^_87M.QYC MUKW8=O>WS((1XQO?#=0:/-5?/A^5B/5(!@-"5"XEO7DR=XCT5,T+?^T=-59P M/6EC" M/`Y*4;]T79^-SWP'E#;?^Z0;\6.4STOKL\G\J\DE`@,QUX-)7C#FKJ6-R&R[ M*NF77R_>_=SO=]K#9D#ZAA1%9Q>`:)[:KN?>,&0+F`"Y+\[@R9']:"&;,@%1 MIBY"`]9`78!U1HZ0'.B'<,_@EHF9M3/FCAR3B@IV[8F<>#7#>JWA<:KV\F0B M6LH3XTZ6PV:&:;DU.^S-4Z^Y_L.?6-.(F"HP)GRA-C5G)L=[=`DDLC9%L^/4 M9L:KK`F#`^84FSOB4'/;D=B0^&7E[;4Y",?(G!O3>LT8C1R0E]J#[\$JS0US M7#.%:!"8I`W/PDG-G[FU.=>Y\#4<-2`?OF[+G"88"W19!`4&T$P!R;S^88J7J%K\)W!]T?Y3RF]@O2-C;@=%J# ME?&1H?%,*SY<$C5CVACTI@G6B3X(GP]>".ZI.9NQL0DR!^^>H]9'TCC8IA0D MQ+UDQX'$KBUX6<3VB^&!ZS:&O4E6AZUR8MI-V'G)IF2US*[9:IG M[,'C']YB82Y\XQ%EWCMQ73BP,7ANQ,QG%*\ERK&;UR.(3:K7ZH:36H.R+<[G MLVU8:\VA7[HI+)&T^,S`.'PW9_YLY43)TD6,=/ZY7L*W'-`6EJ=0&C_WK.ES MKS/IN)-ZN^"DMKK*)-:_A36:A,/.$ MSL#F+/5W-S(`Z*RWP5D_:FW#GK[WO!S.%OKMEGE7D\D%C'L* MMM'T;,?=[(1VU)-.8*@;>>_L$QQ2,G('S^-FV'O''T,9GL4K+ ME7)K&*4]RZ@*F>=_^R#:R@+QX_6%[6`G53BCW#+G&>XH,F_(@[^^P24&/@R#R`&]_E(VR#E#BKFFN3(CZ]XI`-OV"X MAJVQ6%]MZ_[?OC$U)R;\YKC5/AG67Z;U")KA9/QLHO*6>^V"!5=%?$2^*5.55&,@;>_JNYJ4*30[_49W M,`@FD9M(9:J?&0BW`P1RO9S-\_==SY[!&IP\PB+.$J>P>$CM1`Q';%R5(HQL ML?$9&_LCL)SF%'3?!1MC*/9JCO>:,-7/M@M[U'%>)[;S8CCC]$/I&K8AD=H5 M\U.=/SHFT,%M346=>[J@TK\LF(OQI^V(_6D-)8)6R&U6]=U6QK=):]2 M!Z1YP,RYC49+N:87"J]T;6LQX-8/IYXPB$+"5^9]-@U2E2;CBA&M4A&^.S"D MVVUT0DJ6C95*TH5A.K109Z8[FMJN[V22GY5TM=/H2A@P2ES$E'#JO[EXQP6' M)9=Y(IQY9WSGMW6$LK\1Q:!5VKUFA-X<-&P\B4_,>V',NIT#8>CC)>R,/%-K M]3N;3BV9,G7"MA6XIJ1"A!<)+_4=^./Y;#ZU7QD+O-9"W=X,3F+$L*]-K3I3 MX3E2\T1D#QA;^"%X'W\5$K?N@1>?650TDN3LPR80&TSD9#ZWS85C1VXUV(U1 MMSA.`C'RIEH<)]GXTCK_/GHRK$?9J9+\\34I3%OX5B-&8\;A%<)APUBP'3`% MX_R[(3.\TF[*4XT7O*)&S5]KX%,/Z>H8;XZ9,0$?J#;A;O3TM8Y=":Q:X2?2G7ZEYRYKJ.3'A,/#_ M-B3.2DDL_5SF\@6 OKOF1\N< M_NN=Y_CLW1*A@!,BMH:[Y]OI_FSU,4BJMP\%4Z+>YVQ&BVD[D=`L\(_LW%I2 MI\:N5[\R,GY2SLO*7,36X((]$!7_QQP;9,F?@RQEN29:ZO>V%9=O"64*_45N MV$6"NG33(@C*ND]36G>C#_-(4<9/K^%70*WB1R<8=UNX'[E";^,.'!UA%T5* M+^KAD\='ASV"AP'ZV0'OWQSQ.,+:`MRZ%^Z5C$NMU`M1`=[K;+/LS_6G%Q$! MN?K[G.>NV*YLI/9A*THP*0^LO5-&+YMRQ=B_OI+6[%]"RPWEWM,9C3LG/K_8SAS"R[0= M?K[N_#'XTCS;(]-3)UKU!,!//!!BD"`_U[J6X#,VLDC;= M!ROU4G?[>FDC;AS.>A5D1_IZO7@(MH2;*WS/^.$*\+\@@][FOUY9+\R)^W#8G[E3MH[9/_BB#R&]=7V1(&" M8\\6$M%2KX.(DT&ZQ[U*#%W!)]R$I(3O>NW6(+Q^V/[\5C*3TWGB>T^V@V@% MW[!H7DG'6G+!E-HHK-VF!R3MT0CIA#4C,W8"$6,'=,^"R4:K=5C?R-`A].I M8,47]<3(W';/.NH[#GYHNB-C2HE0UGBA MT#/U_4='S=91N\E'2'M5.-B9/2*[PK_">7T!GV63F)__+09*?4W:2$C,&N/@ M_Y-&"EZS.`XG8BW>\9K7=L"^Q%L7VI6=+]3+#%/6:K4Z_ MT^I$2%HR9IR^"W/*G%-@^J/M9.3#+0P/#]5N&$'@P#S0GAG6JTI#Y+WQ06_8 MHPGN%JB@K\8LX\*>7GVYOCG_]?SK[>5OY[73DQOXW]7-M3IF]+5\4(GK*&MI M1>Z8V+:KSP@K:DJ;3:[-E@^S(2D9T^:;S6$_-S%AC?%7YA7$G4ZWTTLD*&FP M0LC*RJEV.S=AX[&);AFH8##/EY8P79NRJM4=#EI1DI('VI2:C!QJ]5JM3@YZ MIE-[A)!BR;[N^7?\<8W@(/?-N2.<"4ZI&Z4Y$SG;G4+,IUV:XM7;G/H9JN3_ M"-11++G'.AF4[6N'S4P_<\WR*L4WC'%ZU;B;D)FKW+\SV(A`UV7>LO-CIEV- MQCE*!;UVS:$R;MEV/S[EU,$*TN_=7J>?,&*RWLPX<-;)D@+/-O2IX3YM.E5> MR1P.A^]<:Y2LEJG?:V<8Z,0:XS]X)'\VIABT.O%DQ=ZJ=$01^%].QZ#=6B!C MY:#%TIE5$S7[BQS;,:FY16A/+,TCA(60RH]YEQ9'N)%(-P79I':GF8'J9!(* M(CZ7I1ITLG`[$]TYP)>W#<.WB!7=:BESS4'Q%N>6?1P'@WM58 ML*6@E[%I4>B$YPU486+1T'2&B958-%=CFZ^6Q\;69Q=`_"`(J@!$P'+?3Z\; MZI+E4$H%T;2;":ZSDFG3EKY%A>7BT)$&-)'+(*T-;9GMTCB5J":K<&S[K#?[PW: MO254J>AD^2E:AU4%T93EGJ185BW?4[K"3)NA)Y[SLHV=% M_QD.UAI?PIWXTJO#9"8AURFX/QBN-;;(5L<0>&$,Z+>ZW04BU('6(",7$UJM>)!H M*0$4QN:0NXBRZV7#]BWD8+^0O-*)R?A2VHJ>1K$X\X-=3R6;;E0A)G=&6HBQ MNEX<(:4E2$ZZE4X&:V/@W<,+X$'?R;+\:'_:_052T\8OF%)DQ3VFF^407-1? M"4S>$>6YZ&T-!HO2O"."3./!./Z?O";JI$UI&;6%S[*8DURYYUB4F4J99:-? MNEGF-V9I*YFZ`?/.<:?MW_I4]+":D%P$KRBXZ!XU!EL;>VGZZT9=T?9!\$H? M/EC.+5)8&,0E$MO"]=^B[!76Q*]SU&CNDM"-6O=UBA'2;Y;!,Y/9.):0_)45 MD2<[7.*W+!T[3C2_I;@SOO-,V_2./6?V#,L*1QL2W\6$OL4SY-IDQ.>#K/""+A&&O1C%J0/FHRQ?,GR%0ZD5!E5,+D>S4 MH0H@*6OB:UZBS@T'X<=V%BK.M7->< MB!#!D>.O_"-_&'XE!)6TRM2CH?M&/N MVM[FG8/]8+0^,8M-3(]:>*\H,<[3,:*]/F]6$A6=Z"_P7<>84I?<&6P&!%]` ML[QFD?2JA,185?>*4?.3F+.M^+"9G[RP_?.5\VA8XA#&:^OQ)]'HH[`$-TJR M4XC-./[F1.?C;:O9WYQ<[B1B@(`+]:*7^(E-;"=T)ID+FMUV"!6.!Y:I^93Z M%@Z&]85Y3UB3)[M&%Y6(.(ANW1U.H!R$ M22Z,M3Y!N9B>CY9(">NEM8B^4@"86CR4DV78!$)Q=&H),^KM(# M?6.PL6&C%QU6>7F>4;."BO4'W=;:XX+)6H2A+1R9:=6`A9&7%\TI-X$%7=BU M^NU8D'IQC`UHR(Q+U^ZG+MQ2*EXO;.>;)3IB@XMZ;;L4.G._VM:H"/)X@\8< MPRZC-\0`1D08_L/X3Y^?.H2:Y#B)(`4Y[FU M;3>&PT3V;X7<_H,W[WG[[J7+PLN#K*`=L2VQ6`0YTL&8E?/+^Q5A$DV:X3Q/S,/K.P]3%Q, M,IK9U3MJKR`V-O(6291HUWP7-1DRS/?208AW\ZDTN^(.2!3:_E4 MTRA?/6IB!3+)YQ&=FS"MO5X)PLP$7>,@%T_8Y#D MZF%J/B95.=ZM$\T#R5KC=S$)WPOB9Z`ZR+PNGNQW;?]D)*(3PG+=5 M,=]X`Z+#2X>BKI0:<=+"(;*.GOM:II]K[)-GPYS*F&B``2,.O9MD6*[#F]5$ M%#>#;?!W;?HQSUWDYL<27Q&:S9R8;%Q41"'NPJPQ]C:(SAJ"V`79_.O@:108 MG6BO07C"^%':08EA.`.[PV0M1%)+D)3'%][+E6/A&K`7"U\EC+0>*3FW:Z/1 M7I,.3#8Z&8T7#%41:QKW6:P[Z&Q)7).!]<]!,H"8=>7XM M"C)'0'/3D$F79&)$N]%-(R)58:Q)1U9VQ#SSK)2H![K"[%DO05@3!MJ8G*QW M",U8K'P-@H!Y=E0Q%9O4UTR0XM0Q$^D+;5=1Z]>*5UH^F?V<)=\Y"<2W&RUXRD;CDALACSK="?,%I/Z2%-(B M%>J'S`3M0B$V.NW.@O47H7Q>JV^&SMA=VI26&'D;Y'M6R!^M\*^BPGLG_\\'6?+UII"5$OU M=<8&+NL=A1=N?%JM):Y.0HY0(:Q:Z[B;B4U;-[&;KU?.X,5^5RQGB&(5JVP, MZR>TE"L.">;\;]^8UCR[UFTTZL"PFDLJH&9/8$#,?:BY^/U4/BH4QF=BCQ@; M\S)B'UXR8\ZF=\%=B$<=))4:\""@R9IU&D#K=`5'(D?3F&8<:\T;CL MIX]5"%594T3;>>FZ8?/@RD2]C"MJ"5O1^YFTX7(0E:_(+W9#FY4>+)AA8PFA M=C(:^3.?^28,-/7 MF@UK!;;#F'C,J;GF]]J,V%>;V$[-MMC1DS&=H,$"1Z5F"U`E<%_%`\V6^GW\ MCL-F(`OH;XMO'Q?,QB1[F/O%O%0Q1*!=`%*ZL)T),['0R5JOJB0.G7#/LQTW M;-2WPXF6GL,+\&>Y.-R.=5(X0`[_0O`:^Q'@G7$W.LERL[88R24HJD-F;@", MQ_MMK_2OFH6P%5RP;K\[:.^"K[$9EH^QQ2J#3F,X:&G61N-0A1BQ[E#+[&*X MJ!#6]MOM`Y=9)23].T/OFHU/X(!D/+(;ZV'39V[J MI*5;0R'_?-WYH]GXTFR<[8+%.>9:F678T)?#A>CK==C>=LB\"NTO';T(6]L, MF>P"+L-A+P&W,5<3D4HDRS+AE$K>?B8#"P;K_M]`%Y44WI^9#AMYMN/>8\PY MLX4=-)J]WJ``9J^848GXQD7MTL+>3N8SNU=)(.8E-*%+\ZD[P+QBCH'K\^]A M]2@/\5&$X)]_9\[(='&`2Y!OTW+-$=T+-M>_&(PB,J9UT/Q0D``L3F"-8]0* M0E.W2".:RU@X\?OG33LG;WJ-8;.M)HU4AS=3TG9E]<"-X>'S;_,-F83 MT4PS-$4X]X<'R?/H)=XOSAI(-AEZ+,1@``N[FTPGOECN*(&8 MZ'FT(L?1`NG/LF^V27_FZ]Z(D:U_3=O*FB*3&BP=?&GU"PSSY9A"R7B8*^3OE1#!>3H8DC:TSUW8\U(0I/4-51K0&%^QAI:[B%?/J MM!9&B)&`DRFT<^11JS7L1!'<%P?9@(BL9<&M3C/6[CP3&1P&2.U^Q86`?WYA M.[?,>8:%7A?>($40%\K]UJ(A2O^=8_L@:F,L%K]AF.()IA;?@1_8C@!#%C<6 M8)$12?_*BGSS*_.N)G?&]\VKVI4Y%4A7=,(Q/T-NNS-SZL.GG&=IB#L9\0,2 MKI,0=K_5C35J79.4XN:11_((,F78[W2W/@55;C_E[4B3-H%6MC58H*$`RK?. M]4V(5A9IOSR/$U+4'';$_03R__GA^X,SA1_^/U!+`P04````"``JBK1"F+?T M9\P*``"T>@``%0`<`&-H8W(M,C`Q,S`S,S%?8V%L+GAM;%54"0`#WY*:4=^2 MFE%U>`L``00E#@``!#D!``#M75MSJS@2?M^J_0\:S\.>>7!L[,2YU,E.)7:R MFZI<7$[.U+RE%)!M[6#DD2"7_?4K<;&!(!`&#&2GINJ,8W?NMVK=QM9!C+` M[Y>S6S"&INZ8T.:JX!9;?[Q`AL"8(FASB3=L+\$37"P0!2\?8#8#$V)9R#31 M1W`]H/4/Q'^#PWZWZU_ADMLP`/_-O<+@0-O\G_5Z;V]O!^\OU#P@=,$U^\->(-CQ),_> M&8Y(OPT#6:WW^]WMH[Y$*]C%%K.AI6^UA)DD/>WT]+3G_LI%&3YCKOXMT=V` M*>`"4@GQ5S<0ZXJONMJ@.]0.WIG1X3$`X#LE)IJA.7`!G-D?:W3>87BU-@5P M][LE1?/SCK[4:5<$LC_T]'^^^M/!]L<-=Y,Z*V39[`F^F(AU@##Y8W:S0:Z3 MU5J'%!WP#SWQ8T^JVBL=U`39$)OL";W;#C1W`A;_I!OQA_K!&U.TFE((D MTRP5TABRY;5)WG(C"BD6!C0ANIN3%Y9Q9=ENFLX)7;D.J^!*UZ^(PMQIIF2F M>"PQTTW"'(HFB.D4K\55.%T<#K0^'B\=ABW$&`\5'Y,QAS*EB'$$*L'F%]*Z M_5%WV/?C7NQ:)?IZ3VS$0_DA!J:=G8@:*1%=WA%$#K&*865K_8:7B"OT!-\S MZP(YPHB-XM@2\HJEYU7^$J*$BQ1V-)Q[^3U(TRX,+<1H?F0IRH6!C0GO[*T% MO['!:H5L3*$P@&N(Z6_0=-##_!I;O(;`T,Q9)V::*`QRBNCCDE]S`FVH@B@J M7W6,U.]"%`V5&B]U=$E:Y29X_K:7JEXUL?[U2F!V8ZE4:G/@2U0K#.9"UXG# MW9LA'>%7A<+%Q9*D5;S`=5X8^M/AP;YZY?\H%;-QE0KBD8.B%.4])7J.=IG3 M8-GT[H`XRT)AB+?$6CPANIJ@%Z7TB\J7>OG\T4G3]J'IVSE5,:4:@8C\V=<` MI+"YRVR<;Q/;0KU_U#\&7;"MR_D?GB8(J8)OGO(O>P$:CTT4\*A_/%!![%L! MOIG]0$\`FP/K7L.K)6#5\@16JP1N;,HO"E'3^AS49H*$?^:U"R,F-MQ%!U\7 M^,HN-H[.)'H$D2DFX0F--G8?D#O3/H?LQ9UN=UAW`>%:W,8.>LBT6?"-Z!8& MW;[FS[K_['_]?,%8"+8)7Y#IKJ-$?NS5!FSL4.J.PBGX?)GGT?#PZ%@[/1T< MCP:'0^UD-`PA#Q%^0:-.0*H']OG'"-N?ES)\B1YS5MXT7!=S:@/].26KS^'S M+T;R`"?40/2\,^AW@,,X(.+>Q8O.Y0WAQ=(^[_#FL*:84)[N7*XFDCY5)_?( MSN`L1:6I%*;!2R`WKX<^UX?-YOK!7B*JTBH_"WX-7A7]\MD<-9O-*25K1.V/ M*1^`W.4%/FZNQ1#%\9Y8NFH'N95M4PM2=\`G[[C93><6PQ=L8ALCL2KR:!/]CR4Q.7+FW4Y( M>,Q6J\,99?B?!2,4'A\.3T9'->>@*C/A[%3TJQW]2B@`V5G80K(BZ',.M#51 M,A/3"18RKB"UL+5@O-YW5B+6R)B@.=:QK-_/5FQ>`U1L3)^)W='9=K3*"\/` M'JXIQ,:--89K;&]G_N*WO,G27XCL/!ZVHY&/R6I%+#<@[HJ&K+*.B7TA3I5< MRWFS6Q.94VX+\2+5R.0S0?(+4:KJG<_J2;-9#94.Z1-2GP6?Z[ZW2BCK)%51 M"+%28ZOOYE?7J8,,95;2E9K$4`B2[%XXS8UVE#0!]H]K0G]8:SZ,CTV(5Z*2 M]S\8_W&8+>;)KM[7R&)HAM:$\G*.2]QXDP#&I6/?$SOXX>;R?N;I9C3,2J[9 MF@RJ/`KMJ+B"91-_MZ?:*E)4^'G0$LKE\-M14+F=7GAWB$)7GR#^7'(6FEBC>"LKD M\`.Z&EY&A;''4L^$C+E/!*:4RN>Q65F\)N8M6JZ,.NP^/W7FR/7K4;]V)/*_IF-[OX-/5=?.!;Q%8E M>PYE3]#&8`]2-Q]NC0`R!ULSX-L/"SH&SPSCESJV)-XCVWNXZI8P=O$*L2DZ MCB<2FI#T)[_$\VNZK!O-:Z66T2(,4L61FON$':F)#`91=_SNH7\PU`9'C>[Q M-P_\^3?AE\A"<^E:GT2Z>;L\$E,P3%@>3[*GNKK-H5(X?,UCX3U-YF!KL>T# M+]&<1![YO<.6B_G&LA%%S/:F7D)6O(GX.V0O"?_E%7D3-K)&O4<$K4VY^J+3 MC@U__KV21;RH6`O/8;^9IM\?2I2:ERMUIX+T%C5/!-NQF3^(5]#/$TK)F]BZ M(>W#I/)_I4RL/Y-&*KNK:<2(^1!-]I1R-4'RKUY%H5=1#%L[GBX8$V:+]2L_ MX66Y$A=K7J*HTI*T?4;!M[SU,BQ6A-OZO_[*CY-4#N4;S M2%:B*F%Y(:>/.:N`83U<_XO?WE%H"H>,%;8PLT4#>,TH*S.TO@SGN_B9\VZB M)MY%0![FCXB^8CVUP]X*?1E6%=S*.>[61.*_$33MY1A2]$`7T/)[(V]N7GR: MH5=D23<_*FHW;T/D[J-T$9=WW593_)Q%@4Y%0M0$^3]7]:+Y3`18?[D]/1D-*IMJ4``GE+RBGDF M7'[\8(BC]=^S8RTN=#X.I3TGI&X@W>=:^O6BC"6N0Q0)1SLV=<[0&G[X'4'T MS4*)*2(7KWN^N`A5G[F7^^G3*E^)ZM;U",,&L`!ZPY@CEIS=>D?V*(-Y:8)4'Q9A,+ MC/&)!OY/!O1$WS=[/QN=#D$?]D0N=!XDBJ1O+LD8`K(-M&9$2&D+2=W_CIZW M9!^#)$:;V^%=^XL$`\U+D/UU(:KAR"P>FY`S)94/VT=MJI_.2#\%(SJK(>8T M`OGP1V@9P%,&26=H5+XW,WU_Z2!U?ZE\HV9TIVED:J9?XUG MR*KPF;L(?-O_8""P[I+JVA!- M.:`C#CQE%R<>#*@\BY(/N+I.PMY[O$L]+7GB>=!!('G1'>2O&EG@H2;_+I M#6H_;5[U>)`X]MTRH\I7MB<>)!*'G9D;52),.EXDWC=\>DM_H`02#B4I\XXA M?N1(#)C[#OD(L*T&\,ZMV$_(I-2J1*Y);4K:+8P^U69YVE:EGF4=51)S12%I M]H,[:=UQV^8.XRB%.!#R('($2D6`LO(A`YXL@M\WAR+S/_X'4$L#!!0````( M`"J*M$*_K=\YBQX``()H`@`5`!P`8VAC&UL550) M``/?DII1WY*:475X"P`!!"4.```$.0$``.T]T7+C-I+O5W7_P/4^7/+@L3V3 M9"]S.[=E6W;651[;9WN2S;YLT20D84.1#D!ZK'S]`10ID10``A1(`#)KJ[8F M%AKH;G8WNH'NQE__]KJ(O!>`,$SB3P##!_Z.(#PX&__ M^Y__\=<_'1[^X^S^V@N3(%N`./4"!/P4A-[3TKN_]R9)'(,H`DOOT9_-`"IG M]4Z.W]'_O?_N^'^\\^1YB>!LGGK?G'];@SH\+-8X\S&9D\#EB[U_=[+Z)8+Q M;Q_I_SV1WSV"=8P_OCZA*$P_'$!8;'GK9B,D@C<@ZF7,^5CNGP&GPXP7#Q'%*7\;W,$II\.@GF`R#0G'XX_ MK";Y\YD?498\S`%(\8%')_IR?[5&.D@6SX&/P#ORCR/ZXU$#X$@_%G=DO3B= M@Q0&?J2,4@-:#WX3@`,$G^GWO)V>$P3\>(G/,@QC@/%I'!(%@/AV>H<`)HOG MWWT"4A]&^!&\IID<&1H6T4/M39("PL>E_Q0!=3)$T'KPNT[BV2-`BPEX2M7Q M$T'KP>\\B5-BC(E1A@"K(R@$UX/AI0_1SWZ4@=OI)8R)\D`_NB+6$>6[1+FH M#+*R,^G!^^+W#*;+ROPR*#*`>L*FH/:D$U8;X'ZQ4Y#$UBGT8'H'T,.<+#SQ M4U]!])A@>C!ZR)XP^#TC)%^\=&-=VPQ5/'T4R*+*\11*UXFZ"-_G%,S)%"C( MGL!A",FGHU[=@5`)($=LZ:-^8^E&DAE\.4&!%@A+O[Z4$>Q,PA3&D M#I/WS35QI[RK%"RPER:;,=_F(4M)3[@&(,-_J]%$%!C$(0A+JNC2\NYR,1-, M*=#QR=_K?%[I"Y=N4+D M/X$HCS>9@XZ,8_L0@-A',#E]A;@-Z?K8.NX;63A%=2J(X)43%S+8T:RNYIBB M9,%G:+%PTHI]@D*`/AUL_(@CADAOM&22:[7W.==J[(UJ,)A@#8E[@<:7&#^# M`$XA""?%%LG&GS_>'`T`D7CHG(2_4X`0"!_2)/CM<[$9L:D001BF8Z),!P>B M`QW;_B[]R[]NTSGQJ/.U))"3`^G3E&Z[>T([RE+;FCGERWS3I/9$3]V_8A+3 MIL[O*=1-+JW^^;>TC@F#V/:,*X, M[%,O\NA+:("W,&8ZLP6#-\J\B@L_!E&"0?CI($49V/PQB5,BL1=1#DH"3C"C M_Y#4EJN8:!_,KX2\:8*\36CXT?,*Q#YNHS^JT@#".2#6IQ@3IIT^X13Y0-J$"19G.)[$`#X0DW0#4@+QO&8 M*P0Q1DGN4M0^/`=_UD`[I%I&F@WB>H<2XF6ERSMB<]/3.*2W),_4F)'OST%= M#&*#K-PD<2`K+M6QAB5&*"H&L;N&_A.,B%\`Z,U][M+/DXBX-'AUI]9BN.7! M;:!0;C,2`>@[Q*AF'SS,$Y32JWX.9C(`QOA;Q>L>1-3-N_-1SKW(QSB/*L7V M4FD&LS:HBJK$KL4<;DX3*@DEDJH@@C!&QR0#CTE#4(3?0@1@5IX8#!;)$W.X M<5]42A]X@XWO"\O+!'V)GWT8$FL#%W0?*_X1_CO#*75^+EZ?08R);7HF9A>$ M9,35RK$(S[*4Z'CYP]79S?T*MF5KZ6E-P_Y9$*`,A-O;I]!1XP,9EXQ6"NS" MNF(;-HZO@H%G`5E!#=4._QFF?G0-?`QNGR(XR[-*N6HF"6R#A+6+EM%#7,5X M0',$P/&=ZU<01&[/LT5&=G?X`D0>M!28P6B]BEV>JLH-TADCS9V5)8M%$K MI@60IYTR@!;9&FD;8XJA=H_^@(VDK'H&5: ME"M&EW\<6E+BBL45'2:6M+ABO/B'BB4EKE@NWO%B28D0T6)#B*D>#Y.E:29$FIKH@_'%-%G$!,CR$S!.A_;-;PDJE'U,XK5OHO[)5K><08 M>?EJ=$QU/>^;8D6O6-*@O@9S$&81H*R*B'PG:%6[C9`?SW+QH3RCA4N!;`GKEEVR+C."(;M5I!OBX`S: M=Y^D7*FD05GIA9)L6JR\\]A/%=(M>"9Q%Z<8 M\$;K\_`4DB^^!W1$HAQ@I94$/AEHJHSZ,/]GP`E MYTGVG,3<13$?;Q5H\U<<0J$7FB?[ZES%.K`.%U0%RSD"5210RU7*Z,"-#ESE MT2>"PU6,4Y31$%ZPB;(&.NFZL0A15*S1;[-!WHQA?>,OQ"X;?[@^O^>Q?4\4 M^#TJT/IP?@`O.V&M!M^;?_P`8I@@::Q5H`W>4*_96;4[PI.P%AB#CUSYL10! MK('ZI(8OH2+9B@)H+VXH7]M*L[,^N6T/FNJWQ'6>PF;:-0LS96?4L MUF_"#=.-')D$C6II5)AW.5ZK\E@B^ULX?(!#O\]^2CXO?4[N'L3@*_G7@KZL MIW3ZQYU#9^I]-9B]17`&8S_*%X;I%:JKAR(:RY())0(H, M@,Y>CRSQXPJN<+CY3?@L02CY2I_=:C-:U9&6R,05V2$1P.D]^<2KAEK%":8_ MDY,1\0264'GI!X`I7^W#^[(O.+>U?L0O=!&/UXO7BMH'$.2J-2/1#DY/,8:S M&(2;E]>;`JX.;E0>BK(-^B)F6KZ(V284`AA+9+NRK:_^2<IK7RQW.LF,:>AK4=94P=6XIMG'UF)B)**A\D+%@L>MY5Y#GJ M0LB&5269+GD5W<*HDE)G'([=(ZN29!?<$H5`K"1K[:58T_9C_Z_WQHIJ4RW; MM9?XCEHSUK,-5,]F1&,T%:!(UWZ.^C*FC#K?`VJWYZ:OARTMH&%IN=.U*<)W M346@P!Z%]BBX19I0MTBBY$;F2$OV#A<[!@@X+]DHP*X&3V]!/]ZX9^5B]?I8 MC6QI/:NUU0QOP9"YNM%OG>8)<;\V7+[0@CO?&-C6UI]#R*B`I@5YEQVYRF:) MT@7A<#?3JO:F1&&OT__K5U/EEZ6BN+K.%Y2P2$(.AVL7+/46!JT?*UX]MSPA MGRR>K1;*W\:F?Z:[SQ4QXR"[G98Y+J=Q>`G8*=T:)M58+++.P+F=TKG)$N5J MQ3GDV9*B0Q"LX,TBJ^M,O:?0/D.4-]7_%?CLODTR8%9%%DS72/V2UGQV2#>R M+$\K[>S&6II2*ON19+Q^ZDH&D7-&-;" M#8<]U%P/:Y`2?_)VND)+W,6:.=3\72Q?9/AZ;=T]K$B":AUJF1]AW.AML5]N M;_1;")TM;_+*5/KJ:/EGD556F<`QQT"%-"O?>7DC"C> M8&0X318`GZ_7!>*X7GYQ1*^V0ZQT[PU9$KSWK2SQ>8S): M'KGB,G1E)J`UAVA,LC\3RN?1<@("!'Q,>$"[O/!SC92G,&=Q&9AN M+M/H73VO$Z`4I+ZO\MG_=X)*9X,*(A4Z?AZ5<+A5[A5OCV"+N37)+2I$J&J# M-+'FJGT_78GQUJ//P%]TQ:[S\F!4DO&DS^Z3 M/B,JUO_AFNPYNQ7W7I<^1'FZXNWT$L8D4H=^5.EC6*C;MI[^T-13.I&7S^0E M4V\]EU>9;*V]YK1V3>[9\LR/Z,'$PQR`]">49,_DFXI.LN1`C6EJ"WJ;;T5E M:^4%8X%UZCZ=%1=I*M^YJM_=R;8R*V?4;AMTP`0'F,@)-VXYT+Y>V1'T8I!J MN[`+)O\$*#DGWS2)6S#A#-1:Y$E4B7!>@,3V&'WK*W;)4&B+H:-P6!JO%@#S M-[R[&BKFEB746VLN?E4L%*<]/;>SAUM$<:R)-<>OG8C:MD[6G+1VHD>FLXSY M@]9.I+582<5#U\&3*T;?=N\B5P9RZ\^1OW>1-W_WGZGXM-YO[SZMD>P.7=Q0 MB&IMZ_ZS*PM&@_.&U'*G<&?]B/<%3N&"/JBS1@^SO[(H=V6GZ2PI43WW$5J2 M+Z'P'&D3Q!)*UJR7(J(RVA+\O\3^(D$I_`.$U'I0WMXAL(#9X@;(?9B6&?3I M$9GN&OI/]#H2`BP4(8GQ?>'%<)+;D6,"V>+M:W01Q"IM7TS:&^D50V!?Y-H; MU2VFPKY`5P,G)$R1-9UV>J:;:>6:/7FL22AYLX[X>*LUR*V6D;P4\U<"+J2K M7/R>P719T<]M+?]+4\M7,)8I]296?)@3"L]\#,)S0BX1%7\E>8@^8)*C>[;< MC+GSEWGWG:\^"D5G?AKG-_>^V7H[6_7CRMN)B=YGXX^W(BE%^S>OO8S&)][* MU)3]T>2^I'3(W.D**N+,:<9`> M&@G;'V%T0$8'Q&H')"]*>B2K$/'.7P>/P]6WS!]%SR-G@:&7AMY_YT2:%5:V MJMD;G343*?K%C3YV=W3HT6;&^TL MCF*#/`U2^$*KY`496=RA[EG0+2F]38G2/<[]^'9UUWN3Q"\`IR"\R02NX8#K M:\S3ZPWIVRS%Q&Z%,)[]`N@K'R`\?0'(GX&+5^)'00SN$`R8>4(6(+6'4LRG M_1Y0CSE_6V;5'2;S(UJ^H-UH]8/C'GZKGZAMQ5Y$9J&([XBJ"U^C0)D&?DPG.:/=(JC93;')9UZFQ$T#'.G\YF",S\%%P10F",8<"JCK$`'\.']SV=Z`T7 M=UM3K*&7D[8$W=94A;@FJ)W"9FLJ3USC=C,ZMJ:4Q2FKH!(76_.&M6NBRHA] MK7D;VREIW3'$M>:=;J>8SHAZFT^#CXS4&O*6*3''(W][#W)+7IM/JG*5U]PX MMV2M=++K8`6V^Y,1,=;F&"]LU5[H,JJ);A$;\\)[R@LWHG"#)EL[]=C!EL(6 MFG?"4-P3!G_"@FRBL"*-<;L?TU6@V`WBL3W0&%W%D:;,FZX M8K>A(`[O(C^^\1?B=X/Z6&.71B]JK\I*Q^,NREM[N%'_M@S%S1U%=X,II&.:BYD<_ M@1@@/]K(`*\=^$!KNL?+[52@?JK5^.OL`\\4TI0'7]TL?Y_:*7Q2II!W/?I> MQ.NA,7%6KEN35GJ2:(EU]Y>G!BS(\/4W=GR+MJ*<'M?9!YX9D-0^:V_LV.O4 M4X%.>MKK.F'BK%Q7=G9A%P8XJ?L10_(QGWEF3+N9R"_TCF(9LD0^G?JRA],4T7 MU>?TYME"F)7F)1PYOI^V8SJ\Q'?8JY?0K%$)R\70S2+,01](BTD\DD*B*'=D M6H`0"&6>2VN!*H$J1%7.NU5'!`E@B^@ZG-0'X)=D*`" MJ`_3FR3^/V*=X!32E\<1"`@@IFOQ<6P%,5\^\?8>]VL1;'AT(O.C*[RX%;Q6TW7@+ MTAH1-RQ60^,H#`)J(PRV'7F%BVPAQ+0QQARN1#]:<:V/T1<$7%'=]".^R]\8 M8-[!WU*3+1MFG>?+T)IZZY>:(#J#=ETFK?'4.6BSI+GIB8^>WNCI,<]/5YC1 M\">)*6(R9ZAL&)<\PA92%+5G]!*=$,D!:6F@(SS=YXPU>,"_6"2QS)'^UC@; M.N/(-L:QQ^^3$ORJ]>)(C#7NE5#ZZT>\6R+D'A$,F=+2Q]!`MQWS6XE-GI8L M+M><#A>MHP?M+R.)^SJ@X#%RXCGY!19?H54ZTX;5J2%`P0/;RM M`JT/Y_I-U^H*C&[IC\EJ][JG=T8L="4!]6%Z#0F#PM455KXV(/IS!U">!,A] METT&JF<YI?0WO:$$$ M8.Y<8?$<)4L`'@!Z@0%@R^3Z\<9<\O!CDOI1]??S!*DEBE^LO%*_TGKY6%KLEM M.&N3V'JYH]W;=YE/(?Z$$JR]3:1HI;Y?6V[Z>5](P(DJYT5YIADS97:7Z=R3 MAE6-==&;%I^^D)"8'C80*Y9_-MTBT;J<>QQTL@>F[I?+>D&0)5$ M7N7TKFJ97$G9DUKY?IZ!4*I/I3:XX(&2M/6P>C\E!-5^^H_);4:^;%QZ'NLT M6Y9(=9A$>_Y3=?O;2'./_$3YY.3S,458[)W* M`NOC=/Z^YNVTJ#1@RN36$+LC@RXAT&:F%5#S'R/C7?(T MT52>9!GO2]>!'KTW0\;[S'7@0*>K(..-X'86W?JED/$F;!WHZ?%^QWQG-9OX MP;F6V6JAMC=,DKAU*8EWPF5JO8,IJ7'"5^KU5J7DA!..UN[7+26Y3OE@_=V= ME.QX&RY<:W?Z$R<5#BA&,HNB$I"7'" M>1/>KY24..6)R5ZOE,0YX9BQ[VA*$ISPJ"RX3RGYY81+UNG6I:3P37E9W#N4 MDAM.^%J[79J4I*X=*.N;KINOD!I;SC9D3D?+62--T;7WP!RU9R#)V_L>8$;T M0;EEE'3CNU'PQ[8F_;RG)W9S7'ML3V9\J[;)21V[D`FZD!$%?%-=R)S1#$W2.*!K<0/2 MJY@P&EPG>)/75!9YY`9VGD1$ZO"9CV'`:52V\VR6T*]"G6VXMW);SS7"[*)S`*"LS7&I?)/QWAM/\?KS#)U:9 MU1@_B"JB?-O.$T(6ZWR[-$7P*4M+U2SK26ZG]5B#PX^=9[6;']OI$Y7GH'=A M2PYSJ+FD?_"21"_$UZKC)2X# M$,.83SGB"Q%?X>W+-A+(5*W.0?PU1E_`,@OGKB\P`4_I)H(3V&;60*=\`18! MJB5$HR]@D;P9P_K&7P"A/\`?KB];;K-%5'-3DP7$.$'+FR1EE_TIPIK?]_D" MPU?N*L>MV?O;9&B=("C_=48_P#+KYJX?T$2'K"2-=LHCX%*AF$T^N@5V MBI]9_(4>@F"\+32(*ZC88\V["RV"U*+^UCD-K7(E($BKE]!C;@37 MG/*']NN/(8B\R!+5ZG.\.3-7C%.A]Y)$RJJ,U0KW3VX`-?A<\XN1[RH$8 M,QJ40[?3QJFU_PH7V>(L02CY2L-:_YG\DC:?2^LVA564GBZ2+$[;DY(E8?7) M&&O!O+7Y:M457]F/9TF#6O4EKHA51@"G]WX*)AE:OT:B\$'X4UA%Z<7K,T1Y MU\D)093W.+<49+_R]ME/"1?3)5WL@FY)U)=G?I5N4^A\<8YS[K;)ELV;64X` M#A#,$RI9%'2:1B,5?A1D4?Y]"1_K2Q*>!319=`9.GY\C2)NR3D!,<(SS\:Q7 MXS3-.0Q]93KH68:)&&$\\9?,LEWU.72^9DK;!.<]8OWX-UJK%H>GX0ND4E(T M&,:7@)F5SB)EI^E,I_75.\:N<00!57<(,,UN7>\ZOP$=$1#^3^&G.5$T5<+M.:83!III[:TU7EEU)9+BWQDN&5&A3\X6- MO\NHZ[/QG6#C)5&Z2-QR@XT_V*A%+H6^LO'2+F42.SG3QBNYU,G;+W+21+?L(AL&W%M7U5L5#WWI!T9HB MO[V^[QA++_2KD%S!G\YZA5%7AI"Z,379M,YHRO6U[T60O=:;,7?/)AW2F@#7 MF@%;_)W^WY./`?G+_P-02P,$%`````@`*HJT0D]C_C9\5```E*,$`!4`'`!C M:&-R+3(P,3,P,S,Q7VQA8BYX;6Q55`D``]^2FE'?DII1=7@+``$$)0X```0Y M`0``Y7UK<^1&J09R6M;\MH7S9>VSQR22W(DRQ,7#A"H M;F*%!GH!-&>XO_[J!:``U`O/!+GA\(I#9F9E%C*SLJJR,O_X?[[L(_2$TRQ, MXG_[ZOTW[[Y"./:3((QW__;5,7OK97X8?O5__OU__H\__J^W;\^_Y#@.<(#^ M\^3V$EUZ#SA"EV'\VX.7872:8B\G?_LGM'M+3I+XAA'$7XN M1D+OWWU#_^^[?WSW]JV@?4)H!(C\C='^[IOWY5\^$':V(?OCC^@/W[[_EV^_ M>_?^>_3^_8_?O__QW1_0S0<.&A6<$)GB[-^^>LSSPX_??OOY\^=OOCRDT3=) MNB.8[[[_M@#\BD/^^"4+:]"?OR]@WW_[GQ\N[_Q'O/?>AG&6>[%?85$R*KSW M/_SPP[?LKP0T"W_,&/YEXGLYFV4K7T@+0?_UM@![2W_U]OUW;[]__\V7+/B* MS`%"?TR3"-_B+6(,_)@_'_"_?96%^T-$&6>_>TSQ5LU%E*;?4OQO8[RCWY*. M\`,=X?T_T1'^0?R:??BO$(7\>+O1"O1#C99`^I9S&=%_4=6I\8F%?A6<4GS# M?#'R;)X944HV\6L$(SKI25J7W'_TT[=4A=Y]SV?N'^AO_OLL\8]['.?K.#B/ M\S!_WL3;)-VSC[9^R/+4\_."$&.?4W+$^[9DD:*NTSJ?7NH7I,F/%K$%Q+=^ M0K3QD+^-^,QR]&V:[#LQ)MA(.B#]=_00-26JB9/B+#FF/N[T'64INLXOYXC8 M)<&DG@O';S_>??7O!2KRX@!Q9"1AHT\%_O_[(Q]_7)$",3P;;$K1,!F#AD$=AYWH'ZW.^^Q5&>%;^A)O3=VW?OA?OY!_'K_[XC M\F+*VKWW4#D=(;8.:%[S,+-*;4$-,9OBFX9OJ4()A#XQL)8R`WQ[XMKQAOR8 MV023`(%UH,6R4@]**#A=:+!@T@<*BACL8*7(L/_-+GGZ-L`AUP?R0U,-R*]* MGW9/R#8D:?]YWD^N8X]^Z.;?9ON\ZH'U_I["S/4MUV3$@(YZ$7D[!=^-O\__ M-94,%I^S]L=9OZ=BY-8'+6$0!9K;.F]P&B8DZ`C.B*\P:&0##LY>E0PW#;<& M!&+!"@[TILR!26`:(`H^MPY_?``)0`"4'.@T0P(A!(P(^EPZ<'M.TYJ_T,:,>='Y- ML+%=*(,.;E9],#/14@D!7EL4YHXAN5I>A!%.3\FPNR35.X8&%)1;4#);=PHU M$`"7H!A?YQ`8*"I@9UX1DOT^B>_RQ/_M[M$CTW!]S.G=&+TUU+L[(Q+86N$@ M2F/A,&!`K")6=K1+"L-$#'6%.#*2L!=PBGR]O0AC+_9#LGU*LM!P$]<-%?BD MV4$LY=FS`0_N--K*5'O]2N(LB<*`90N<>!&]5"?ZAW&>&6[D`-3OSL>Q1_;@ MZR^A]1ZC#@NL8"K&E1HE`\*I4)L+_9T&\50"FN@*@8?4$\'(QS@[8)^EJ)PE M>R]L7O4ZP`/IBTV`FL[H@.?7&S,G;=T1\"LD8:!/'`=2?W`:XNSTAI#$)*(/ MV$K\`>\?<*J3W(0!I$-V(6I:I`>?1(^>AF')KWJ.G_$*1_`0>/=4`"2JAS% M*/.I+/!S*[T[3W:M3R@9H?NS:?L``1A6H>,-W==J_"B"6!/!A@@DG,^A_GD` M$\#6649">3(V'J%ON8,$A"^BNFU-$]R+[)O1.PC$,J<.A0Q+ABP08?^J@#,MPPQAF@ M\84QL(#3L\O0>PBC,`]Q1M8`=I7PF$0!3C/JV/-GR^F\.SJ,KG853]9F5UPH M%]R-OY;F76[6)YO+S?WF_`ZMK\[0W?WUZ7_\Z?KR[/SV#IW_^>/F_E=T=GZQ M.=V<7YW^.KO5#)6N0F=ABDP`<0J+N&0HSG%NO&=ZAN-V;-@$ACTP5+.N.BJL M0T(?$JJXT9^S'3@TV-E@-VX%]`(VK(4A/E\DZ2%>VK4XH?@+\9725[\87-R=49BY MTIP$>,)B,5?&^?>,`W@OO(V$MJ`PP&H3R[$#-]V?2=^MYQ_.6E*_&BWO&.Z;@=SRSN*ZWP\)2/\ MGMT$DA`YP-O0#W'L/_\X_Z.0(1(LZ4"MGA9ORM%50D)=AVN9KM^"M\"F\=[D MFUJNOC6,V!Z#`-QR=^=4/')BP"NTR3(23@.FH5(?."B"(UTR_>_?-N_?HX*7HB>+\*_*.^6.2AG^C.LZ*(_R(_O#N MW>H=_W]V?/&=]&\"<,!^'C[AZ/E?4TKH,&ND\Q,U^[4%&#@MVHF-AI M'X>6T(@>![X-8^1SA/DO5X8PC@CCIVK&Y]/X6YQ[88R#\?]\>( MELPX8^&D;A/@@@AC!^XBR29AQX*R#E?.VE4=^5]GMXK>#!>(J,!$;R1<))"_ M7M)6V7D[M)RML=N6&.981\>'YG0G,V^#%[`+=MJ_B^WO.L_3\.&8T]L]E"?H MQEO,0:4RA:9GYLT"CC2-XG3)X0(__#1P93\19=L&0'/I*407)>')DXSTT9:@CWI1-';41-C&?:CYLJA MG!6O!5H=@$UB/QU/HQV%$>5]SN127,W:.*OVV1ZPA^C\I>I56]?:+P7K#?BY M88<9*!"6XP7J(M@\`(=>DO7+'#E;?J@\[P6Q"4?^Z_8`?5ZM$D1?(]L9:SE6 MH:F2[8BR)/NPE\MN*9DPDD1?*AO$4GI(LJ2BW]+]5,>MFA,F^*UIETV:`]H" M[E8[;FOJUZUP>[/!$BQ[5]9J"&#=DADQP.W&93-F`%^`G3@&]W7[F&OY0U?VV7D#?0\F"0)O MM2YSOJS=4X?V0FXH"[%;RZ9I]L9"?2S8OLE0FC'D7JF_#`O<)6UBXEUPV0W% M\B)`"PUC$1;F96/0@,[>:\3(A[FS48F4T3*]UP>E#^>$D=\G>Z\./P; MLR6>IDE_$LQJ)';&AM'NCL+)2N^("F4+G=AK:>`'+_9V-*`F^"@5ZCB[N0R3 M@6/3HN88R?@K5%%`@@1DR)WE--='5&FP+0MZ<*A0V\Q^/=U1@7"_`M(+Y;7-"-,("QB2:%L76_O; M7&C4@83$8![=F4W*90$&IZ@_X9CL'2)B0.M@'\8AM1SZSDQ8DT9(*Q:,*CL* M(^NV!05*V9W8:JF5P&(>W*OAS6X&PP6HXQ7N';`B`%C(0Y"R-9A`(>R#"M+BB=1%08W#0EG=L,8@?^U@7^XL-XQGEM*&.\2 MOL.\]%!SH7G9`59MS)'+:DMQKN%TQGI[_)@TWO&#U\LDTRFM$A*HLIZ>Z5HY MO388C/9J&6F7GBL@T9N(0'V-0H8Q?]V\'AQS4/2&`@.^3;U*XJ3.O;`RRQF+ M`QZ,MCL+).N^%0DJ5G%D3%.4,10Z)ES\U_.?Q?3E7\8K3$5@+N)TALVO5CB= MF[`@`19>M8K2*KRJQ0`MO&KA2F,G<1*_K=2-6PU,>Z0!0JA,YHU`!%Q@JB7Q M@JC=:1(3_HZ$Q>K&^01ODQ1SN'OO"\X^A'&2AOGS)LXQF>"<%X*6J/"GNQ]P M_IB0OSQA7L19%XK-R@%DZL*LD]Q.AYAE>)B0='8!6S;.X\1B17]@HQ7_RNEX ML[LJ^#FIA="(6@2JV)!36L1TB8(9G#R2Z*\*?\FX7)%(@\0721J$L9<^HTV. M]Z(_%Z%.YB7B'I;+`.U9"TT)`>2\M\V[NT0*'B#",[.AV% M--&.K!+P,M1^(S`@-Z@XKWS$^LD+(UKHYCZ1\B9%]8\3+PM]S4QTI@*T>>TG M;&TKVXT$S'K:B\GV)A'G]8,?Y#5J(G"NJJ@_5[S3,SDD#2R,VS$R+CL7)2!,,6@#*RU=4NK%Y';0A<.R M=&'Y1!-Z1MF$B,9&WPU?'_0-.K[>M1PHF+>](`T;[>PDJ6T4G`C#6 MTH/%A5C1&)P7-)`@@C@5EC_5>CT#;GCERXSK[:F7/5Y$R6=;QJL9!:J$J%V, M>C%1/?SL#VOLS'1Y74-)($9C$9<7)+2B'-VDR5,8X.#D^6.&@TU&/3EM:S55W2U377;`5ETQ>"4)@&O%L<2C MNPPF8D$*/3RC-Y0:V6%]C:KK^HKB"S/AP3.X?),=9JHP`5E7_I2:ZU/-/4B: MJ[+.!1OG>$:Y.$ODMPLC+*9&0HNR3`>1'2S40&5ABZF54^MB&A84EKB8=A?/ M8K,PO5[Y.U_]=CF&+"/_$Q^?,-$8]>4M*+P\->WSVV"P&@*HF= M1:P53'3&'M=$?^#*&^,=W5293+0KA]HN.QD]7#X(9/Z0L<")9UM"2XU'7T>GN&'W):IXOPB=G[#8N'4V+`KI0&(51+HP(<>BW4 MLJ1X'_:0LUIV%!#Y%!)LL7/GNES=DBUB$A1(Z%0EP1*7LL&>9/E+U[`E"RP] MI1-_^L.9(W?:RA5JP0O4>`L3X.M2PBB)D>E_:'C[Y$746=S@-*2YI7Z*O0R? M8?Y?S81U(P'T*K6'F+47JQWP@5ZS=N90J;BA`$6L\VOV./][U^%R,..C&S;V M@T1EA3@=5!!";PI2D(TOCX=#Q*Y!O:BX1MW$VR3=\\?KEDMM5VR@^^UNPM6N MNMU0H?9IG=AKMSB2L%$09GZ49$=6977+UT2Z<2-&6-*;?Z!>@C09K.>_5_]'2[EO\F#(GE>_1QD* MDX[,3\,#<])D/58CK`'W#M,%!M+IF.M M^-R)!ES'E#%5\%A)!*T2PN6@SRF*4R.B(3?#@I:OWH7%EKJ]W' MDSNRGR.;.'3^,_G?^7=R_5D7F*R&4-MZ%A%O5-*=>I%_C,0=Y=5Q3Q_0)^DZ M#LYPG.S#F/YK$S>7FGM6M\_9U,89!-HJQYPJ:L!DT(GG:$H;GX)[HRT]T-I; M[#@Z"*,C+:6$Y5B,!6&+JGHY^PQ)0]!_EH.P29.&H7GN[;*"Q#6Q65N$@V(O MO4O[@'#MTXR'G>Z!1A<"4.WRNHI8.(W^L@W6,.?K[2WO#KWV_>1( M##^X2-*39WJ#KCC9Z(0)8)7=A"IMU`T-Q&*[L*8Z0J/(4@]PY!7X],&K+]#G MM>911+K>(H&.2GQ$"*"39W0ZI5A6:Y_NBVV)>-)7&],;='8"R[/];B:_/$OO MHRZWR['J(>POS(+'^1(36NO'^."%P6GDA?MFX0W%WP%L4<5@:7KR'T$LK>DW;,4C_XR-`G#MXZCILXK%PLR_:0L1_K,04>T[#^"Z?):7(\)+'% ML#2``(9E9+DT+"74O.6R;7RT/C2%?>LS8%K&L_;1@4RL*_N(`R_"QCKS+J9^ M=",[PP^$3UI'1&]?;1@`T](Q6EI5$P!DI5(SH3KD%F!`MK,P/JWVTIG?,6WD M#L=ADCK'>49P`,MQ8+\T(@,LB#U9^6E?Z3*,YOT7E)V]$/ZM]M=;CF:L,*9= M7B;Q[AZG>V?+M"``V*:3"*5U&J%![-.!HY9F4!Q$D99BI"])"*NE]A8FI\), M::Y7.+\,O8P%A=!"AMU00,8JIVAI3E/:,* M!_D""7D,:UXK[CG^K@8[_':8ST@LO3'_VHJ/T"-,NDA()W%P- MHFAL5H&Q`,/5]G8 M6$608J).>4C8O2%D<9KB@!4Q4&YAG;&@RAPY"5.D87>48DJ[=6)'<<"1LIB2 MYE04J&3_)'#YHXGY-[3]9)$P4(F"[HPB##I0I5-WUDW].V&"'+-V$4HZ<75! M`SI\=6=-9QYGRS*/$>7J8S-S'=8.D.]4_[E&O5.A!#:;E?<$"$<0!>1*OMWP8(Q?W?.U*684(F,9&S6(!/L0N8%"V4W_,'"A:5P MOBS<@:*/>LR4Q'\^>E&X#7%P%J;8)X@995)O^%84B",F-S&J`R8S/,SQD@M/ MBGK',2K14(G'S`#(M%^:(/:CI=X"_;44*"@%HC8\I@EOXC`/O4AOL`T``/-4 MLE@:8^VO(*:GX$#QLI?!`-G48CBT&DL'3B<]5;T,8[S)L?HIA`EZ":>K+>;U M)ZPEZ#).61OL.!U:4AS$D*"/6Y?(??=S5T9VFA&/6 M\^/DN0(1+9'7G[TTN#I2#W.]97_-UD]>&-'SYHLD_8G@:JNO338<4&&?B:>O M+/$ST[Q-?;X\X7RUVMVP-EP9\@I8]OAO1Z'GK=XSG\@,\NT#)53?E4NCT>>/ M,IP8$;$A5X@/RLJ.L6'1NC9]/ZFF[P5X*Z$,U\<\R[TX".,=%W1L-Z4?YX7Y M)]N$#79,KC.U6(]DF"&=*THJV$E!?&M.(8>O#(B/XTN2Y\%L_CX%7.(6;_G70"1U\)>\Y; MSR7PNIBW:WG>^(A+6_I$;'#,'Y,T_!L./L8!3MD9-I>"'7B??\&I'V;X)@U] M?$MGH0@MQ%_H\BZD[K0@3C#ZDI;)R2;7O'A./JLP2^H4LZE;:'$%O``/-X?D M.K^W*N/X06"G/R$L!V6^!(!/C&K).HRCLT)PK@MVH=N+3K#CT"#W?YT8+NSUIPD9=KT.'#+3@)<3 M+/Y8?PEUNQ+I[S#[AA:#162OY6RRT%-FI54'C_X-?:)_!2S'SK@PIO37(`"_ MJ#I5W\#=M%]5FZ\NONM9LO?"&/#+?O"^A/OCWOAM&S`P7U?):/%]C1Q.O6=N M?=(\;Y3VER/(3Q3O76KQLJC-YV$:M0 MYS[R3*9!C@(T%:MZX+JBA[8"%3%<5"#KGMTM1NNJ1[`T+80_<<\,84U_4%IL$[:79*[G)**4I*C9DX+&Z374+(!)&[4J!QYF5N:G,+Z+,":_(_M7UAF';HI//;Z1O=2DHHY'%MKM M#IN.MOL=9QYF<,.]!3<9@,X7EY1121H5M(UYJ%`=S\IYTBB^%GH)OV16=!'9G?=&4>.BVB5T[)+SC8X6),O[^UP M[4)V^CQ!\^A+2HN8;'(GR"GL,JN#K6W>]#O+C,Z64/99\($\SDB1?$'?S1-6 M7F/6WHN9^M>1[#=@ND=-`2SX0(*11KK,RUT$+Y)TBT-6,'P=!^=?#F'**&2; M^(:9U43+G\.X+W/AH` M/?.MML@"_*TZ`J5O!E^Y2P8,3IW<]2L.6Z5L]$E?9E^5SMA8_E2ZTPM M?YNOFB.E$EOFLKM?D`42/SJ._>'\U9T38_!CR&8SP`-Y)9L`I1]QY7PZ MO3:PVJI83$%8X19>>QDX0TSFV)@/I@($*MVO9;FLUF_E=3)54#)GTP'PE"UM M\6W^*GF394<*A>E(PS2Z*JT->8K3LZ MC*UV%:\PT+YR36V5'>31Q?AE-H&?[/=$"X45OD4/%'%6LQM#FB)^;E6VX_@T MWU,AUGP&)G=!/!*'0'8F#UF>>KZNAJ8)`<:(["(49N/.^]2&8N2YY;@YA-RI M[L=9#:$3MQ+P"A6L?RH01NU@Y#_BX!CAZ^UYEH=[FA!0)I.28+7,F):JXVJ4 M>S@YB%8GP\6O&J#TIP73%F4HO^VC%$&1NNBJM6L<(%P,('6'9+N<;9F1+Q53 MGKF1RJ334-*4TJZ9Y-5;A%HQ;*V-CS()]L8KDTY&-S48LR1,O7S&.HZ/7A0] MJV9`!PG@G,Q,EWY'#0;B4DRL:$N]B2HEQ%%P\'G-OQ?+`AJMIV39:JRCS#9T MY?H'^YG_0^<$XUM,3\W([\G^FSDG(NH]3O??F6[QYN8$\$8/9M)KMWNPLSW2 M39_]I;CQ4XB=$X)^,3-]Y*CY`I);"'* M%]P"M\XRG#N>"6E@818)(^.%&W?B>.I#(!VGNO,?C\'/>_3CRB.'&^O`9QP5 M/O=2:E39#4Z9C9Z%T;%=3=,*#:/&%N8+17;D>FI5UG/;>M+-_S*K$KMS5T#2 M]&7NV&E)$B7',^XURH,-=EGWF$0!3C/>R.LJR?$O["5GGEVGMW1AR>[QE_R$ M\/.;;L?0GQY0W#]T`LKH?2S)I[:G(1*;3K$^[!MX!&!3CX)5\_]HNIAKPPD#I3 M&$M5JP"A4M5U+%)P^453RVK*_6P@2DB/6(?+Z`\'0=!"$%]:*?<(Q3 M+ZJ*M>E2<&8:\X6%K%TF^6YY1X>YU8C(S&T M5*/1E!XT9ZN(OR3I/1DEN][2VI*TJ`([+KC#_C%E.8N&MV3.V%#M)3H)5S6> MZ"759)KO+D:[$03!1`R5FB\K'LHJ4_`3H0H?_'F:@XS&5VL=\!>KB^HW;KTE M@]1'[8NX#AH)_EA.[)6,>Y,&#-"C&16CY"%+?)X\[,'#>P@Z?">"/K8%N9Q;B@VVIQ8&3`M#E'*"/, M%US,TF^"3)8T8`NIN4^^#,E&-6"<\XH1F"A&D46G:N[CC`5PR^PN3'GA;$#/&N>]D!Y%F`JSRMSD#U9AKJDG_D)C/B]5 MLMK-MA=FTQUL>6$VW$,SEF*Q/2QU:?;9=_:AGZ'VNB:D__,S?=0>[W@VVOO1 M+^150RPT6NTQ3<.OV^WSL]S;=>6\-(VFJC(F2JH]<0QT4/;R6.89HINH8]R? MLU!>C#2@W8EFG2_*5Q67$*?T66<4X6`3GW_Q'RF3XEB(E:92>"Q)RN%.&^L,;:HY15<20AM M8G0NBP'3Y,LSVYQ1"OHW">%:&/'N`*IMZ'T*4F45G M5)`@@^Z3RO?(E&!\S/C2:C_C"@42J3']"\^BJB,0OY[ZH8G6#PR29`,@B=761_HV@*<<5SC? MQ&31P)=)9GL_H(&%.7SA$'1&\H MZ-=HG>=I^'#,V:-OLBS=>(NI3[+>)VD>_HT9+L\MI?GRR3'.;U*\#X][7=:! M'0\H$\%5H#([H:LD4YN!BP2M*U@)A^ZF`IKE&PBT>8OUC,`]RU$NT-`;@?CU MF`=128ZS&^^96J1#R&8$ASA@LK-?'2;I86$.CFS\M!TJQ4`"90'AV8N1P'[, MTU.2`T>!OG0:4)Y/W^],5Y[/>#NDI\C:;49?$4I$_0,!@0Q8-'1_B))GC.]P^A3Z6"WBO??E M!,=X&^871%'=S6PLXD`E24>=FK*"Z21S,K49CS8731LA..B!(V7(:QQ>L30: MQ,VF=HF&.3THCS#9;!2$D:"L=1PK1"=.T$=4;Q?F5X:6JZ-Y030%@.<%E8UM MQD[:LXWVPO+WW"9OK+*/CK,VPR9FDKG2M65Y8AA27R2T4]4U7&9Z7V>IQ]QE M\%'EBI!5IZT13USYC0AQD#AS.'`U00.-AT<0>HE++:%S.6=Z4[.NI%?*\$;HP)C%]Y6IX/6_!@2IZZB!(5?^T@P33 MQ3X6EC6I/14<^"/\!N/&5_0:6*`C$1/CY0F'"\?3[GJOTT<3Q^T0F\,6)YS<#`]P4.4B0'E490(&.:RR,Z1N5R!0$.;A8U`B MS7M6-91]$?V>3G7R,Q;J.@T96\A76/>;H1`%F M5>HA9+%4#9!NZE"NFU2M8BDXRWY$QPH+)AU^F!!LK:O05T@BH$B07R%"9BFV M=NJEZ3,)--=[RJ23<351EF!-:C'4YF/F?^IXS\)W4[#!1;B M:("F8N7_,HEW540X?A\[]6TN^VVV/N8D(*56^#$F2Y[46(D62VQN[X>3@X@D MAXM?!9K]:<'$H4/YU=V4B!)$K-9%AKR2U,QQZNCB\7HE)^U\!$X4553)BAS0 MXHA2ES'$*`/%NJ-/Q0?O2[@_[E%6Z(OIB&YMB`[>#]VIS3AX M-_1A7,ZGJ[*AD37%Y[9C*49F0X+18C=1"I7N)L/4^FWE77]4'87>0QBQ=JOS M%B_KQ3.K)B`2+@;5*G,LGIE5[;M[U-$T82^@I*9=.&UU33WJ(@IMVMBSUW7, MT!NI)[]W-O'<5)BB%/6!`\Y[P=R%40),+V@*?@7\`C8L-VGB8QQDM("!7+]- MH^-Z=:3JGAO?FL5"L?L[(9S M.L'7V],4DZ5%M0BU0"!ZN*G9K!JWU?\.TZU-Q8,B[XU"L7MG!C9S6[8./&:4 MR=/IF+0W8'-B]OX1HRQGBX"W+UY_>+%<,9[=X@>TX(*''KSX-[0[>K3O`,;L M*0DME\G@DH%W,GL8!$ M%R=Z-<6YX!$#Y6-)25LSS"]="JJ\+I'01?X?IT^87]#1E8!6/E6E='F[%/.N MVRA.RD6#`WIL.E'^Z.6T?%$81,\(?PFSG+TQI%]+TF;DL:4S)]R(0JN$%XQS M%)!52G[$*"X=^?B0._.R"2,[4/\YH=T%;^D=LNXEK`D!:M]B$Z':N;CR/O7. MW,BSOE$FO_7@X(C#S[R)Z<_VRLPWV&,(F@&0YB'97/$?,YI&FH8^UN40=\BCV(OO2?^/$F?Q4:ZPD$,"=WBIS";.;%PB$2MET<2 M^JHEWHB[F;KQ5P/=)SR'_I8N]JJHP!$18$_12:1R6^"$!1+9=^!,D5=6:DY* MHA4:QQSJ'9I)_)(G9=(\_A4<,8C/;53]Z-1Q,XWD3+^W=C8!&)?C\NH>9<%(H$[2`EH90+MHGSE"QFH3]E4T/#>"^SK:%U`L=J;.@\F4_.T'Q130Z[2#]FFT-IW%5S,H'=USA-Z^NSJ4LKFW)`0`+"YMJSMQ]F$1F?A\VE_AC.C%IX%&Y37^#G)BI^2A?:!#H>AQ2W'.,N^96TOA6<\9!3R; MNO,?<7",\/56$SSQ'?TSRX^R]D/J20QH<1XD>KGPCB+SY(MJ7UE;*X8@1-6W M>#LD<.==)J<02%\EL2`G$@71P!9/X]NNW*O*D%9J1H&W0YT8*FNS\3^+[BD8 M-FM8LU<8<-YI70(RFJD?L1IV"=WN&HRKF]UI.)XPE%>S:&D@MT(4%CP9M,6] M,1%4"[T0[5`G@#IR/9^&:!,_-3H"GO59D^#2DO&I`UZ`CK185ZJ(EN=Y-.32 MD.'96EDNAZ5WCJ,>IY&751NBZY2]?.4/V\GJB?UCRFX+3[THHI>2Q<9)`.KT M:#!5H+[8XTQ&V5)[W%F8>@LR7/JFRA<@13I)GJ`#8?J1Q.^U-WJT[`"*0GQD ME8?H/;8OGW71W)M)\XF,3WOAID44B9BW%?KHTC**TLD/HJ7H*?"J*`Y"P^Z2 M,N*DZ:%F.4\%QI@=V@J9SL(4^P0I6Q\.21CGK2Y#5FB`PTL[\^4YIAX4Y$C3 MQDX[M:74D:!`H0;S@)%78,Y[WCE`@A(%K2?EW7H,.LI7*.QC=%)1WE!0A*[G-H%%PM4=&!U-0ZTRA)=8Q<250R0 M3(02WLZC*;6T1A192JM7]JNFZ!#712/*;0@J"F*B=HITY31)'"&N5W]B)1L# MNA&\2-)-IJPRHH<%B"%LC)<1A`X0)'XP,Z,MYT>W$)N[ZPSM."*B^_!YXX:> MG`MXWDU!B`$3-/04H)AQ-N6%!&.6,*W7);E*XM/C_A@1,9ZPJ0.$$QIXP1^C M.)IR/TJYE2DINO(T M>UN)#-[48;0O1C\/JKX/Y![!RQXOHN3S%7_)5+VHB(.+XE%3]2[B+,S\*,F. MJM:#IF?&%]-2>YA&4R1Z,A-N0QR8VV=U MH@#T9KJ[D.6CZ?[231W_=)-J22VXAG%>:U*T6F!O+M;C6);1H36V$ARP-;:! M_5IK;`>^I[8#`[\+:8W=@3G4T&YP95:T]>[0:KB%`=]G6",$U6H'\+FC7V>6 M%/70&!0Z)&D1IT1E$2E:^&J^'6Q_(32-XM$'6HN3[T@GV8;>8"(VB=AVF-ZM MTTH<<(@>[3)J,ZY!Y.$ M.08?B>WVAD(0*ZI4W:>8]YJ3[WZ1&'[F$_*I9*X(\Y0:,0-\/T5SY_BY.B5/ M$X7X`.@,-0_>^2!`I^SS3$X@34XML?`@)BOAVPX?I\=N'1VL/8+3G)$CP7]!@W7=F[@T\CFSTR4W9.!@5A)"@A"I2 MM-$.1IP84(/A4246WW);2*SYJ*)+,>1M?4U@PV-7%2#0C;J69?ETH`TUB9,P M;:1U++0/`1KV`?W4MH"_D;M5H0"YU\.(6N8%Y^1=5M7 ML<\)$TCWW86JF8(=#N?I'>@:3XJJ(Q62MLXP?8SZQ; M]_Q6U%M`3>!-7VL4Z.A,(=)\-G:^/T3),RZJYZN+%ETE,6^+SFKK9?>T/KG\ M]],DR\FF_5>)([+[N_M&+18*\9JX!^8'Q!^`?0/8R8,Q` M^2Y@@57-1JH"`#ZAFQ&O6-"+E0#/$V*K# M4,9H`@$BK*&*MQI1@MZ!#0LN_<"-L_;%)H=$`E0R\&2$3H*4ZKGVQ3OK&+ M\)XF$4UO2[V(6O+Z<,!>=)+$@?X0WX8!T?+128BJ\Z,1'*8!I`-+BJ5/1D(4 M7NC_"G$2,[>#'$$(CB7+`M0;<@19/"[+`Y4%_+C\%TP?M!-1B"H2CU(5]HB. MN0@OY*X)&L?6F0K,\MA36'FM[$@":N'LQ:8B/8B!SUO=8EP1"BK(XV3*/!:& MC]ZB8$(93;'`R.(),G))+"YAK?6(YH/.>$KBI3'A)+O!*>//5G#<``]TRF`3 MH'8*H`,&VZ6;&6JG@YW?HKL_K6_/T=GZ?CW_MKDCNP4\S5@4N\]/BRCD?>&% M*0O1JW>LF4WU+3@PZN\DB&P"1@0H,W!@JJ5;%^O-+?IY??GQ'%U?H(O-U?KJ M=+.^1)NKN_O;CQ_.K^[O9K>/7G+0UJV\`XZ$M6`[L3S[,*,LQTI,#S],\+/? MX]N9,>D4"3S$`WZRQ9'[("_AU6DIVLGSB4Q&.<_IV8H. MK':.XBE5T((+[K*=^#.V:*"U)O;LF4/5QIJ]E]Z6BBNUE89SZOTDK6QQ16O@ M"A*(T4`%D9&ZG&@.#_^$O2A_/"7A%SVRI#:?;>(P)Q-+V!X`%7OA@A!L5")A@0>2^>'.3T<\8ML MI"\R9CJ_@L53ZD#H"2:1ZI..PIKLWD)B M*;[`B4U';?0E6N@S)T9KR(HBN80H>6'-/\^9[\E-%":TF?AR+NQS6FTL3G/\73I-3LH.GN8"T.D,>$KN^(3H49EF2 M/K/GOLJW*YVQ`8+Q[L*50;@[*DCPW96]EF)2`HA30!4>J]DT_Y.8\4622#3% MRZ:5SQI1P\LY*(FO2!@,<;8.@I!*2<\:K(5K73%!DOJZ""4E][F@3>(>M)DN MG1E3K%@2,GI3H2/P&K$O7"Z'3$`H^<;R"%W]P.*LOY/-+\S2>^G)LHQZT2)T ML]^I1!E4D7[K'NJKU$P=R(4-])KXK)DAE^2Y"2=7C7="`*L2[LZ:HY_V0 MHX.7Y2AHO]Z8UI('\LV1Y?I8=(=,"?!_,-6\<\8>XXC&GIL>*B$X$X3/ MQ.^.RV\$>%%\A?--["=[3!_5KI^\,**W8T2\JGHNKUZ;T48JOB7]N#I^'#,6=IE]0>I'+* M8MS9,TW'G1)"#7%RZ`TE^#4J23*W)A77%E17K%61OXC4\.93(RYQ'(@7K+33^9M3C"1!^>*M,"KJCP2-11@8<0TI MNREG16VH?V'O4]>27Z2>IV@ZP-JC257K-;,WF"J,08XT&;*A#B0Y[WGXJ$PK MJN&QK@2GHH<%OW!M="B8W]1Y8ILHAS[GY]Y4_9;6F%&M]B..@+0*XCQ)ZGV_&$\\E#6 M/[H([8B=-0TC*QW!I(G5?!%C-UD9>O_##W]@C:T)T]^MD*"'.$$D]<2>W9G, M,#$4_>U#NRZKG'K^\(QD.#$0KPVYXO]IS-HR^KJ2;WKJ'4(2V%QBPOGU0Q3N M/%--:U=D^&ZO=M%TC5_UF#"Q>1?>#'U4`]9'-<8Y:R94[Q$+VA!V@$PLR87& MV8(`8A201&(AMUPNY_^+N)&RWC--8P.TI+7SW9'A^N--Q.X]0@8+>YWC?DG3 MV$3>>+`QJZ8N8JL@HN5&ICN9194DM8KK4)-42V-A14DM?"JR\^*$I7PDZ337 M-7U+DW85Q%*;-*D(S7\M-;:(G>J3OIP+JW9X+[T:'7)$:"&\X'-JIRGI?%QM MI+K@4VL'OC6[X43='V,9)]A]Q'(_R%;N9J4!%A:=Z&HVKX._'+.PEJ/R^LA,!F#>7 M/5ALJ:EH'T1L\5"]VX_9N_V4H\_^#G,,L0P%"9"@Q,ZW!"W@SBNCB]SXEKPY MIA!9?-8)WGC14\.J,/)U&N[(7C;Z(!ISTB:6*O%=L$`>=+H*(SWFM*$`^`E7 MIMH/F4`:J@[CF9U;5YBH0$6E,*I6JO.8^3"AJKK-*"F$,K:\'N&625^P&GS?5%U!!SNB#`Z+9=!%G%]=!0E]DVC@!VBE;[[,QS/2H^ M%6E;4$%Q;S$:\?#*'`>DU[`P),%.S`4J>;F-G=QEB"U*,'>"NIQPT7GH^5ASEV\"5$S&WV M]?%R!;N,:+G)C^TP)$-;@B$.$8##32OOK6"38FB.<8:4BO3^DJ2GQRQ/]C@M MBG+I.[(9P2%*1]K9KTI(ZF$!PD,K-RJ?2&.(E(4L*[2G!)`O*)0ET4`:I747 MAF&@`J4L4P?:]ZRO%+IO,.8E0I$YO?9I"E?YQ/'/1R\*MR$.^%-']M)1)5HG M=``[[B%>:=<=<`'LO#-W[=.3,M?=8S3HPR#QP/6O!161YLO*G\Z7ZSNZ@)R& M](*WI%)[RPOC'@"^Y)@>Y/J`:86"7[&7GG_QV,L7,H[T[EDELP,2@+=P%J7T M$58,`,_@R%-+BVB%"(J$/L8!T28)=U[#[\L_Q4.E$!+JY(_PK28^2"1:D>29 MBH0ED8(*%_#:4I)+LSNI0'*P>BXTEQ7E*K?CA"F6\1.*97")Q_HOWSG+< M%6PWZA+2\6(ZS^]0+\#H.KO-'G$J"G869'R79,<6TM]1)I*][VY,65&&< M`8+7Z^3T(`16,Z\_LVV5/CV]_GAU?X=NST_/-S^O3R[/`8KFC",HF2WQ-67--$G2A4QLF.^]RO<136J0V-$!R2`[;6S*.7VVHH!TB3& MD2LGSP_?-/%%2F/=<<\MU$YQ$!+RRHO>0>1` M7HP.%E]Z2MJ;%E#3WX'\=EJ/O"P+=S&Q0]KM\#.QOH+6W*]1QQ:ZH$A7*D\Q M`<&158,JYB%CQ6.WW**GG02'5ZR+G`S(MHI2AN@MCKRW!I>Q&:H8/(!R;*G'*BY%=I_HR\'/E>FC[3 M(D]/7C1C1_11!:YE/:^0H(,$H5&?I\OW)KQ2%BWSCI4)H"9HD,?I-N:EM^DZ M4*`.QF9V;)=O17G7)X8S][/TWKSS>S91C^WGZ7AW>)0^Y?P/L,>[XT.&_WJD M52V>:)5*AV-D*PJ`93J*49JG!7ZVBT)W9MK7RB46XF@+.F>=4R*HISCK+Z'N M($@%N(3G-S++^HRM[;'_!F^E?T7;`!EMCNPI6KK3LJ2'#[?GXQGP>WEX.8?$W/AID*/HA@\1C?<0L`K-.R"#N(ON#+:T M[Y^7XB]&D(61>`D^8QFRCE:\-6.5H[U(_WS:#`]>L%4M@*94:QT8Z`+-QI#F M6+4X/$XY!LB;Z1[,-\+F#`DDT%?3?>4()3GJWV',5X]%[W+1N%1OFAI``)LT MLEP:HQ(*Q`H-G+0;=0A8=FQ*;V@@+*\7PT7G6TA3&V&F1ZU)(-USK8.`M2SW M(H?S:D=$B#H$742J*A"X8('89@?.+%4;WU3H"#P7^F6+9:\T`"7>P%"85R>Z MH^VE<+#>>72)7XNT(^DUABZ*<$8'"I0[BE>+FQUQP<+H3OS9"VV)0NH9IX<\ M3E!^DC-_L#U,1!:S"K$$#22(H(+*Y/(Y!>,CR.FI/U^90E@EE$'FBK'G7RXU M*E6`@&\8K=4HVU"@KP]="C8R0&N1QLGOH4;F=XK^?T:-[8:ZI&Y_>JWN@@>R M_G7BK4O-54"#>!6"]>_F-[V`\RUS]VER))P$=&6^Q?30S*=EY^,=_04M6,C2 M2/EAP$]DH;Y,LNPZKD%>T?SQ>^^+QFN..@+,PCK!),DK\HCDH9;RT45HV1,) M+I-='/Z-!(@T8$2Y&!$%-*9,94JS!P;32U^,P'JZH!KF"O%15F7O"S[0"M&A MT!LZV-+=,&&[\SB()RN*XL!%232[\J>LA\+QUI(NLA@B5HM2M3B0:>* MP,LY6IJ(Y(;YCQDM&YR&/MG#$([$!;K]JMV5#GA:23>!->DF;D3`>P5W8=-^ MC%Z10(P&.E`B1;H$9+[*(#F;+P;DC7A+9$:OR'190HK+(-$EJ:6:F>)G)O6A M_:''O+0_C3RRL]F*](#K]#;;G7XA3##/,I"C_F(F_9C:_-)PFQ$GF2!-1 M'7$.)`C@N\9AN:7D!06ARV0O\9D3@?1?$\G*R%(1!2ZBSHHBHW(6;HI9*'-R M"IAL"=YMZHGY7$U,RB8&Z]0C*V&RZ1S@A1>F/].Z`-?;BS#V8C_T(BE_T2%] MJ2L%B"U<+R&K;5PG=)BM7`\6VYL"0@0Q*E0+2SJU'%OXRH^O3U3[=F])(L]W MV'J^W>*BNTRRQ_?>EULOIU%F'L;',-Y='S!O_Z5[Y]R%`,PQ;'<1Y3-9=VRH M`]JN'+:#IX(`[0Y$*+"^(NE4S;Y-![$CBL(IL-X3E`8[BQ944$4&\I:#U_8@ M#*ZS#)-`AS,5[^C=S"FM)[1-4A*F!-D9$23+0U\S:;TH0=V(]!:Z?D_2F0S< M[4E/5MMK"PX(9H1B>D57$$$1H<*K3Q5D`&Y/QA*QH,2LEM-:H9(:HN10C=X* M%11'#-1Y1WWIA/,:Y_P^^6-& MW&QRO=T2URCRK(FKI+?H/-Q1S4U?2A!OH08)73V.ZD4&YK74`%95S=9DW3QF MO/1NPNB4*?4YIU3$^NLX)IO1Z%D MD/](QIMO6S#^%-'\IH;[$B\L/HK9XB3+AQ:"J-A.`#W.&GL&&DY,).`XZ0N\ MCSO!^6>,X[L#]EG[6OT#ZW'IOQA_:)Z@@5Y23?P%^4Z3`.-XU`<^`O.CV$NC MD/9I9XZ3I<#17Z^/NR-!)";Q_D5ZUTZ3.-#G(C$8*D<#?1$_TX0-<-&E`F;E MA(W_$E_D-'D[?+UM3LG=\>$OV,_OD_,OAS#5U\/M2@*BVG,_,:L2T-WP8>I" M]^&QG4E44J%7'XI#JHR3HNJ+2V+T^O48>T]>&#$-)ELILW+/7'9Z@JE1N,.[ M:FHJ8D!%J@&5`?!A;Z-8\;VA59H:%*@EM('M6B]H!=SL%5OU3%BK0*-/#!JT M2_)3$CT1_>7M4"X\GYT+&1^!6W"@.B<["%+OH6Q`@+I6<6!*\5A,X"".A`HL MN,?C\X@Q(,RK&-2]>]6_.7''!0CLN@I61G2NB""A7#?F3*JE?Z@,].SDY8MF MC;U`182+M@NX8VRQHM&=`FX5)],<8MFM@%Z$W^C!="0@5GAN8<=CK047CDW`- MIN.788PW.=X[+JP2^"(TO<6^0=E+6&C_V&#$06LH!F(H@)I#F;C>-O:@WI=P M?]R?)&F:?*8QJ7<@?\F?-1/1C010*;P>8M:*Y'7`!RN?UYG'EI(*,=>U*34'DC,7XMON/#,'I-M4Y05*F:E)(0*2LNR6WX?>7W,L]R+ M`\)GA[E2X"['4K6"V4RTA;@DV]0PIWC%'>;T)5&0>I]IW2;>.1MMEV1JKK)H M;4RD!4@41DWK;G/\4UK>X'.[5K<@=D8%2=WN)):4K.V$!Y2>W8&WKJ:"=BE` M;O80@33V@AB%PF@*&E`)V&,(J/Q21>[+@Z`!6?Y9(>4FSC$M-$@?F9VQ*GK* MA,1^)):S^MK$M"W".OPEK<5F'C5%[NQA,/)8BC4*!7F8IY4C"*Q=MPLZ[*4E MXI0T27HC+^`?/%JY,G\^(P.??\EQS"KC:#.".Y-8R(+N(*9Q83?@+V:!M_*H M*/HBH$1^(]7-O:""@CF-;$2A=(M]00E14J@2'3(7=ER)FZM_[5,BW/C8HU:H MTMVW-JIMG>',3\-#Y]K@)C)+JJAO%]=>75]/8UF5]FU\]KM>7[7KJ@45Y874 MXN\LNBF?H%4][VQB>?N7Z!\D]Z&2FY8O-G[G47V3%_G'B`E+7&VC^E^99KL^ M'**0/D$XPS'A,V;PK!"-C,&U*V/8X+DW-]I/] MGNAWEB?^;^@SIF72:&\F,B8%Y&I/,_;]BBFVD#=,8V:W-\T,G=9E;!<-K69P M7T5]O3XX9"3JS[,Q[5E;N MZ$YC80[1)*B3`U016)S#TS/9?E/'0*F2/@A@LJUXSJC*9F&`Z0$.]60!IL7_ M"]VD=2*;7H\[0Z[>#YC@U$*!^7>=(\V/S;U5\U<00Y3:\KQ9?YE;WBM6Z\R8 MSFH3TV;)5-@3+_Z-;"[6<;`.GD(:9][A](FPD5W@4JB[1X],Z";+CNJ+JD'D M`%S8".*7WFP`+1#'-IA?@X_+&#`*&33R*C?'E9UZNK`<'CWP\=GK=$]P@#+! MPKS>;/Q)J2BB$TG.@B@JJ")"5O)RG#+BI&&\W*1S8?SF:(ME[U?3IG%#M>SQ MQ@L#4^GC-@Q(J*5F5`JEZ@!`H9**"<6RESVB`X&C?N#'N:,5=Q8I''A9X!$9 MGK--<;R[%TVL:+7A$S+6;[I[034L5+-B`^/U?L4*0+B6Q5IFVI<=UU<_H?OS MVP_H[/SD'J!;<0=6">Q;NAWBKXEM<_U^"3N`I^,7F7>VEN88Y!E?R`>8?CR!_+JD4@FP1W$!_+8 M!\+\`X72!TJJ0"01'TB.`5M7@G5#@JQB!_"5;C$M[<"+UK!SKZ,7T1,&[;/S M9?'XVC;9`S[4/!OQ'@R^SLUZ[XG0KNQO"X>4%@3HO5]!`;&C/-F1+2!B^GN8 MYE=[6##>U,YWH"#QO&J'6B7?2&(<,_O=X\'B1I%M,^W&"[5(4'+RVC8IVDN?9J[2&'W>=/**MB^NLS'?#J::]Y>UB1%\'\FW7\=! MU9=I@?N:@:R^JJW.*)]MAMW/(#Y?V89HA+GHO$?:*I:#U[)AFF(^Y\K7D'A' MA'FI:]_?\<9JN@\Z_5YK*WU0^B0.2Q]TV@W8["&#F';:3T_YTF'^X5_5TJZ= MWAF6Z];8KVP)ULBG3]W'%<+JA6PX'3EZO>O:F(G]JYJ/`"C%MM09@U@4_\XV@V-\H&YK MZ.!%]+7M[GHFZB^1P;^35=_GK7[WY?;M[]<&LIUYO=J.4<9_D>Z]TN9;D,&R()F930UQ;ZAN7G MM:[:E@\P[R*M8>;U[I"-`K>\3PE-VR]Q<%YR^I4OM]UF"6)UK;Y,R2)DA?3% M?I5Y5TY/9R]C+I.TGEPU8:Q+4("#HG,0;QFH^D9N>`#+3A>!RN7!!0G$C;LS MINN)UVB6DE&UG,S1DBAN&F$*X*H3E6A%26OBJ@6==R49(!LKZ5CAHE+6LL\8 M1X=QQD,%JQP>[QNF^(B`V?)UZ>ZI86A2<)60,-GG!J;E+'$%V"0^S)2XK.6A M[:[\1QP<(]9^KE'N5(YD/C$:@%5/ZQ)=AC'>Y%A;8D4+O03-:3&OUYX2%%B# M&GQ8?>DGBH`81B^=T?4_;=3N/7J1J7"Z$1RBKZF=_:J'J1X6IE^IC1]E\61V M,LB]R1N!]?74!=G0.48:T-8B\++O>BBRT(GJAP_,\6/T&QQ43 MH@5")Z&JQ@A.:##M$CJPIDLQK,)+%CF(/&%ONM!9:]^#I&'(-`@JQ"JW`\QH M1#X[Y(Y@'/$^V[_:J/U-+$SW$721QM_9[!=I\#U,?5DV;E3_:[-U+].LAQCT MN!W":2?4.]K[CW=8.CNF8;SC3+(S7/IKNDO(011QMIBBA]ZNAJ4T3'@.I$/I.*D*D) M^-2(6(9?<:JT)VQJSYANLFHE?+VE_!,Q"HEN^`W`R3,5F66/E'.CFKJ^E``< MXC"A2R_8CPR(ZQO"JJGUN$H]F\ZMN$JB%Y\A'Z/6IWQ>YS?A3%!R;!9*9W93 M22YH(ME)POBX"6=@6\Q`J126;S_=WNTZO:499=6CYE^QIWPXZX0&OH,SBJ/9 MQ"EQ%K"/,_!EV,H5P.B90$/NXKJPWSJF25+$L*4"!.C7J03JN)GK)=CG2K"4 M"=;X4I`USM1A'$O2$6UW+Y*T:,RKN5CJ2@2HTE@O46O%PCI1`"M/W(-+0]=M M7Q&6DZB%]MX^1GE1S*\(Q'W>AI>E:\U?VVL,R?5;LY7HG[TJ_DH[CM]I.HI/ MNTB3>.1#$N>//1U6A;[,1;LI7I?%N\!=ZB)>Y^_%+N86,5JGL[I%G87"C-)B MEW2;JGE*J+?CBYTO"&?DW^1?Y@::]DG_\?U!+`P04````"``JBK1" MH:[!XK,P``!72`,`%0`<`&-H8W(M,C`Q,S`S,S%?<')E+GAM;%54"0`#WY*: M4=^2FE%U>`L``00E#@``!#D!``#M?=MRXSB2Z/N)V'_0J7W8GH=R6;Z[8_IL MV);=XUB7Y;5=W3O[4D%3D(QIBE3SXK+[ZP]`$KQ(N/$F)&G'1LQ66P"8=R02 MB/)"M#HPD=62(;\P.'SZ-%: M+)`_>GH;W=^/)I[K(L=!;^R#H_'N#OV_O8/=SY_33YR3-68C\EO\B;V=O-@/Z.E]1F[ M06BY=CZ++L.;-SX]/?T2_TJ&!OCG()Y_X]DQP33@&@E'T/_ZS(9]IG_Z/-[[ MO#_>>0UFGP@-1J._^YZ#[M%\%`/P<_BV0K]\"O!RY5#`X[\]^VC^RR?[V?8_ M4T+N[B?S_WV"`]OQ@LA'$Q38/EY1<*?S"V^YLMRWA_,HP"X*@C-W1GB%@^F\ M*`>?1O3#W^ZO,_QL,L^V?+1#_D$Y-OZ\>_1Y?_<+'?>EX;>^M(?KK1>BX,YZ MLY[HK)I(E!=I$;K+/R,@T;@&P M<\NA.\'#,T)ZU%F;T"X`=^13;OB,0FSKB9!L=F/0'HB-1C'!I_/I"OFQQ=8B MDFAFJR!=6,'SE>/]J`Q186)SN^G9L4R2[>W2#6,QG7O^4F$0]W`4Y MV6"]K7]M0F,`KBSL_V8Y$9K.K[!+K"ZVG(H[JW*)QD#>(?_AF7QS8H66#D3E M\5W32-]OTURH57KI0\>;U:Z`5]<]Z?2N&9M^KP7.9BNURMH*\'&G-0;FS+:] MB*!WCVR$7S0.J#$LO%G-78+H*4!_1H38ER_D?[2V__4I'="C`HLDD[..YBT?D+R?H24O\RN-;_7QUZLAFIZ"M"KXCC:FF\-#I M6PFI%4F"TG!O]E<<4BAVR2='GT?YA^A_Y-\:>?,1<>Q'Z1?_(QBQ;XXL=S:* MOTK'E+X;(T_0=SR[!()#PZ6>7V9+2H8X)CJW@J6M:+TV/N"G#!@ M?Z$,W/N\.T[CH_^>_OG[U%]8+OXK_C[9``//P;/X/PAIBK`5="\_RIP]$2VT M[)`!YEA/R(DCYFVN_:5O9,EE@LKU.0'SCRXHQ/G,]Z/]@\/C\>GIWO'1WLGI MZ?X,^;]\VMO]-(H"0A`O5FUJIP@IY\CWT>PF8:B05#&=7I#_Y`4H'IO9 MN"_K1JYUTU<.Q.O9M/UUFQ8O,F*K&%#%(A8*@\,?:L)^/#Q[?L@V.945$`TV MJ;@RJA?U4`1[JCH'/-7!GH_#MU\^C7NB1YQPOIXR':\K4[+2J+B4`>%,H%#H MTOH@(UH4$EEZ]APB2D$"#Q5+_>U5>SZX?9//HI+B-<*MYSM;Z7943Q=/UG4Q M66.4+&)`N#,<NF/#>@ MK'R'.AOAZ*=D\M\^=D39CF@_HUGDH.F<;_]_MWS?HI>,_CU>/(>!2!W)GYJL M!7-K;(A4-]I8IA30JA=P@89L=XA<"8*Q^2H^JYF(P!:8I5DQB MCG=.QGN'P$XZ[5CT]0!MV;(?[1[OZ9CV=)51NLQ0;?QFI)S^Y3M_FUR#0#H2 MIOI(01ZJ-65!Q`O'"H)TESE[Q0%O@Q6/-<%0#5G,=E$QY&*^FF!'$;Z)M[2P MR^$#;Y`)!B@H6V8!#VA@M/=C@[)U@,WI`/DUOJ<:\2C-A,K$2"BDSC\`SDP)][=J$*O@%%5W6.\=R`PDO M]29"9J4>!BDGQ[O067GKN?]-7./X<=<$^\@F$P.*BIB)RBF`V:>$G3$.CD%M M9]>\M]P%$CB,A=^`.X@%2,4W?<;(*W1`2K^:THX-"2@15>U/F"#K5^L5+Z.E MD+!KOQLE;1E(1MPU"+L,O3?<":Y='&++$=O]M0'`B,T#498-`&D3WC!^-]A% MU^3`MFZME:,!VV\E['WQ?M=Q2*.+@A"?WI0>1=HV8`>G9>WL/>F5C7#O6?L= MIM/+`;0;=AD-BB8B2@]CGAMG<"H"H_SQ@&VG!O0I6P]A.&YK,`ICI()QQL.D M,HEB#!'`#LN#)N`M/5<5']T88XH!4KG)@Z(;\((+@[:8B3B-<>%R3S(.+`OVPV&%YOGCW%AS<)/HS#O/042!R^P02I MY`E/#B.BRI\3Q\T\>9W5FP>&H4F@S#NO@!>ZX5X6SU3@Z-$Z6.0@GT-*. MLU2^4XU%-HCWFYG`:Q)/**5-'Q_LGQP=]DX,:F+9T M^5L^Y,YZB\LY_;#\6?P_OZ&`UN4@U@][LS$OG-#J\CV3KO8),-2;5V'61U$5 MOZWB]\1I;=8J.4RR57HH4[7P9*(#QR=I*8JV7#G>&T(/R'_!M%@@3]]N*2&" M$"5:%3QZH>44?[_P@O#6"_^)PGMD>PL7_R7<$#O[WO>]W@GC5FC"!/?D0W#U MB);L%E>>G_Z)CEO?F\T`\2'B%0B5A6O!R+THTY%+BV0O.HO"9_(Y@N492? MZIDT=DL,)JE#V\=K4RS1XV`:A;1A`^UHD="P31$5?^,]R::8"JE0[L/99+L4 M2JT]Y?(5^38.R-&2^#EQ(B%3[?07JM8I1;5%M8,O#T:`.Z`-$VLX<2*-IQ4% ME(GK/(U\\B-SN[-W"*K'%IJ+]$QXZJ+)Y`!.T$>>6)UB%'L,&Q$8V<`^\E.` M"N,9'(]>P+,RX&>N2Y!UWGA,$XWL(]=$N#"VP7%O*QW7&WA1MUZ8A)RO"('I M9J5_JF_WJWT4IVW0A8DFG%2B+BZS?_/H55E2.DCK,KL\H6?"HX,2BYP?=U[I MLZ%)*B.1WUH]>DD:ZSUE!L^J:$[L&6^KH)8=8*&PN/64;(TD%<'H(66H5$&1 M1=H:>_TA$3DPUOXK=H7O7`5C@#V_%$`I4^$>[\Y:-V:/UNLYKE8=%`2/9:##UT9_]X8.JP6R8,B= MA6>/7EH\LAPS^T=<8)X;-FQA53"BI`PDMH`LVW".0&TXP/.P\Y622=/P&?F/ MSY;+3YX!``\8F0:2FZVF&-OCP=_ZKJ,:W".'!@4>/>:P3)`O>OM2:X6>"5,M M'%E!(3AY5MT]$\X3U+1N5]DRI@:FJ:2XW4AZ>RO3U#W]+;;)S#W- M^HD+1*RSK_54$#NC!S-LP[I";.4QMC3,V.H7P`AEEY+(0SR[GMK6<<,T@2OF M`C2)]!YRJA]".O&SJXZXL1?*N@ADF<^*UX.5IH/AO^[]CQ963'M:B0[#LM]Q M8XDX\642^5EAC&)"S)7GI\=`H8FNN$@?A*0N;EFFD$A4^M\E+R-3WA>O0EN\ MH;;#:TD?56NPW"R*H$MWWX3L6>-=66 M%6X6#C76EZ`UR3RM7 M7=7)(=E1:D=F5TE(.+3\L,WD_.ZH4BAQ\#NBEUEH=D8TU%J@TIT7STD%`!1D MB89"HU3,C[G)R,8$';KQ%I/W'M$-D_S]PG-CID?T7MG?.+L#A1&RR@`E6:I! M)SOMWN(-787*CR.VKAWKGW_?@K].#98R">G)P=:=GS)1X/@_5>""+-:`R)3) M^]$)'(&';L&O/'^.<"&)=>M&G`,!9($W0I!,M$\.&ACSTT2V7;2@;S)Z:,Q3 MRD3TN8`[NWQ=83]>&Z!];P@J9`V`3;E,54[WQA_[0%\CF=_W8>N`$8+DHGVT M>]K"/LCL?'D/QXD[(*Q]/1!NI# MKM4T*DC[\>'AR8>H;U),UV>!"."'"E2C5T$=3HZ/3S_\E)A^9XN%'\=MKPF] ML!M@FU?G`P`\'^(N)4]!ND_W3TZ[=VR,/!I.7_]F7;,+CX?'%5X/C\8?[X=- MO!^.GX,,_>UPRT@*4TV-U/&/`2-?$;P'7OO=V).CKMZ-K>$'Z^UG?5QSM-P9 M+59R:RV1\-5O-Y\Q)2IZ>;3XZ)A3_J]7LI.75?L5N>3@[N2>>R#PCQM14.][8"U:I1?26R#4 MARG4Z_G:I@B+O]$[L:VB_6VU6^#035:5I]ECC"%)%+3\*DR#467#7NRC)?M0F(JKV6KFF*8OBQ"-U3=:6!_E#G7'>P@ M&M\-JBY7\=\DLM?)RIMWNF_FZH!T'O MI)Y+.2;+@J('[S.QOB\'ZP_1;Y^>3"':J)@`4R.,'J\S;FX;BO>C)]NF;*XQ M'Z^S-DFJ>F;2AGD#\I:D=]N"^-7)8<,J"^]`FK?L$H%^;=)GR=<[ZR:E%$X& MJ0\--LSJCQO&'3A$M:!X/WJR;T=$;$H[L?CILX0B%=;YY9CN39Z>$9H ML\WC>+P[^CS*.D&0?Y/-+O`G>\='>\<'^\08`^D>HL$8;F,8,5JR?%:F M0GN&.?=@(]- M2HYPN%D)2V`<13Y&P<4=VY?%W7LT9L#C:B7.<#A;$5<(#1P%Y1?B5_@)/AK, MUIDR&&[71K:M-&,`_3J9^;L1/(,3#X0G!HUV9#E>L!ZLG04!.58HW/CR(+C< MDA-^DV,:>$$PQVUR^B+R*3DE3PH%XTPR6(-/Y8BT`(-.5OZ(66`X6[=[ZW0G[X1LMQA#1Q_L\(KZAS0VR;@-FR*6!X M7VLOKXTA>\G#0#&=OL/6$'1SB^-U4'#]Z]AR"::!5+5%W.CCIJ'V*;X3Q<.)O M!3*H#_FRP2:%H!$ORS$`&8K#"01<6,&SP!(D/X'W\Q,P4X[LM_O8TX@>>NZ" MYBA.T%,H5T2M&:;XIS8G)1LL0X'Y8#NGXY.#QNG-YCG,XDYWUAL-.NF%WR^U5E=`:&<\0='1P=P6HNT6">TBFO6(V>LI7VX)N;=;`8-SFR""_'R+2\Y MB5Y$R\@A?'I!`E'0GV;6%:_);WWTVBHU!^Q8ODDY;5L`Q@94%6VYHLL4_'10 MD=M[VDK!1;-+RZ=/5@*R428T0[,)FF,;B_8%]<1!R$9--%-9.1Z8I)IF,]9R1@^"^+EXL8M?T2`#JH>?FP5L=U&?G;4-MVVN$AKBPYZ&!HY.C M@Z:/&HM^H+EK6=OV(P*P+E/ED_K#8#4>!68?[#5F-C`;SE!^N_+\;^Z*N#`7 MCH67-&Z2_F/VKR@(Z7U[#P*;[V0_7!]?GN? MS%78@TZ^V1_)ZYP,N>`>[K=0=PF8Y,:*RXGZNLK^A*QT5'6MF[`Y+.)3(-FZA MHJUJADP^C4XD5UPWR`K0],G!BZ0SAH;IETWNF7W5Q(I=_9SN'.V>-J\6S+\` M,)4N$A>+F%0NG2*8T/ZG`?U>$^JL-]5(?[J`[W41T.#$<_JL-]5(?[J`[W41WNHSI<_ZK#E065 M'#:F?HS'+$[4NR/R3*M\:Z4LBB;#Y:Z<49L<;H`O!+/>A<3$&`=G4?A,3@5_ MY<=EJ:2L3QJJA&CA.9P=@(?\=1!$E:0BF3!LB9#@V$U%,RC24.B!4D$D"K.& M+1;J7;R@MQHLTWD1FV3 M\C!P>ZB"!>4")AJX#">4FZH);4A+273C!:([&\[($FU.3D]/CHYZPV===-J* MS9I^O7[KN5X9Y?2UK$*WE?/Z+`3UD!M.@#;!^=%Z3=$^1RZ:"TM8"4;W60"J MH)15L^L_WV]1F)N]LQ<+._22^]$K'!G3A/US*\"VR#146Z7/K^5 M7'A!2!]VI#JC\@Y%P_LL#Y5PZC*Q??N%SP/(@<%RNQ#H^YQ78 M=7,Z,)YU_2O9&WW+(:0[FRVQBRG9:.6OE)`":5#,&IIXU$&WZXYUAGJ<3!`! MW\8)\P@]EIX?XK_B_Q3(BF3&T.2D*JI=M[DS9%/6J:CI0@Q-&K3PZ[83WH&I M$VB("+M8Z:YSS_>]'[1PL/`,*AQODO_U`@F\\Z@0/79\:)#0<9H(@(L6-&!N MON:)@&:B`*1T$CB3T)9(U$";.:`=W0AM5U;^@2PG?+X@])[Z"\M--\GD)3G] M5QJP%PB-YFQP-Q9:UQ";PM($W>%<:N2AFBM"U`O/)6H3$W(PBI)Y8JO*'SVR"\O**DX*=ZFM@8!.,-7.?QJCDR#;"[, M6B^P]%!)AT#Q4.`")`<^B[0.K+[G.L:RX#QW+!A;(>??IJ'0QZ:M70Q4#?EU M]"?8B3;SGGA$S49"YK(4\*ZC8Z;*@!9OE'0NV,#;9`'46?'=O<8O$4!ML[\C MO'BF5<:)8%D+=!O1;,KI?"/55G$[5GV9GHA!=<2R"$?S-RN@K+:4U MP&SS376ECCR],]=`0)9T^]1]$5%YE8%*DQCAK;DAV\ZWIJVYKQSOQV:Z]7Z% M=&NZRBA>QG2Z=:$D6H::?HTZSA1#WB&%Y,[W7C!AZ_G;MP#-KMTL:?7,#O%+ M4F!5D;Y9>2%PFX<.0]?\SS90'DXX5$"0)#C6@C!)%AJJ,%5%>3@5/@0$2:M/ M-A9.IC MV5JZ.MDWL36Y8F>+;VE,'\%J3OX#5VB@WG([7CR39QD=M["F'Z" M-D*S.)VEV"9-)$N"X=\-MYQJZ;C#$10)PLS"M)#[""K.?X]6J7I,Y\6N.@*9 M$`T?K$S($,X:N^T<-*EL!,8^Z!.Q<>QEL/)2C02Y!)WL[>XW[R+,SV0XAG2T MOHM/N[=-N71.4_/]*)VS^$N`C3!@>UX023,2&UO6:/2U.!U9K3(XH!0\N<$Y=V2O.UKE\`=Q?MX4L'R MRO/I/3RQT8)GYU4G&WTFV)+"9'7A*N#=EM$!&[+A7/`VOA0'MU>U=+G=Y-9< MMJ4U;^A:.'.9#.Q,Y_3P0+6)MF*,W^'3;JYMG#@ M$FPV,5DL/!-X(H(Q_7SL9$*_GK%(\Q79^.(_+7?94)D+VS\%Z^S!!.M(7\8UU)R)^^)Q^_1XNX4HT;WEK+]3.^:!B8-].5 M&4$5J!)6XC/4MCAT05#S+>>::,[K?Z$W(8O6Q@V%1SIHB>]_NF<2P^R1+,OA M3?'G_K-$B4T7S6FK^-ZG8!*J_[-]%/5'G<&*A:L36X!Z&VE%Y&3AX^6.%JN(4%+O&C,`5[; M0A.+K@N`;_6M^`0%MH]7";K$PJPL]RTXCP+LHH#6K*7U%HCFWA4^.4&AA9W@ MD7PIVE3>HUVJO/GE-OV/_!M48XF"CM(O_47H!9SFYH5+H?DMK&WF-8S^C6>0@*CP.0EPLY&WAV?/#]F+:+T8&F^*$21*<)"O2:(R@K$P'%(Q#TJQ M.3X*@.,`&Q!/O*6%12T>A:.-,DDF8U+N,.C[PA_525`TN+:>^2B'XAV)XXV*IG57,/8$4[#F\]?2%9&BW%]O+,[/CP:5NFI^(UO M5F*`O3B\M\(D669&3J1"=*JHL@!T^:B#$POL$.'8W3_8@R$;P@AQ$:^I MCQ>8P!C+/?D.)W=9>Q9TSFHCPG3]<.?D].2@P?MV`PR]3&,TU1C*G]5#AO(1 M80P]V=G?)QR%S4_^AB3\%!*0;9*[:=\?'N*0S&M7QN+S:!EQ_:BR.A MLU8*/.,JJ`VS"V=*8H9U)O2%R3(<K@+A-4"TWOE17Z(D)OZ=N)3@O!@ M7'6%/AR.J^+$&-Z\"#AP^`&]-&)RM?F] M8',UE,#EMVH%'((X4,I>Z:M##>OCH;NX&BBPK)UV3C/`[N4N'"L(IO/?+9H7 M&4[]>]I7-VO)BVSJZ6,47%B.0RM0IN."=*`P([GIJJU(ZOPQ( M0J!0%>N&AVCVR$7RCUN&76*TT'(00Z.[JIJ&)=7.:E.AZVLU;*2=K0OLZ5M?D]X5G="[ M,-@L'\%]X?91/N*C?,1'^0C0/L:C[T5$R6=4W>\1->DVOKF0."$'1='DE:&0-$&"%)_22:1Z02[Z@?1M8978OO-\J"($K%-#%$;9P M'$C^&1`<[WQLH['6F58ZOT\:KXD2T_[C5K1_FSGI8K3NZ)?3VU3UU;'N.M"9 MWP`U)@2GD(2@PXOFRU=B+G&`8E)D/]:Z758N!5ULFF&7/6#KA?-0!T>5,6F^ M)G0):0G-+($7DI&I]?I)_&Q&;UXO&*Z'2O:H3!PAI94;+1Y@O_2RF;*9,,AX%& M_6ZP]80=VAS&\[^Y-G%#R?F54.#."^+(5D!+)":1*=$5I; M&@&1NZ`1_POBG;_-/?^' MY<^X:7HU%P+.VB:HB9N=PC+`]/:FB$;BG7\+T.S1F\[G`0K3_$1"+.K[)Y3C MIJ#77*D/0E`7-Y:CV[3``TPI.$?A#X3WMKC]A6@Z7Z?!0_3T+V2'C][EZPHG'?)XPE)YB3[(0V6D&,N/=AK7]@)V MO)NDL!.ZG05$$0+Q/CHAY`U";`O\Q%HK`9>61K@QK^,8CIUH1V8NYW.B(?@% M942DA<]H'7/L1H0F>!*.6>8+E`KHWSAT,L MNKJW>[@>72V/-_+894G.$:S'1PD<[?!JQ37,O.G1`)'*]CD!XH\F>&:+E/H, MGYR>GAP=F6[N4H/5Y==!C?$?5$/8*PO[OUE.A`J-)PN/WS?5_VA=_>D*HW@) MVLDU6V147,6`MF2(Y<"J^K+*IYA0>1Y$*@U7S#&IO3H\*2JK`A7-A/A^W&^2 M0TS MI$*I>%!R:<4HO*<=[;'T'IYIV&&M?6WT4[*:D12"86UPYV_GED,[9CT\(Q3^ MZGO1B@BK]EZGG-[+;4^)U6!W0)&6*O9!HPK9ZPVQT&O5?)/N^=?NQF["DM=DZMKV1_JR];:-]Z#4OGP&5Z3VR8-/,'+[WDDX M*@Z5%P&3M2(4#>YU+$F$%."'VA?$&F!:7R/.M9"4)^`--,DLN;25(GPZ0Q0O%,*J9B? M:VAMLZWE112$'CE"G2U\A.)>).+B6J*A<-C`E:C\H9\(`7#E>CNRHS>*9L>R M"7"87,E.WFRT.VZW)X>XAET.0Z5*V;HS>WGJJX2A+$6]=H2F^&"AG1+:GO\' MP>;"6N'0"L>:RREJYJ@YI6TA9B`LZ6B[ANA9__Q[#D$VN#R MSXAZWU+>RS*\\_?Z.D$5E9W9E] MXZLN7N!*H0DX7)FQ`^.G'AN;O^/KFH_?W)6%9Q>.A3><3\[O?>-2&7K&E&&' M9=XFUM):$"K1%'\TB^_:]<[PW(D]8GD5M)@L@-]*+SS'L4+Z:A3_A69GJQ6R MG'//E?115LWH$4>U\&&L!+]GED_*%4^@MJLZJ-1.\-%3"IC?N4%I4.L@:.IRY M,UIA^E%67+O23!B,U7>/=/%BO3W!M"(1Q8XH-+\3>$+DWGHAMM&C=T'SA!UI MW$AC5M\XJX-3UN@-S+MM`5N3*SWB:OR#N._A\YUC<6LX<(?UC7%<))C^@6>4 M]2_:OR&YD66")J[0(AT.@W%*=LE0:.UTJ:C(!>#U4)I?O)F87._Y4+KQ@%"UI0'?)#O M?Y'O71`A\UP%KP0#>\4K`0Y=-&MOJUT!(0'=N<5\V1S3*Y9L@M^7_)N*+*@`A=XB35M'QDX+E9VP'X@O(L3Y"^L&&UA MXGC9;ZN[I''!J76$J(NM>*MMQR9G[^0O@Q`O+9HTQF`.^`$967)`H^7,,[:9 ME.?VO@D5NO&#`?2CI#5>"4&5C6;%4XP%;EO0$DE7RC4LV4,&,"'Y+J0A(Q]G MBQ".[#O_I<@-MMAQ&>-OKK7T_)`FS5$'C(K\G8^6.%K>(CVKH%BA[T)2"VF6 ML59;=$X3T7'1@L+=V2&"`,L:/V$42+<$C?%]9[4&BNQ^MFVKT`$W.0C+DG;9KDK'&[*)<*IEK*X$<2Y0PQD9\[IM(QN-Q`64W[I[HZD0Y&K!OH(0= M7'?1=G2,G`"37E9QQ\07;2\6[@5UH3SY`=9E? MCZPDBN/.)MB)0C2K&+02SNZYU:B,KRQUSLCSPPZEI8IL@.M"6%'^E<+0:9M! MT)8CI1C'DQ".[!GCI;B`*SC84L0%X<4SI0>!RUJ@VX@>?(>3*,P""UW M1N\5Y1M%]64&LF-41YQ=N;\G0;H.@@C->+M)'"S3GFI2:.IJ2A82U,9RH`<5 M+@%2^[I)Q=F_HB"N_5O'\E19M:\RU1H!NGB48US8B'WWXYLORTFM>DR*LS#T M\5,4,GM/KUD"3#M\E>]9!,+6>%5PPE9=_XJRUY@>@_28CK3 M&Z,%*O7RKB-^BH7?HP0J2/*.#:#E.,F=%ZVPGUY:-I(^T8KO4>Q$M&CKW24H M>1.X,B(R5SM'BE<9F%Q5QK^M5Z``ZOFDU<>#>V0C_%*Z#$XS0O=V]]8S0MFD M46&6`>G/OZXJS,,=::;.MN4&\6O41]^:(6*AIN$S\@OPY816=0NNN99)Y95P MK%Q]NQ9F@VK[^Q`]!>C/B"QW^8+R]Q:95HYWU[4RGS&*IP0F='(-;)5BBH>; M;?*]#I=^YV[A3'"W-"I6\3MT5\.OR_>Q9K9'X;L)G5T21@/NK>Z;@ERZ3<)J M5+/7F`1X=]-%86O;F(&SL16@M(0XNG;%OB?O$*R<:BQU3EN6-PZS2IP&&279 M1/06A1>1[R-AJ0'9E-+&N"I2[4C&G>_9",V"*T)/5DU7 M%!D3C.T7XP5(R%[602JT+C->DP@]>JQ("PJG\WF,9-Q$P-O@:O/E^L'XYGBR M+:'SPA-PRDFG]-STN8_&37%BBT@A\:/GK5%?I01+H68@-]'1V' MY>ZL-VJK[A'MJC:[L_RX&D;BKYRYLUO/M:7N7-5%C-GV>OI0RHBOB.K6\I`, M!#%5]EPCI@G#>/<[REF&AE>S0CZT-T%++O1MV64'B$$NM^7BU*F0#03$RHV7 MJ#*XV[*2,)G(+7,A'VJ2D6()%+-17>^BGXR\1R^>\X+=Q5K[1-FS?<4<.*P5 M/^17H##0Y.IRU3^)Z>4-[(/IY<$M"TF#XL>MM4122RH>;I(W8J$2?RX<%F[*8193T$=GH!9TW1"1[TG,J'!T'VRI$/BV M[G*@N$`<1*5F6#(>$E_71%/!6GC6N!/FRLM1\<<"8ZJD.A4?_O=ABF\$M:W4 MPR'Q5],8WVR4MVJUP+_-SS?>_'1N&&:E/-5=;6$[&\X9(N1@.MY\##/T%=_?A&\3):)HI`CWO6BOP2OE60"?$2?1<-,68#O4+G$>':#1%A M7WAOA6@2^80,K'N\MH2(E^B[A(@Q`Y<'*7`7A/&=_)W^G8]M-$&![>,8"9[K M4&N9/G"_/G9]ZS1FR"74,"-Q_-: M;[6T9G]DHS&J\-I^UI`4]C;Y/`J(G0R"B?7&S:2MOL8@)(&/&N,\'$]3P/EK M@DSR7/W<L*^S$;)\2/&E?P+#=F]D$X*B'$FGN!$8,*8:>O5AC1KU!4+FE^9FP.>:>' M>DOT@=GU,&-<'U@/S[3W1EK[9NK?T_(FF?U#-B5(W+W0<=#L_(W5R$D'"M,' MFZ[:!SEJ#5FVL<`YF78H6Y>OQ`/'`8I]L.S'6@*E7*KW4J3$D(D._",M'SVV MM?X363[QQ;YZ;OC,/:-4F=X'ME?'*@N!#^*UQXWG+AZ1OZ3I3QE=LBI2!^MO M.^CP$1T_BB<8J<:4`YR_P5$\YE!-,E-6*H=)73:*.];D%;`>'\H5HKA(#.KQ M5!%'U4-8A7+!>#4U&'4KYW?*'E!Q1_9+U;@H#"VMK;>9_!)1U$SD;S==YB.1 M__TD\E]YD1\BY*;W+P_()5\HW]P%XE3^*K/AL%&2S%\%H8'FOI1I=:-((16. MAL-N38-ZLY$_VN[S*%$T>,T+5J2!2H?#H?F&V.0!7AD"X%1*6#.IB.QE>B9@ M<>HD3X['/;UYQN(D&K)8J'^D@PJP-A5:[)SZ>($)C,5K!S4S^;-ZR$H^(H,L M8EA&7,)OG0G06:V#0V]2\4H!6F9\*!&2:T&Q!=:="9V;E9#I37Z=`I\Z#!T( M*_N4^Y8W@TQ2=(KIOG$B'_TS=S M-ZER><[G=$Y!)Q@P9-)B:^=O%-OX;7U&%IYTU%VI%R)1%SEX>7'U[Z!KWCWW MA,-:F&PO&X5[,?;W+Q3F)RM`Y#_^/U!+`P04````"``JBK1"[E19H5D/``!P MH0``$0`<`&-H8W(M,C`Q,S`S,S$N>'-D550)``/?DII1WY*:475X"P`!!"4. M```$.0$``.T=76_C-O+]@/L/NKQ<"YSC..GN=8--"R=.V@#9.)=XN[U[*6AI M;+.522\I)?']^AM2DO5A293B.!)Z0H#`%F>&,QQR9C@[?/:`.>!8OY[?WU@/]@*6 MQ+H00#Q\]D2]A34A\SD(:[JV[N^M$6<,7!?640_6X.A0_1U_=]3KA33/B41D M;-,TCP\'FY9/R,:,ZL93ZUU_\'W_^&AP8@T&IR>#TZ-WUMVG`%0&?*`D3)X= M+#QO==KO/ST]'3Z=''(Q1ZRC0?_73S1`@G?M!Y9'Q!R\6[($N2(V;,!MOES91,`A M?M!"'YV<#%`S+BR!>5=<+$-J+1=+GT!^$61LA0M2Q&SO@G)62&];S_VLU2R'?BXQL;L M!_UY)4#B+-*C<8,/0NP0I`S3)J[MNR]`C#DKQ@N?1AIX'<5LJZ)\\(]-@]\- M=7*H'_RIA*\^BGCYB/]DWCHPP)2OA<%15ATQ.2N@URV'C1*'&OT;<)?UFDLGHH!FOV?I!5H2)O:?H6GUF;'JQ$%YU2RY4ZM&WNXSC= M@PWTD4Q=",BA:"";_ M7V4%=&.?'/L[$`\+?#(B'DE9H;P&@_WYD!U]I&%I(I:BLC$]GQ:TF55`,U:.EE5JU3G6'I;"\:4Q1F6"[=4-=8)976ATDA+UD9 MG98*O7R.7S=IH-R3=V.='.MKAA]A0I[SXZGB9D,T]7U6!P$E2Y/J@JERI=QR M#^0=62?242FME+0;U'*258LF986T.KV4ZV4$TA9TI7H;SRZPF;"U//L4E*^@<^*J$JV'!8"7YYE*VLL5-2AU2"%9*Z";=4.= MB@I5E*,5DR)*5TQ:$=W`)P?^\JNOW7CV9&<0**&XV1"&_W,K#@](Y9=O#+KE M4*Z5`FT8M5!#"9T**BV,U&[6!&12SU890=DBZ?:?E?24/.XI:C0<\%1:-MUY MSE:E]Z!W]+YW2C/^83;S9U(&#+EKYTHZB:"<2(D<[=9#:?: M#*HKS^1VBC`JHB"^*`,PJ*2"R>ST8M1+XL@IJY%DDT$7I>=/_P=:4/_4):M[ MF%GZ"M6INN]S=B#I5E MY`S[C2@086\1V;KAU5\)O@+A49#]B/>(@$<]A7X1]V*I;N0_+.(BG_U7$QTU M75?T[.38D^RITYC]".^2:5WA$07G%I*KQHNE*L`_G M_!'G%JW,2Q9'?:C=>X5+I%5TDL2\#1"54CXHI0S>[\3*R]AX(0^E-V-WF!F: MUFY3`Y[M1>VYL4'2GW9C0-_J$.O:/"3QHB\OXV3KRG5%$%< M!YC*,?Q6=JP[G&(`3VSL5_%7?@0AW)EHLHXOPJ1!D8!CW,R+ M!T3!+2;Z0Q`"G`>/VW]\@N441"2;$2Q?K."*^JG#EX2R-Y7K"Q=_X%A>D!7U MB*OM(H.+VI$*6G(%'Q'HOK`=MT^`(!AM@2KUB@>Y`V/A@/+N'1V`^ MA->JP+GBXGRM:AF3<[$J=*@FU-$JP'A3)542I9($;Z\N&U=`F;X^LQ6ASH5+ MZ%)&HJ2?M97S.\&75$HNUCIYE#8$!8UM6_[_`<$OD#*&']LR%#2V38813/&[ M+[+L;S]O&^=@VGK?,P`UE M>M'*0D.1@&C9-C4Y8_3:&.O3:#GA8U]@X^5RY?(UP&8VY4VUBH@I4=652=G$ M7`OY_$D0M>G)S+EL8\,LJQ<#.KX+X]DE=K54I84;=RKS[TMFDR<[D6C99$UK M9X@&@+CN)O-0U-JP#K]@=(<<#6UT.&@5LOHI;&[9V-]0-&I.X"EU6`#H1*.; MTWHV;>+U"I"I](ANV$?T5TL6LPPIWEL7N][ZREV.9^&$PET%HKDN.-?L\ME> M$#9'&Q`,M92QI+71&EY.R9#M@DOU!B57&;4)CR08H;9L/F?TO[%YKXO5UA12 M-K(("S2S1L4(UC+CDJS$*A"I%*1EXB0*9PJD*8-HF3`ZN%MPUP$A@WFUG?0O MAVEIXE\;-?V2YZ1UT$_ET/<67"A;\)FA4(D`5V\3-W+O0F*OAM3H`[?V*$/' MT740Q*UH5,HP6C:';\#S<&J.9Q>A?0V]?/9Q2UU[_C0;*LBF=#JEL+GUB95PYG"AIA5UX`'$ M([6A.,]2C-!2'Z3.-60";3U.LA_U];816KA-V*1SAJL5I\D,2AE$DGWU M:`ZBP<2!&EV<(]=RL\Z+VQL?^+0)NL7MB[_49;F/D'70E4!;YIE?\'*6@O#D M-2BU;'#"8A.BMN`C^H@&C3E:-K1@6L=WA.(6-CRX2:O_9QV-9\I6=J*TSY(6 MH]M.;O\>,*[VU"(MVR/F`+5,N^I0(`H]KXBMCDO7GSCS%B[NGC`DQ/G*YAAA M0/KLN#9:6W,9%]Q5.1A!7+5)0F\!Q#WGS$F+:X)JJ6/_&=GT%A<8"D8553(\ M8E!S,A+.!-6X]\EA,$P0:L0O@N(.2E7[4)WB1MG]VJ2`DK`#8NKA0;_YQ,N7\R)J/T47T=COPQK.9.HX)<@B)FKZ=2+35 MJ*:36<'9["\@$YGK,HAF#ZNR/U%9,%F-8"V;JA.SL\ILL^M@M,V_/:A[=C7E MK8?3-HG3`:34H3YQTRZ]'*9QGQX=O2D[@,LCS7M!8^-,)_/?QGQ.1>"6F8XX M9_$`MH[IYT29T:&4=,[`B1V63,ZTRB@-[4,-V>1B$Q`J,'/B7Q6\;88CLY6I M<-VQ#D;;I$V;P(32XD*3.Z'2XRI5%!K(?/-9%7>OA2K&:.;")3*N:AB+>SI? M>)?/J#DJ07,;ESR$K3)/]MWI!.,0O2]$2?&9T3<]SS3]*ER^S:Z+U3+C?4.7 M2,P9@>/COE=?$%U?@:,.]\*7RK/Y#9?!A=@9%ZJP;&/&7XC2X(5>"O?3BH.@8'CCNU^(W4[O]C)ISL%[0L/_L`);ITS2(=KK MTFSGN"6+.K+RXI;P=["]";]\7M%H76[7@E1":[3PXQX>N?NHWBA3+1M:';YM MX4!>80=V%%$S(1J M.0G5%Z$V?>`>OS=459BEH]&-Z1FN5BY5QG@$C$>9XM05O-WI[--N[38.4?H_ M*D\OO7D#E#YY&JV1J58%_!AOL@PQK4:L<7 MHG8@T6R25OU@E2J?W*HJV7K>LG#\Q9<]MNKN]5OL)@O"MJ^!?`&U_P)GB/,8 MUVMJF[;SK9/78Z39G?'^!D"7M,OKT!LVJXPZO.Q5'TTNC2LN9D#U6\;4^RPW M879+=+0C>W]:M85R*@8#'[1_5>1TV?!IY%N(VNSTK\S(G]5?%`_`/:@=<;"Q MUE&,'U2I&RY#-\94XU'QFXS'<#X7,%<%>$P%D)+:J4U4LSRT,VU67MZ8+9^N M`MO6#$NBSKO@0*$4I&7;E?2Q3Z0+_69032=3@EP1NJ6Z,[%?5/,R.Z$F@V@DIEWQ0^R%7$8 M'LR?KY4(VI]M9,W+V]?!;C1]7W!6&VTK5*FHX5@W#9I4X%P]:M`$Y;*(6M&W M,6M(%:-L2:>?[TW$C_W@AQWPX_\`4$L!`AX#%`````@`*HJT0L]=&UL550%``/? MDII1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`*HJT0IBW]&?,"@``M'H` M`!4`&````````0```*2!$&8``&-H8W(M,C`Q,S`S,S%?8V%L+GAM;%54!0`# MWY*:475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`"J*M$*_K=\YBQX``()H M`@`5`!@```````$```"D@2MQ``!C:&-R+3(P,3,P,S,Q7V1E9BYX;6Q55`4` M`]^2FE%U>`L``00E#@``!#D!``!02P$"'@,4````"``JBK1"3V/^-GQ4``"4 MHP0`%0`8```````!````I($%D```8VAC&UL550% M``/?DII1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`*HJT0J&NP>*S,``` M5T@#`!4`&````````0```*2!T.0``&-H8W(M,C`Q,S`S,S%?<')E+GAM;%54 M!0`#WY*:475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`"J*M$+N5%FA60\` M`'"A```1`!@```````$```"D@=(5`0!C:&-R+3(P,3,P,S,Q+GAS9%54!0`# IWY*:475X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``!V)0$````` ` end XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value of Financial Instruments (Details) (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2013
Schedule of carrying and estimated fair values of financial instruments  
Less: unamortized discount $ (39)
Net liabilities carrying amount 5,504
Net liabilities fair value disclosure 5,503
Promissory Notes [Member]
 
Schedule of carrying and estimated fair values of financial instruments  
Financial Instrument Carrying Amount 2,880
Debt instrument, Fair Value Disclosure 2,853
Zero-coupon promissory notes [Member]
 
Schedule of carrying and estimated fair values of financial instruments  
Financial Instrument Carrying Amount 230
Debt instrument, Fair Value Disclosure 225
Debentures [Member]
 
Schedule of carrying and estimated fair values of financial instruments  
Financial Instrument Carrying Amount 537
Debt instrument, Fair Value Disclosure 534
Senior Promissory Notes [Member]
 
Schedule of carrying and estimated fair values of financial instruments  
Financial Instrument Carrying Amount 1,771
Debt instrument, Fair Value Disclosure 1,770
Long Term Promissory Notes [Member]
 
Schedule of carrying and estimated fair values of financial instruments  
Financial Instrument Carrying Amount 125
Debt instrument, Fair Value Disclosure $ 121

XML 17 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Notes Payable
3 Months Ended
Mar. 31, 2013
Notes Payable [Abstract]  
NOTES PAYABLE

NOTE 3 – NOTES PAYABLE

In January 2013, a 14%, $100,000 convertible promissory note matured and was renewed on the same terms until April 30, 2013 at which time the note was again renewed. The new note utilizes the same terms as the previous note and has a maturity date of July 31, 2013.

In February 2013, a zero coupon promissory note in the amount of $230,000 matured and was replaced by a new note of similar terms with a face value of $230,000 and a maturity date of May 31, 2012.

In March 2013, we renewed a 10% promissory note in the amount of $100,000 and a 7% promissory note in the amount of $50,000, each for additional one-year terms. One of the note holders was issued a three-year warrant to purchase 25,000 shares of our common stock at an exercise price of $0.15.

 

On March 15, 2013, we executed an agreement with a creditor to modify the terms of a previously matured but unpaid promissory note in the amount of $1.4 million. Under the modified terms of the note, the maturity date was extended from February 28, 2013 to January 31, 2014 and the conversion price at which the note may be converted into our common stock was reduced to $0.125 from $0.25. In addition, the exercise price of a warrant to purchase our common stock issued in conjunction with the note was reset from $0.44 to $0.22. We also assigned certain receivables (see Note 2 “Accounts Receivable”) and a potential arbitration recovery to the creditor as a source of future repayment of a second loan from the creditor in the amount of $625,000 maturing May 14, 2013 and a $75,000 loan from an individual related to the creditor also due on May 14, 2013. Any proceeds remaining from the assigned receivables and potential recovery after repayment of the aforementioned loans will be used to reduce the principal of the $1.4 million loan, but not in excess of $300,000. The modification was accounted for as a troubled debt restructuring, but we recognized no gain because the effective interest rate of the modified promissory note was less than the effective interest rate of the original promissory note.

We were unable to repay our 14% senior promissory notes in the amount of approximately $1.8 million on the maturity date of April 15, 2013. We are currently in negotiations with the holders to resolve the default. We completed an agreement to extend the maturity date for approximately $1.3 million of the notes on May 13, 2013. See Note 4 “Long Term Debt.” In addition, we were not able to repay a $1 million loan due May 8, 2013.

On May 8, 2013, we executed an agreement with a creditor to modify the terms of a promissory note in the amount of $625,000. Under the modified terms of the note, the maturity date was extended from May 14, 2013 to July 15, 2013 and the conversion price at which the note may be converted into our common stock was reduced to $0.125 from $0.25. In addition, the exercise price of a warrant to purchase our common stock issued in conjunction with the note was reset from $0.44 to $0.22.

EXCEL 18 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\R,C(P-F9B-E\T,#%C7S0P,C!?.38P8E\R-V8U M9F$P,S)C-S(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O&5S/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D9A:7)?5F%L=65?;V9?1FEN86YC:6%L7TEN#I7;W)K#I%>&-E;%=O M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5S7U!A>6%B;&5?1&5T86EL#I%>&-E;%=O#I%>&-E;%=O'1U86P\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/D5Q=6ET>5]);G-T#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D5Q=6ET>5]);G-T#PO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DEN8V]M95]487AE'1U86P\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I!8W1I M=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O M7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA2!);F9O2!2 M96=I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^36%R(#,Q+`T*"0DR,#$S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^+2TQ,BTS,3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'1087)T7S(R,C`V M9F(V7S0P,6-?-#`R,%\Y-C!B7S(W9C5F83`S,F,W,@T*0V]N=&5N="U,;V-A M=&EO;CH@9FEL93HO+R]#.B\R,C(P-F9B-E\T,#%C7S0P,C!?.38P8E\R-V8U M9F$P,S)C-S(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\R,C(P-F9B-E\T,#%C7S0P,C!?.38P8E\R-V8U9F$P M,S)C-S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(R,#9F8C9? M-#`Q8U\T,#(P7SDV,&)?,C=F-69A,#,R8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'!E M;G-E'!E;G-E*3H\+W-T M&5S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M/B@Q+#0P-"D\&5S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\R,C(P-F9B-E\T,#%C7S0P,C!?.38P8E\R-V8U9F$P,S)C-S(- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(R,#9F8C9?-#`Q8U\T M,#(P7SDV,&)?,C=F-69A,#,R8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!O<&5R871I;F<@86-T:79I=&EE'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\R,C(P-F9B-E\T,#%C7S0P,C!?.38P8E\R M-V8U9F$P,S)C-S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(R M,#9F8C9?-#`Q8U\T,#(P7SDV,&)?,C=F-69A,#,R8S'0O:'1M;#L@8VAA'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@ M+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#$@+2!U6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)VUA&-H86YG92!# M;VUM:7-S:6]N("@F(S@R,C`[4T5#)B,X,C(Q.RD@2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!H879E(&)E96X@:6YC;'5D M960N($EN=&5R:6T@'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/D]U2!U;G)E;&%T960@=F5N9&]R M&5D+`T*("`@<&5R(&UE;6)E2`H)B,X,C(P.T%33R8C.#(R,3LI(&-O;G1R86-T'1E;G-I M;VYS+B!3=6-H(&-O;G1R86-T2!U<&]N(#8P('1O(#DP(&1A>7,@ M=W)I='1E;B!N;W1I8V4@;W(@=&AE(')I9VAT('1O(')E<75E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6QE/3-$;6%R9VEN+71O<#HQ.'!X M.VUA6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)VUA2!O9B!R96-E:79A8FQE'!I0T*("`@87!P2`D M,2XP(&UI;&QI;VX@;V8@8VQA:6US('!A:60@;VX@;W5R(&)E:&%L9B!B>2!T M:&4@4'5E'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA6%B;&4@6T%B M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'1";&]C:RTM/@T*("`@/'`@'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/DEN($IA;G5A28C,38P.S,Q+"`R,#$S+B`\+V9O;G0^/"]P/@T* M("`@/'`@F5R;R!C;W5P;VX@<')O;6ES2!N;W1E(&EN('1H92!A M;6]U;G0@;V8@)#(S,"PP,#`@;6%T=7)E9"!A;F0@=V%S(')E<&QA8V5D(&)Y M(&$@;F5W(&YO=&4@;V8@2!D871E(&]F($UA>28C,38P M.S,Q+"`R,#$R+@T*("`@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA M#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z M."4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@65A6QE/3-$)VUA2!M871U2!D871E('=A'1E;F1E9"!F28C,38P.S$T+"`R,#$S+B!!;GD@<')O8V5E9',@ M2!N;W1E&EM871E M;'D@)#$N."!M:6QL:6]N(&]N('1H92!M871U2!D871E(&]F($%P'1E;F0@=&AE(&UA='5R M:71Y(&1A=&4-"B`@(&9O28C,38P.S@L(#(P,3,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS M1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD M96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/D]N($UA>28C,38P.S@L(#(P,3,L('=E(&5X96-U M=&5D(&%N(&%G2!B92!C M;VYV97)T960@:6YT;R!O=7(@8V]M;6]N('-T;V-K('=A7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&AT;6PQ+71R86YS:71I;VYA M;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`T M("T@=7,M9V%A<#I,;VYG5&5R;41E8G1497AT0FQO8VLM+3X-"B`@(#QP('-T M>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.C@E)SX\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/D]N M($UA>2`Q,RP@,C`Q,RP@=V4@97AE8W5T960@86X@86=R965M96YT('=I=&@@ M82!H;VQD97(@;V8@87!P2`D,2XS(&UI;&QI;VX@;V8@;W5R M('-E;FEO'1E;F0@=&AE(&UA M='5R:71Y(&1A=&4@;V8@=&AE(&YO=&5S(&9R;VT@07!R:6P@,34L(#(P,3,@ M=&\@07!R:6P@,34L(#(P,30N(%=E(&%L7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@(#PO9F]N=#X\+W`^#0H@("`\<"!S M='EL93TS1&9O;G0M6QE/3-$;6%R9VEN+71O M<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@2!B92!S=69F:6-I96YT('1O(&UE970@ M;W5R(&-U#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/CQI/D-O;F-E;G1R871I;VXL M(&UA:F]R(&-U6QE/3-$)VUA&EM871E;'D@,S28C,38P.S$L(#(P,3(@86YD M(&UA>2!B92!T97)M:6YA=&5D(&)Y(&5I=&AE2!W:71H(#DP(&1A M>7,@=W)I='1E;@T*("`@;F]T:6-E+B`\+V9O;G0^/"]P/@T*("`@/'`@6QE/3-$)VUA2!L96=A;"!PF4Z-G!X.VUA'0M M86QI9VXZ(&QE9G0G(&)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!W:61T:#TS1#0E('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^ M/&9O;G0@3IT:6UEF4],T0R/E=E M(&EN:71I871E9"!A;B!A8W1I;VX@86=A:6YS="!*97)R>2!+871Z;6%N+"!A M(&9O2`R,#`Y(&%L;&5G:6YG('1H870@ M37(N)B,Q-C`[2V%T>FUA;B!FFUA;B!D:60@;F]T#0H@("!F2P@=&AE('1R:6%L(&-O=7)T('-E="!A2!V97)D M:6-T(&%N9"!A=V%R9&5D#0H@("!-2`D,2XS(&UI;&QI;VXN(%1H92!#;VUP86YY(&%P M<&5A;&5D('1H92!L;W=E2`D,2XS(&UI;&QI;VXN($]N($9E8G)U87)Y)B,Q-C`[,30L(#(P M,3,L('1H92`Q,3PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0Q/@T*("`@/'-U<#YT:#PO3IT:6UEF4],T0R/B!#:7)C=6ET($-O=7)T(&]F($%P<&5A;',@;V8@=&AE M(%-T871E(&]F($9L;W)I9&$@2!A;F0@9&%M86=E&5D(&%P<&5L;&%T92!C;W-T&EM871E;'D@)#$N,R!M:6QL:6]N+B`\+V9O;G0^/"]P/@T*("`@/"]T9#X- M"B`@(#PO='(^#0H@("`\+W1A8FQE/@T*("`@/'`@F4Z-G!X.VUA'0M86QI9VXZ(&QE9G0G(&)OF4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!W:61T:#TS1#0E('9A;&EG;CTS1'1O<"!A M;&EG;CTS1&QE9G0^/&9O;G0@3IT:6UEF4],T0R/E=E(&%N9"!A(&9O M2`D,2XW(&UI;&QI;VX@9F]R(&%L;&5G M961L>2!U;G!A:60@8VQA:6US(&9O0T*("`@;W!P M;W-I;F6QE/3-$ M)V)O3IT:6UEF4],T0R/B@S*3PO M9F]N=#X\+W1D/B`-"B`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6UE;G0N#0H@ M("!4:&4@87)B:71R871I;VX@:7,@=6YD97)W87D@8G5T(&AA65T M('!R;V=R97-S960@2X@/"]F;VYT/CPO=&0^#0H@("`\ M+W1R/@T*("`@/"]T86)L93X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C9P M>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^ M#0H@("`\=&%B;&4@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@2!C;&%I;7,@F4Z,7!X.VUA#MM87)G:6XM8F]T=&]M.C!P>#XF M(S$V,#L\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P>#MM87)G M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@#MM87)G:6XM8F]T=&]M.C!P M>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQI/D]T:&5R.B`\+VD^/"]F;VYT/CPO<#X-"B`@(#QP('-T M>6QE/3-$)VUA2!A M(&UA:F]R('-T;V-K:&]L9&5R(&]F('1H92!#;VUP86YY+B!)9B!T:&4@8VQI M96YT(&1R87=S('5P;VX@=&AE(&QE='1E2!B M96-O;64@;&EA8FQE('1O(&]U2!T:&4@8F%N M:R!T;R!F=6QF:6QL(&ET3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\R,C(P-F9B-E\T,#%C7S0P,C!?.38P8E\R-V8U9F$P,S)C-S(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(R,#9F8C9?-#`Q8U\T,#(P M7SDV,&)?,C=F-69A,#,R8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\ M(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#8@+2!U#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/DX\ M6QE/3-$)VUA&EM871E M('1H96ER(&5S=&EM871E9"!F86ER('9A;'5E(&1U92!T;PT*("`@=&AE('-H M;W)T+71E&-E<'0@ M9F]R('9A;'5I;F<@7-T96UA=&EC(')I'0M M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E1H92!C87)R>6EN9R!A;6]U;G1S(&%N9"!E M6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2`M+3X-"B`@(#QT3IT:6UEF4],T0R/E!R;VUIF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/EIEF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(R-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D1E8F5N='5R M97,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C4S-#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/E-E;FEO6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/C$L-S

'0M:6YD96YT.BTQ M+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$R,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/DQEF5D(&1I M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O3IT:6UEF4],T0R/DYE="!L:6%B:6QI=&EEF4],T0R M/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/C4L-3`S/"]F;VYT/CPO M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@ M"!D;W5B M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@/'`@2`M+3X-"B`@(#PO=&%B;&4^(`T*("`@/'`@2X@07,@2!N;W1E6EN9R!V M86QU92!O9B`D,RPP,#`L,#`P(&%R92!E>&-L=61E9"!F7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM M/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`W("T@=7,M9V%A M<#I3=&]C:VAO;&1E'1";&]C:RTM M/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2`S,38N,C@@8V]M;6]N#0H@("!S:&%R97,@9F]R M(&5A8V@@F4Z-G!X.VUA'0M86QI9VXZ(&QE9G0G M(&)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!W:61T M:#TS1#0E('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P/@T*("`@/'`@86QI9VX],T1L M969T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$9F]N="US:7IE.C9P>#MM87)G:6XM=&]P M.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/FQI<75I9&%T:6]N('!R969E&EM871E;'D@)#(N-B!M:6QL:6]N(&%T M($UA6QE/3-$9F]N="US M:7IE.C%P>#MM87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q M-C`[/"]P/@T*("`@/'`@'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/E=E(&%LF5D(&%N9"`R-3`@2`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`^#0H@("`\=&%B;&4@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D M97(],T0P('-T>6QE/3-$)V)O6QE/3-$)V)O MF4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L MF4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C,U+#DU-RPU.#,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4] M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C$L-S`P+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C`N,C4\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M;F]W3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R M/D9O'!I6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@F4],T0R M/BDF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\ M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\ M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T* M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T M9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^ M#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C,W+#,S,BPU.#,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W M3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V)O'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/C,W+#(Y."PU.#,\+V9O;G0^/"]T M9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T M3IT:6UEF4] M,T0R/D]U='-T86YD:6YG(&%T($IA;G5A6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C`N,S4\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(U+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/C`N,C4\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@;F]W3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/D9O'!I6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/BDF(S$V,#L\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$9F]N M="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T* M("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C0P+#DX,BPU.#,\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M;F]W3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V)O'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C,Y+#,Q-2PU.#,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W M3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@;F]W3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$ M9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP M<'@^)B,Q-C`[/"]P/@T*("`@/'`@#MM M87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/CQI/D]05$E/3E,Z(#PO:3X\+V9O M;G0^/"]P/@T*("`@/'`@'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/D9R;VT@=&EM M92UT;RUT:6UE+"!W92!G65E65E(&1I2!#;VUP96YS871I M;VX@4&QA;B`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`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D97(],T0P('-T>6QE/3-$ M)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SX\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/E-H87)EF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/E=E:6=H=&5D+3QB&5R8VES93QB3IT:6UEF4] M,T0Q/CQB/E=E:6=H=&5D+4%V97)A9V4\8G(@+SY296UA:6YI;F<\8G(@+SY# M;VYT"!S;VQI9"`C,#`P M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/D%G9W)E9V%T93QB2`M+3X-"B`@(#QT3IT:6UEF4],T0R/D]U='-T M86YD:6YG(&%T($IA;G5A6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C@N,CDF(S$V,#MY96%R M3IT:6UE MF4],T0R/D9O'!I6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$9F]N="US:7IE.C%P M>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T* M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G M8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\ M<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ M+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/C8L-#(X+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/C`N,S$\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@;F]W3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@65AF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/C@N,3$F(S$V,#MY96%R3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@;F]W3IT:6UEF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T3IT:6UEF4] M,T0R/D]U='-T86YD:6YG(&%T($IA;G5A6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C65AF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V M,#L\+W1D/@T*("`@/"]T6QE/3-$)VUA3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/B@T,"PP,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT M:6UEF4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$9F]N="US:7IE M.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T* M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^ M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T* M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R M(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@ M("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C@L-S4U+#0P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT M:6UEF4],T0R/C`N,S,\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@;F]W3IT:6UEF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@65AF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T* M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C@L,#`T+#0P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT M:6UEF4],T0R/C`N,S,\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@;F]W3IT:6UEF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@65AF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD M96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E1O=&%L(')E8V]G;FEZ960@8V]M<&5N2`D,S4L,#`P(&]F('5N2`D,3`L,#`P+B`\+V9O;G0^/"]P M/@T*("`@/'`@F4Z,7!X.VUA#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA&5S(%M!8G-T M'1";&]C:RTM/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/DX\6QE/3-$)VUA"!R871E(&9O2X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!N970@;W!E2`R,#`Y(&]W;F5R&EM871E;'D@)#(W-"PP,#`@;V8@ M=&AE(&YE="!O<&5R871I;F<@;&]S'!I M&%B;&4@:6YC;VUE+B`\+V9O;G0^/"]P/@T*("`@/'`@7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&AT;6PQ+71R86YS:71I;VYA M;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`Y M("T@=7,M9V%A<#I%87)N:6YG3IT:6UEF4],T0R/CQB/DX\'0M:6YD96YT.C@E M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/D9O6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$ M)V)O6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O M;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!(96%D("TM M/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L M;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S M='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4] M,T0R/DYE="`H;&]S6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B@Q+#0P-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/CQB/D1E;F]M:6YA=&]R.CPO8CX\+V9O;G0^/"]P/@T*("`@/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^ M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/E=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE M/3-$)VUAF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/E-E3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M;F]W3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/C,L,S`P/"]F M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@'0M M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF M(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE M/3-$)VUA3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T M9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M;F]W3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/@T*("`@/"]TF4Z,7!X M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE M/3-$)V)O6QE/3-$)VUA'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B@P+C`R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/C`N,#`\+V9O;G0^/"]T M9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE M/3-$)V)O6QE/3-$)V)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@ M/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`Q,"`M('5S+6=A87`Z4V-H M961U;&5/9E-U8G-E<75E;G1%=F5N='-497AT0FQO8VLM+3X-"B`@(#QP('-T M>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/D]T:&5R M('1H86X@=&AE(&-H86YG97,@:6X@;W5R(&]U='-T86YD:6YG(&1E8G0@:6YS M=')U;65N=',@9&5S8W)I8F5D(&EN($YO=&5S(#,@86YD(#0L(&YO(&5V96YT M6QE/3-$)VUA&EM871E;'D@)#@X-"PP,#`L('=H:6-H(')E<')E6%B;&4@=V5E:VQY+B!4:&4@8W)E M9&ET(&9A8VEL:71Y('=I;&P@;6%T=7)E(&]N($YO=F5M8F5R)B,Q-C`[,RP@ M,C`Q,RP@870@=VAI8V@@=&EM92!W92!M87D@'1E;G-I M;VX@;V8@=&AE(&UA='5R:71Y(&1A=&4@9F]R(&%N(&%D9&ET:6]N86P@2!B92!A8V-E<'1E M9"!O2!T:&4@;&5N9&5R(&EN(&ET'0M:6YD96YT.C@E)SX\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/@T*("`@5&AE($%GF%T:6]N(&5X<&5N2!W:6QL(&)E(&5V:61E M;F-E9"!B>2!A(%)E=F]L=FEN9R!#;VYV97)T:6)L92!00T*("`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`Q8U\T,#(P7SDV M,&)?,C=F-69A,#,R8S'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1";&]C:RTM/@T*("`@ M/'`@F4Z,3)P M>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^ M#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W M:61T:#TS1#6QE/3-$)V)OF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0Q/CQB M/D-A6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/D%M;W5N M=#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/D9A:7(F(S$V,#M686QU93PO8CX\+V9O;G0^/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/C(L.#@P/"]F;VYT/CPO M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@ M/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$L-SF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UE MF4],T0R/DQO;F6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B@S.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@ M/"]TF4Z,7!X/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)VUAF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$4YO=&5787)R86YT'0M:6YD96YT.C@E)SX\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/D$@2!O9B!O=7(@=V%R2!F;W(@=&AE('1H MF4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF M(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D97(],T0P('-T>6QE/3-$)V)O6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/C,U+#DU-RPU.#,\+V9O;G0^/"]T M9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/C$L-S`P+#`P,#PO9F]N=#X\+W1D M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C`N M,C4\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT M:6UEF4],T0R/D9O'!I6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$9F]N="US:7IE M.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T* M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^ M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T* M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/C,W+#,S,BPU.#,\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O'0M:6YD96YT.BTQ M+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/C,W+#(Y."PU.#,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@;F]W3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T3IT:6UEF4],T0R/D]U='-T86YD:6YG(&%T($IA M;G5A6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C`N,S4\+V9O M;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@'0M M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/C(U+#`P,#PO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0R M/C`N,C4\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/D9O'!I6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E M969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/C0P+#DX,BPU M.#,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/C,Y+#,Q-2PU.#,\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF M(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/@T*("`@/"]T51A8FQE5&5X=$)L;V-K M+2T^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O M='1O;3HP<'@[('1E>'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/D$@2!O M9B!O=7(@;W!T:6]N(&%C=&EV:71Y(&9O3IT:6UEF4],T0Q/CQB/D]P=&EO;G,\+V(^/"]F;VYT/CPO<#X-"B`@ M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O M6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@28C M,38P.S$L(#(P,3,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C@N,34F(S$V,#MY96%R M3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF M(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/@T*("`@/"]TF4Z,7!X/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O3IT:6UEF4],T0R/D5X97)C M:7-A8FQE(&%T($UAF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@28C,38P.S$L(#(P,3(\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D9O'!I6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T* M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q M,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/@T*("`@/"]TF4Z,7!X M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O3IT:6UEF4],T0R/D5X M97)C:7-A8FQE(&%T($UA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q M,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/@T*("`@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R M9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@8F]R9&5R/3-$ M,"!S='EL93TS1"=B;W)D97(M8V]L;&%P'0M86QI M9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L M92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#@P)3XF(S$V M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3XF M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0V)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\ M+W1D/@T*("`@/"]TF4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]TF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/C@P/"]F;VYT/CPO=&0^(`T*("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C4Y+#(U,CPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D5F9F5C="!O9B!D:6QU=&EV92!S96-U'0M:6YD96YT.BTQ+C`P M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/E=A6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O3IT:6UEF4],T0R/E=E:6=H=&5D(&%V97)A M9V4@8V]M;6]N('-H87)EF4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C8R+#4U,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O3IT M:6UEF4],T0R/CQB/D5AF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V M,#L\+W1D/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$9F]N="US:7IE M.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T* M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@3IT:6UEF4],T0R/D1I;'5T960\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/BDF(S$V,#L\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M2=S($)U'1U86PI(%M!8G-T'0^,B!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\R,C(P-F9B-E\T,#%C7S0P,C!?.38P8E\R-V8U9F$P,S)C M-S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(R,#9F8C9?-#`Q M8U\T,#(P7SDV,&)?,C=F-69A,#,R8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'1U86PI("A54T0@)"D\ M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L M2!.;W1E(%M-96UB97)=/&)R/CPO=&@^#0H@ M("`@("`@(#QT:"!C;&%S2!.;W1E(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S M2!.;W1E(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^07!R(#$U+`T* M"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^36%Y(#$T+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^1F5B(#(X+`T*"0DR,#$S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^07!R(#,P+`T*"0DR,#$S/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2`S,2P-"@D),C`Q,CQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!.;W1E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S6%B;&4@ M65A65A2!.;W1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S6%B;&4@86UO=6YT(&]F(&1E9F%U M;'0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S2!.;W1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!N;W1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$F5D(&=A:6X@=')O=6)L960@9&5B M="!R97-T'1087)T M7S(R,C`V9F(V7S0P,6-?-#`R,%\Y-C!B7S(W9C5F83`S,F,W,@T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R,C(P-F9B-E\T,#%C7S0P,C!?.38P M8E\R-V8U9F$P,S)C-S(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA2`Q M,RP@,C`Q,SQB65A2!I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!N M;W1E'0^07!R(#$U+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^07!R(#$U+`T*"0DR,#$S M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$65A'0^,C`Q-SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%SF5D($)O;F0@06UO=6YT+"!!<'!E86P\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!D96-R96%S:6YG(')A=&4\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6EN9R!A;F0@97-T:6UA=&5D(&9A:7(@=F%L=65S(&]F(&9I;F%N8VEA M;"!I;G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6EN9R!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA2!.;W1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!N;W1E'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!.;W1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!);G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^-"!Y M96%R'0^-"!Y96%R7,\ M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!I&5R8VES92!P'0^-"!Y96%R'0^-"!Y96%R7,\&5R M8VES86)L92!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^-"!Y96%R3QS<&%N/CPO&5R8VES86)L93PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,C(P M-F9B-E\T,#%C7S0P,C!?.38P8E\R-V8U9F$P,S)C-S(-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,C(R,#9F8C9?-#`Q8U\T,#(P7SDV,&)?,C=F M-69A,#,R8S'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!S:&%R M92UB87-E9"!P87EM96YT(&%W87)D+"!O<'1I;VYS+"!O=71S=&%N9&EN9RP@ M=V5I9VAT960@879E&5R8VES92!P'0^."!Y96%R7,\ M7,\7,\7,\'!I M6UE;G0@87=A65A'0^-R!Y96%R'0^."!Y96%R'0^-R!Y96%R&5R8VES86)L92P@96YD:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\ M=&0@8VQA&5R8VES92!P&5R8VES86)L92!E;F1I;F<\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^."!Y96%R7,\7,\&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\R,C(P-F9B-E\T,#%C7S0P,C!?.38P8E\R-V8U9F$P,S)C-S(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(R,#9F8C9?-#`Q8U\T,#(P M7SDV,&)?,C=F-69A,#,R8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'1U86PI("A54T0@)"D\8G(^/"]S=')O M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L2!I;G-TF5D M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,U+#`P,#QS<&%N M/CPO&-H86YG92!O9B!S M:&%R92!I'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^,3`@>65A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!M;VYT:',@9F]R(&]N92UH M86QF(&]F('1H92!O<'1I;VYS(&%N9"!A9G1E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!I;G-T'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!I;G-T'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!I;G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!I;G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!I;G-T'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XU-BPP,#`\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&EM=6T@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,R!Y96%R'1U86PI(%M!8G-T'!E8W1E9"!796EG:'1E9"U!=F5R86=E('!E'0^.2!M;VYT:',\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^17%U86P@ M=&\@-3`P+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7,\F5D/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L,S`P+#`P,#QS<&%N/CPO M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!I;G-T M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!I;G-T&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'1U86PI(%M!8G-T M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'1U86PI(%M!8G-T2!P2`R,#`Y(&]W;F5R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$"!9 M96%R(%5N9&5R($5X86UI;F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#Y487@@>65A'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!996%R M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#`X/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,C(P-F9B-E\T,#%C M7S0P,C!?.38P8E\R-V8U9F$P,S)C-S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,C(R,#9F8C9?-#`Q8U\T,#(P7SDV,&)?,C=F-69A,#,R8S'0O M:'1M;#L@8VAA&-E<'0@4&5R(%-H87)E(&1A=&$L M('5N;&5S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\R,C(P-F9B-E\T,#%C7S0P,C!?.38P8E\R-V8U9F$P,S)C-S(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(R,#9F8C9?-#`Q8U\T,#(P M7SDV,&)?,C=F-69A,#,R8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&EM=6T@8F]R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1E;G-I;VX@<&5R:6]D(&]F M(&UA='5R:71Y(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!. M;W1E+"!C;VYV97)S:6]N('!R:6-E(&1E2!P M;W)T:6]N(&]F('1H92!O=71S=&%N9&EN9R!P2!V;VQU;64@=V5I9VAT960@879E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7,@8V]N2!S97)V:6-E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!P'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,C(P-F9B-E\T,#%C M7S0P,C!?.38P8E\R-V8U9F$P,S)C-S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,C(R,#9F8C9?-#`Q8U\T,#(P7SDV,&)?,C=F-69A,#,R8S&UL#0I#;VYT96YT+51R86YS9F5R+45N M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O M:'1M;#L@8VAA&UL;G,Z;STS1")U M XML 19 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
Equity Instruments (Details Textual) (USD $)
3 Months Ended
Mar. 31, 2013
Person
Plan
Dec. 31, 2012
Equity instruments (Additional Textual) [Abstract]    
Compensation costs, unrecognized $ 35,000  
Tax benefits attributable to stock based compensation expense recognized 3,000  
Converted common stock 59,776,836 59,776,836
Unrecognized compensation costs related to warrants 1,000  
Options vested fair value gross 10,000  
Warrants issued against notes conversion, exercise price of warrants 0.15  
Equity instrument (Textual) [Abstract]    
Number of warrants cancelled in exchange of share issue 120  
Number of directors to be appointed 5  
Warrants exercise price per share 0.15  
Options for ISOs granted term 10 years  
Dividend Issued Treated as conversion Percent 50.00%  
Stock Incentive Option Plans 1995 And 2002, Vesting Rights Description plans generally occurs after six months for one-half of the options and after 12 months for the remaining options.  
Number of active incentive qualified option plans 3  
Number of common stock issued to consultants in lieu of cash payment 325,000  
Common Stock [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Conversion rate of preferred stock into common stock $ 316.28  
Stock Option [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Compensation costs recognized 15,000  
Maximum [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Warrants issued against notes conversion, exercise price of warrants 0.25  
Equity instrument (Textual) [Abstract]    
Warrants exercise price per share 0.25  
Minimum [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Warrants issued against notes conversion, exercise price of warrants 0.15  
Equity instrument (Textual) [Abstract]    
Warrants exercise price per share 0.15  
Minimum [Member] | Stock Option [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Compensation Costs, Expected Weighted-Average period 8 months  
Series C convertible preferred stock [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Liquidation preference per share value $ 250  
Liquidation preference value 2,600,000  
Warrants [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Warrants granted 1,700,000  
Compensation costs recognized 56,000  
Warrants [Member] | Common Stock [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Options vested fair value gross 59,000  
Warrants [Member] | Maximum [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Terms of warrants 3 years  
Warrants [Member] | Minimum [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Compensation Costs, Expected Weighted-Average period 9 months  
Terms of warrants 2 years  
Series D convertible preferred stock [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Series D convertible preferred stock, authorized shares 7,000  
Preferred stock, shares issued 250  
Preferred stock, vesting period 10 years  
Convertible preferred stock, shares issued upon conversion 100,000  
Preferred Stock Voting Rights Equal to 500,000 shares of common stock  
Compensation Costs, Expected Weighted-Average period 8 years 9 months 18 days  
Compensation costs recognized $ 3,300,000  
Stock Incentive Compensation Plans [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Options available for grant 44,668,000  
Options outstanding 6,328,000  
Options exercisable 6,011,334  
Stock Incentive Compensation Plans [Member] | Maximum [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Common stock, shares authorized 52,000,000  
Non Qualified Directors Plan [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Options available for grant 801,668  
Options outstanding 100,000  
Options exercisable 80,000  
Non qualified stock options to our non employee directors 1,000,000  
Options granted annually 15,000  
Non Qualified Directors Plan [Member] | Initial [Member]
   
Equity instruments (Additional Textual) [Abstract]    
Initial options granted 25,000  

XML 20 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Equity Instruments (Details 1) (Stock Options [Member], USD $)
3 Months Ended 10 Months Ended 12 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Dec. 31, 2012
Dec. 31, 2011
Stock Options [Member]
       
Schedule of option activity        
Share-based compensation arrangement by share-based payment award, options, outstanding, beginning balance 6,618,000 8,795,400    
Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price, beginning balance $ 0.32 $ 0.33    
Weighted-average remaining contractual term outstanding beginning balance 8 years 1 month 24 days 7 years 5 months 27 days 8 years 3 months 15 days 7 years 8 months 27 days
Forfeited or expired (190,000) (40,000)    
Weighted-average exercise price forfeited or expired $ 0.79 $ 0.38    
Share-based compensation arrangement by share-based payment award, options, outstanding, ending balance 6,428,000 8,755,400 6,618,000 8,795,400
Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price, ending balance $ 0.31 $ 0.33 $ 0.32 $ 0.33
Weighted-average remaining contractual term outstanding ending balance 8 years 1 month 24 days 7 years 5 months 27 days 8 years 3 months 15 days 7 years 8 months 27 days
Share Exercisable, ending balance 6,091,334 8,004,400    
Weighted-average exercise price exercisable ending $ 0.31 $ 0.33    
Weighted-average remaining contractual term exercisable ending balance 8 years 1 month 10 days 7 years 4 months 24 days    
Aggregate Intrinsic Value Outstanding          
Aggregate Intrinsic Value Exercisable         
XML 21 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes (Details Textual) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Income Taxes (Textual) [Abstract]    
Limited net operating loss $ 29,200,000  
Effective income tax rate 0.20% 3.60%
Federal net operating loss carryforwards 34,400,000  
Operating loss used to offset against taxable income Annually prior to the January 2009 ownership change 361,000  
Operating loss used to offset against taxable income between the earlier change and the August 2011 ownership change 274,000  
Percentage of net operating loss subject to expiration or unavailable for offset against taxable income 59.30%  
Uncertain tax positions $ 0  
Tax Year Under Examination Tax years 2009 and thereafter federally, earlier for certain states  
Open Tax Year 2008  
XML 22 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Per Share Data (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Numerator:    
Net (loss) income attributable to common stockholders $ (1,407) $ 80
Denominator:    
Weighted average common shares - basic 59,745 59,252
Effect of dilutive securities:    
Weighted average common shares - diluted 59,745 62,552
Earnings per share:    
Basic $ (0.02) $ 0.00
Diluted $ (0.02) $ 0.00
Series C convertible preferred stock [Member]
   
Effect of dilutive securities:    
Series C convertible preferred stock    3,300
Stock Option [Member]
   
Effect of dilutive securities:    
Stock options      
Warrants [Member]
   
Effect of dilutive securities:    
Warrants      
XML 23 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accounts Receivable
3 Months Ended
Mar. 31, 2013
Accounts Receivable [Abstract]  
ACCOUNTS RECEIVABLE

NOTE 2 – ACCOUNTS RECEIVABLE

Our trade accounts receivable at March 31, 2013 and December 31, 2012 consists primarily of receivables related to our major contract in Puerto Rico that expired December 31, 2012. During the three months ended March 31, 2013, we collected approximately $2.3 million from our Puerto Rico client. The receivable balance was further reduced by approximately $1.0 million of claims paid on our behalf by the Puerto Rico client.

Pursuant to an Assignment agreement executed April 10, 2013 and effective March 15, 2013, $1 million of the accounts receivable balance of approximately $1.3 million as of March 31, 2013 is assigned to two creditors as partial payment of their loans. See Note 3 “Notes Payable.”

XML 24 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
Subsequent Events (Details Textual) (USD $)
1 Months Ended 3 Months Ended
Mar. 31, 2013
Apr. 11, 2013
Subsequent Event [Member]
May 08, 2013
Subsequent Event [Member]
Mar. 31, 2013
Revolving Convertible Promissory Note [Member]
Subsequent Event [Member]
Mar. 31, 2013
Revolving Credit Facility [Member]
Subsequent Event [Member]
May 03, 2013
Revolving Credit Facility [Member]
Subsequent Event [Member]
Subsequent Events (Textual) [Abstract]            
Maximum borrowing capacity under Senior Secured Revolving Credit Facility           $ 5,000,000
Initial draw on credit facility           884,000
Initial draw on credit facility gross           $ 1,000,000
Senior Secured Revolving Credit Facility annual interest rate         12.00%  
Senior secured revolving credit facility maturity date         Nov. 03, 2013  
Extension period of maturity date         6 months  
Revolving Convertible Promissory Note, conversion price description       At any time while the Note remains outstanding, subject to certain limitations, the lender may convert all or any portion of the outstanding principal, accrued but unpaid interest and other sums payable under the Note into shares of our common stock at a price equal to (i) the amount to be converted, divided by (ii) 85% of the lowest daily volume weighted average price of our common stock during the five business days immediately prior to the conversion date.    
Percentage applied to common stock weighted average price for calculation of conversion price       85.00%    
Number of business days considered for determination of weighted average stock price before conversion date       5 days    
Number of shares issued as consideration for investment banking and advisory services     1,470,588      
Warrants issued to purchase common stock, in lieu of cash compensation for services 25,000 2,000,000        
Warrants exercise price per share 0.15 0.20        
Warrant expiration year   2016-04        
XML 25 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2013
Dec. 31, 2012
Current assets:    
Cash $ 1,763 $ 920
Accounts receivable 1,336 4,546
Other 261 181
Total current assets 3,360 5,647
Property and equipment, net 132 172
Other 256 305
Total assets 3,748 6,124
Notes payable:    
Related parties 2,000 2,000
Other 972 2,239
Current portion of long-term debt:    
Related parties 1,000 1,000
Other 3,174 2,067
Accounts payable 1,197 1,110
Accrued claims payable 11,844 13,099
Other accrued expenses 6,187 5,820
Total current liabilities 26,374 27,335
Long-term liabilities:    
Long-term debt, net of current portion 1,478 1,732
Total liabilities 27,852 29,067
Preferred stock, $50.00 par value, noncumulative:    
Common stock, $0.01 par value; authorized shares: 500,000,000 and 200,000,000 respectively; issued and outstanding 59,776,836 598 594
Additional paid-in capital 26,224 25,982
Deficit (51,448) (50,041)
Total stockholders' equity deficiency (24,104) (22,943)
Total liabilities and deficiency 3,748 6,124
Preferred stock, series C convertible
   
Preferred stock, $50.00 par value, noncumulative:    
Preferred stock 522 522
Preferred stock, series D convertible
   
Preferred stock, $50.00 par value, noncumulative:    
Preferred stock      
Preferred stock, other series
   
Preferred stock, $50.00 par value, noncumulative:    
Preferred stock      
XML 26 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Cash flows from operating activities:    
Net cash provided by operating activities $ 1,299 $ 378
Cash flows from investing activities:    
Additions to property and equipment   (1)
Net cash used in investing activities   (1)
Cash flows from financing activities:    
Proceeds from borrowings   100
Debt issuance costs   (8)
Repayment of debt (456) (128)
Net cash used in financing activities (456) (36)
Net increase in cash 843 341
Cash at beginning of period 920 832
Cash at end of period 1,763 1,173
Cash paid for:    
Interest 147 158
Non-cash investing and financing activities:    
Common stock and warrants issued for outside services $ 135  
XML 27 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Notes Payable (Details Textual) (USD $)
3 Months Ended 1 Months Ended 3 Months Ended 3 Months Ended 1 Months Ended 1 Months Ended
Mar. 31, 2013
Mar. 15, 2013
Feb. 28, 2013
Mar. 31, 2013
Maximum [Member]
Mar. 31, 2013
10% Promissory Note [Member]
Mar. 31, 2013
7% Promissory Note [Member]
May 13, 2013
14% Senior Promissory Note [Member]
Mar. 31, 2013
14% Senior Promissory Note [Member]
Mar. 15, 2013
14% Senior Promissory Note [Member]
Mar. 31, 2013
Convertible Promissory Note [Member]
May 08, 2013
Convertible Promissory Note [Member]
Mar. 15, 2013
Convertible Promissory Note [Member]
Mar. 15, 2013
Loans Payable [Member]
Mar. 15, 2013
Convertible Promissory Notes Payable [Member]
Mar. 15, 2013
Convertible Promissory Notes Payable [Member]
Maximum [Member]
Jan. 31, 2013
14% Promissory Note [Member]
Feb. 28, 2013
Zero Coupon Promissory Note [Member]
Notes Payable (Textual) [Abstract]                                  
Amount of promissory notes renewed                               $ 100,000  
Maturity date             Apr. 15, 2013     May 14, 2013       Feb. 28, 2013      
Notes Payable Extended Maturity Period                               Apr. 30, 2013  
Notes Payable Current Maturity Period May 08, 2013           Apr. 15, 2014 Apr. 15, 2013   Jul. 15, 2013       Jan. 31, 2014   Jul. 31, 2013 May 31, 2012
Amount of promissory notes renewed                                 230,000
Zero Coupon Promissory Note     230,000                            
Interest Rate on Promissory Note         10.00% 7.00%     14.00%             14.00%  
Promissory Notes face amount         100,000 50,000               1,400,000      
Notes payable renewal period         1 year 1 year                      
Promissory Notes Amount secured against Receivables                       625,000 75,000   300,000    
Senior, Convertible, and Other notes payable amount of default 1,000,000               1,800,000   625,000     1,400,000      
Promissory Notes Conversion Price Revised                   $ 0.125       $ 0.125      
Promissory Notes Conversion Price prior renewal                   $ 0.25       $ 0.25      
Warrants exercise price per share 0.15     0.25           0.22       0.22      
Exercise price of warrant prior renewal   0.44               0.44              
Senior promissory notes payable             1,300,000                    
Notes Payable (Additional Textual) [Abstract]                                  
Warrants vesting period 3 years                                
Warrants issued to purchase common stock shares 25,000                                
Recognized gain troubled debt restructuring $ 0                                
XML 28 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Contingencies (Details Textual) (USD $)
1 Months Ended 3 Months Ended
Sep. 30, 2010
Mar. 31, 2013
Person
Contingencies (Textual) [Abstract]    
Concentration, major customer contract period   3 years
Contingencies (Additional Textual) [Abstract]    
Working capital deficiency   $ 23,000,000
Stockholders equity deficiency   24,100,000
Debt past due   2,900,000
Members of health plan   37,000
Percent of revenue accounted by contract   43.50%
Revenue accounted by contract   529,000
Unpaid claims   1,700,000
Prior written notice to terminate contract   90 days
Damages Awarded Amount to Mr. Katzman   1,300,000
Collateralized Bond Amount, Appeal 1,300,000  
Customer Agreement [Member]
   
Contingencies (Textual) [Abstract]    
Letter of credit   4,000,000
Letter of Credit [Member]
   
Contingencies (Textual) [Abstract]    
Letter of credit monthly decreasing rate   $ 666,667
Senior secured revolving credit facility maturity date   Jun. 30, 2013
XML 29 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 30 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Description of the Company's Business and Basis of Presentation
3 Months Ended
Mar. 31, 2013
Description of the Company's Business and Basis of Presentation [Abstract]  
DESCRIPTION OF THE COMPANY'S BUSINESS AND BASIS OF PRESENTATION

NOTE 1 – DESCRIPTION OF THE COMPANYS BUSINESS AND BASIS OF PRESENTATION

The accompanying unaudited interim condensed consolidated financial statements for Comprehensive Care Corporation (referred to herein as the “Company,” or “CompCare”) and its subsidiaries have been prepared in accordance with the Securities and Exchange Commission (“SEC”) rules for interim financial information and do not include all information and notes required for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Interim results for the current period are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the consolidated financial statements and the notes thereto in our most recent annual report on Form 10-K. Certain minor reclassifications of prior period amounts have been made to conform to the current period presentation.

Our consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, each with their respective subsidiaries (collectively referred to herein as “we,” “us” or “our”). We provide managed care services in the behavioral health, substance abuse, and pharmacy management fields for commercial, Medicare, Medicaid and Children’s Health Insurance Program (“CHIP”) health plans, as well as self-insured companies, unions, and Taft-Hartley health and welfare funds. Our managed care operations include administrative service agreements, fee-for-service agreements, and capitation contracts. The customer base for our services includes both private and governmental entities. Our services are provided by unrelated vendors on a subcontract basis.

Under our at-risk contracts, we assume the financial risk for the costs of member behavioral healthcare services in exchange for a fixed, per member per month fee. Under our administrative services only (“ASO”) contracts, we may manage behavioral healthcare programs or perform various managed care functions, such as clinical care management, provider network development and claims processing without assuming financial risk for member behavioral healthcare costs. Under our pharmacy contracts, we manage behavioral pharmaceutical services for the members of health plans on an at-risk or ASO basis. In general, our contracts with our other customers have one or two year initial terms, with automatic annual extensions. Such contracts generally provide for cancellation by either party upon 60 to 90 days written notice or the right to request a renegotiation of terms under certain circumstances.

XML 31 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Balance Sheets (Parenthetical) (USD $)
Mar. 31, 2013
Dec. 31, 2012
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 500,000,000 200,000,000
Common stock, shares issued 59,776,836 59,776,836
Common stock, shares outstanding 59,776,836 59,776,836
Preferred stock, series C convertible
   
Preferred stock, par value $ 50.00 $ 50.00
Preferred stock, shares authorized 14,400 14,400
Preferred stock, shares issued 10,434 10,434
Preferred Stock, shares outstanding 10,434 10,434
Preferred stock, series D convertible
   
Preferred stock, par value $ 50.00 $ 50.00
Preferred stock, shares authorized 7,000 7,000
Preferred stock, shares issued 250 250
Preferred Stock, shares outstanding 250 250
Preferred stock shares vested      
Preferred stock, other series
   
Preferred stock, par value $ 50.00 $ 50.00
Preferred stock, shares authorized 974,260 974,260
Preferred stock, shares issued      
XML 32 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value of Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2013
Fair Value of Financial Instruments [Abstract]  
Schedule of estimated fair values of financial instruments

The carrying amounts and estimated fair values of these financial instruments (all are liabilities) at March 31, 2013, are as follows (in thousands):

 

                 
    Carrying     Estimated  
    Amount     Fair Value  

Promissory notes

  $ 2,880     $ 2,853  

Zero-coupon promissory notes

    230       225  

Debentures

    537       534  

Senior promissory notes

    1,771       1,770  

Long-term promissory notes

    125       121  

Less: unamortized discount

    (39     —    
   

 

 

   

 

 

 

Net liabilities

  $ 5,504     $ 5,503  
   

 

 

   

 

 

 
XML 33 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information
3 Months Ended
Mar. 31, 2013
May 16, 2013
Document and Entity Information [Abstract]    
Entity Registrant Name COMPREHENSIVE CARE CORP  
Entity Central Index Key 0000022872  
Document Type 10-Q  
Document Period End Date Mar. 31, 2013  
Amendment Flag false  
Document Fiscal Year Focus 2013  
Document Fiscal Period Focus Q1  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   61,247,424
XML 34 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
Equity Instruments (Tables)
3 Months Ended
Mar. 31, 2013
Equity Instruments [Abstract]  
Schedule of warrant activity

A summary of our warrant activity for the three months ended March 31, 2013 and 2012 follows:

 

                             

Warrants

  Shares     Weighted-
Average
Exercise
Price
    Weighted-Average
Remaining
Contractual Term
  Aggregate
Intrinsic Value
 

Outstanding at January 1, 2013

    35,957,583     $ 0.33     4.26 years        

Granted

    1,700,000     $ 0.25              

Forfeited or expired

    (325,000   $ 0.37              
   

 

 

                     

Outstanding at March 31, 2013

    37,332,583     $ 0.33     4.00 years        
   

 

 

                     

Exercisable at March 31, 2013

    37,298,583     $ 0.33     4.00 years     —    
         

Outstanding at January 1, 2012

    41,057,583     $ 0.35     4.86 years        

Granted

    25,000     $ 0.25              

Forfeited or expired

    (100,000   $ 0.53              
   

 

 

                     

Outstanding at March 31, 2012

    40,982,583     $ 0.35     4.61 years        
   

 

 

                     

Exercisable at March 31, 2012

    39,315,583     $ 0.33     4.67 years     —    
Schedule of option activity

A summary of our option activity for the three months ended March 31, 2013 and 2012 follows:

 

                             

Options

  Shares     Weighted-
Average
Exercise
Price
    Weighted-Average
Remaining
Contractual Term
  Aggregate
Intrinsic Value
 

Outstanding at January 1, 2013

    6,618,000     $ 0.32     8.29 years        

Forfeited or expired

    (190,000   $ 0.79              
   

 

 

                     

Outstanding at March 31, 2013

    6,428,000     $ 0.31     8.15 years     —    
   

 

 

                     

Exercisable at March 31, 2013

    6,091,334     $ 0.31     8.11 years     —    
         

Outstanding at January 1, 2012

    8,795,400     $ 0.33     7.74 years        

Forfeited or expired

    (40,000   $ 0.38              
   

 

 

                     

Outstanding at March 31, 2012

    8,755,400     $ 0.33     7.49 years     —    
   

 

 

                     

Exercisable at March 31, 20112

    8,004,400     $ 0.33     7.40 years     —    
XML 35 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Revenues:    
Managed care revenues $ 1,217 $ 17,890
Costs and expenses:    
Costs of revenues 789 16,644
General and administrative 1,391 515
Depreciation and amortization 40 96
Total expenses 2,220 17,255
Operating (loss) income (1,003) 635
Other income (expense):    
Interest expense, including amortization of debt discount of $48 and $195 (401) (563)
Other non-operating income, net   11
(Loss) income before income taxes (1,404) 83
Income taxes 3 3
Net (loss) income (1,407) 80
Net (loss) income attributable to common stockholders $ (1,407) $ 80
Earnings per common share:    
Basic $ (0.02) $ 0.00
Diluted $ (0.02) $ 0.00
Weighted average common shares outstanding:    
Basic 59,745 59,252
Diluted 59,745 62,552
XML 36 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value of Financial Instruments
3 Months Ended
Mar. 31, 2013
Fair Value of Financial Instruments [Abstract]  
FAIR VALUE OF FINANCIAL INSTRUMENTS

NOTE 6 – FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying amounts of cash, accounts receivable and accounts payable approximate their estimated fair value due to the short-term nature of these instruments. Since our other financial liabilities are not traded in an open market, we generally use a present value technique, which is a level 3 input, as defined in generally accepted accounting principles, to measure the estimated fair value of these financial instruments, except for valuing stock options and warrants. The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk.

The carrying amounts and estimated fair values of these financial instruments (all are liabilities) at March 31, 2013, are as follows (in thousands):

 

                 
    Carrying     Estimated  
    Amount     Fair Value  

Promissory notes

  $ 2,880     $ 2,853  

Zero-coupon promissory notes

    230       225  

Debentures

    537       534  

Senior promissory notes

    1,771       1,770  

Long-term promissory notes

    125       121  

Less: unamortized discount

    (39     —    
   

 

 

   

 

 

 

Net liabilities

  $ 5,504     $ 5,503  
   

 

 

   

 

 

 

Due to the inherent nature of related party transactions, we have not attempted to estimate the fair value of liabilities payable to related parties of the Company. As such, promissory notes payable with a carrying value of $3,000,000 are excluded from the table above.

XML 37 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Contingencies
3 Months Ended
Mar. 31, 2013
Contingencies [Abstract]  
CONTINGENCIES

NOTE 5 CONTINGENCIES

Economic conditions and related risks, concentrations and uncertainties:

The United States and other parts of the world have been experiencing a severe and widespread recession accompanied by, among other things, instability in the financial markets and reduced credit availability, which are likely to continue to have far reaching effects on economic activity for an indeterminate period. The probable duration and effects and probable duration of these conditions on our ability to obtain continued support from our major stockholders and lenders, success in our marketing efforts, and ultimately, profitable operations and positive cash flows, cannot be estimated at this time.

We occasionally carry cash and equivalents on deposit with financial institutions in excess of federally-insured limits, and the risk of losses related to such concentrations may be increasing as a result of recent economic developments discussed in the foregoing paragraph. The extent of a loss to be sustained as a result of uninsured deposits in the event of a future failure of a financial institution, if any, however, is not subject to estimation at this time.

Going concern uncertainty:

At March 31, 2013, we had a working capital deficiency of approximately $23.0 million and a stockholders’ equity deficiency of approximately $24.1 million resulting from a history of operating losses. Approximately $2.9 million of debt was past due and therefore in default as of March 31, 2013. As a result of these conditions, and the aforementioned economic conditions and related risks, our ability to continue as a going concern will be dependent upon the success of management’s plans, as set forth in the following paragraph, and is subject to significant uncertainty. Except for the consideration in determining the valuation allowance for deferred tax assets from net operating loss carryforwards (Note 8), the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty.

 

Need for Additional Financing

Our existing capital may not be sufficient to meet our cash needs. We expect that with our new Senior Secured Revolving Credit Facility (see Note 10 “Subsequent Event”), existing customer contracts, the addition of new pharmacy management contracts that we are close to obtaining through our marketing efforts, the collection of receivables, and the extension of vendor payments, that we will be able to sustain current operations over the near term. However, we continue to look at various alternative sources of financing if operations cannot support our ongoing plan. Nevertheless, there can be no assurance that we will be able to find such financing in amounts or on terms acceptable to us, if at all, or that we will be able to achieve or sustain profitable operations and positive operating cash flows in the near term. Although subject to the general economic conditions, risks and uncertainties discussed in the preceding paragraphs, management believes that our current cash position will likely be sufficient to meet our current levels of operations in the short term, our ability to achieve our business objectives and continue as a going concern for a reasonable period of time is dependent upon the success of our plans to obtain sufficient debt or equity financing, and, ultimately, to achieve profitable operations and positive cash flows from operations during 2013.

Concentration, major customer contract:

We currently provide behavioral health services on an at-risk basis to approximately 37,000 members of a health plan providing Medicare benefits. The contract accounted for 43.5%, or $529,000 of our revenue for the three months ended March 31, 2013. This contract is for a three year period effective January 1, 2012 and may be terminated by either party with 90 days written notice.

Legal matters:

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. Aside from the litigation described below, as of the date of this report, we are not currently involved in any legal proceeding that we believe would have a material adverse effect on our business, financial condition or operating results.

 

  (1)

We initiated an action against Jerry Katzman, a former director, in July 2009 alleging that Mr. Katzman fraudulently induced us to enter into an employment agreement and, alternatively, that Mr. Katzman breached that alleged employment agreement and was rightfully terminated. In September 2010, the matter proceeded to a trial by jury. The jury found that Mr. Katzman did not fraudulently induce CompCare to enter into the contract but also found that Mr. Katzman was not entitled to damages. On defendant’s motion to amend the verdict due to inconsistency, the trial court set aside the jury verdict and awarded Mr. Katzman damages of approximately $1.3 million. The Company appealed the lower court’s decision and posted a collateralized appeal bond for approximately $1.3 million. On February 14, 2013, the 11 th Circuit Court of Appeals of the State of Florida reversed the lower court’s judgment in favor of Katzman and remanded the case for a new trial on both liability and damages. The appellate court also taxed appellate costs in favor of CompCare against Katzman. The decision of the appellate court also reverses the lower court’s award of attorney’s fees previously awarded to Katzman against CompCare and the need for us to maintain an appeal bond for approximately $1.3 million.

 

  (2) We and a former health plan client are being sued for damages of approximately $1.7 million for allegedly unpaid claims for behavioral health professional services rendered in, 2007 and 2008. We filed a counterclaim for breach of a settlement agreement that we believed resolved many of the claims that are the subject of the complaint, which we therefore, now believe is without merit and are vigorously opposing.

 

  (3) We are in arbitration with a former health plan client in Missouri relating to its allegation that we breached our obligation to pay claims submitted to us for payment. The arbitration is underway but has not yet progressed significantly.

 

  (4) A group of health care providers in the state of Louisiana has filed suit against us claiming breach of contract in that we failed to pay claims submitted to us for payment. The litigation is currently in the discovery stage.

 

Management believes that it has established a provision for legal expenses that it believes is adequate for the estimated probable minimum losses, including legal defense costs, to be incurred from these matters.

Other:

In connection with our former major contract to provide mental health, substance abuse and pharmacy prescription drugs management services in Puerto Rico, we obtained a letter of credit from a bank for $4,000,000 to assure the customer of our compliance with our obligations under the agreement. The letter of credit extends past the expiration date of the contract, decreasing at the rate of $666,667 monthly until the letter’s termination on June 30, 2013. Under such agreement, the customer may draw on all or part of the letter of credit under certain defined circumstances. Collateral for the letter of credit was provided by a major stockholder of the Company. If the client draws upon the letter of credit, we may become liable to our major stockholder for the amount of collateral accessed by the bank to fulfill its obligations thereunder.

XML 38 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Long Term Debt (Details Textual) (USD $)
In Millions, except Share data, unless otherwise specified
1 Months Ended 3 Months Ended
May 13, 2013
Mar. 31, 2013
Long Term Debt (Textual) [Abstract]    
Maturity date   May 08, 2013
Warrant extended term period amount $ 5.2  
Warrant extended term period 2 years  
Common stock issuable in lieu of Interest and fees related to debt 774,391  
Percentage of interest and fees related to debt payable by issuing common stock 50.00%  
14% Senior Promissory Note [Member]
   
Long Term Debt (Textual) [Abstract]    
Extended maturity amount of senior promissory notes $ 1.3  
Maturity date Apr. 15, 2013  
Maturity date Apr. 15, 2014 Apr. 15, 2013
Warrant expiration year 2017  
XML 39 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Per Share Data (Tables)
3 Months Ended
Mar. 31, 2013
Per Share Data [Abstract]  
Schedule of basic and diluted earnings per share attributable to common stockholders

For the periods presented, the following table sets forth the computation of basic and diluted earnings per share attributable to common stockholders (amounts in thousands, except per share data):

 

                 
    March 31,  
    2013     2012  

Numerator:

               

Net (loss) income attributable to common stockholders

  $ (1,407   $ 80  

Denominator:

               

Weighted average common shares – basic

    59,745       59,252  

Effect of dilutive securities:

               

Series C convertible preferred stock

    —         3,300  

Stock options

    —         —    

Warrants

    —         —    
   

 

 

   

 

 

 

Weighted average common shares – diluted

    59,745       62,552  
   

 

 

   

 

 

 
     

Earnings per share:

               

Basic

  $ (0.02   $ 0.00  
   

 

 

   

 

 

 

Diluted

  $ (0.02   $ 0.00  
   

 

 

   

 

 

 
XML 40 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Per Share Data
3 Months Ended
Mar. 31, 2013
Per Share Data [Abstract]  
PER SHARE DATA

NOTE 9 – PER SHARE DATA

For the periods presented, the following table sets forth the computation of basic and diluted earnings per share attributable to common stockholders (amounts in thousands, except per share data):

 

                 
    March 31,  
    2013     2012  

Numerator:

               

Net (loss) income attributable to common stockholders

  $ (1,407   $ 80  

Denominator:

               

Weighted average common shares – basic

    59,745       59,252  

Effect of dilutive securities:

               

Series C convertible preferred stock

    —         3,300  

Stock options

    —         —    

Warrants

    —         —    
   

 

 

   

 

 

 

Weighted average common shares – diluted

    59,745       62,552  
   

 

 

   

 

 

 
     

Earnings per share:

               

Basic

  $ (0.02   $ 0.00  
   

 

 

   

 

 

 

Diluted

  $ (0.02   $ 0.00  
   

 

 

   

 

 

 
XML 41 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Equity Instruments
3 Months Ended
Mar. 31, 2013
Equity Instruments [Abstract]  
EQUITY INSTRUMENTS

NOTE 7 – EQUITY INSTRUMENTS

Our Series C preferred stock is currently convertible into common stock at the rate of approximately 316.28 common shares for each share of Series C preferred, adjustable for any dilutive issuances of common occurring in the future. Series C preferred shares vote with the common stockholders on an as-converted basis. The shares are nonparticipating except that dividends, when declared by our Board of Directors on the common stock, must be paid on the Series C stock on an as-converted basis before any dividends are paid on our common stock. The Series C is also cumulative with respect to dividends on common stock and junior series of preferred stock. Other significant rights and preferences of the Series C preferred include:

 

   

the right to vote as a separate class to appoint five directors of the Company, and

 

   

liquidation preferences, whereby the Series C holders have a claim against our assets senior to the claim of the holders of our common stock in the event of our liquidation, dissolution or winding-up (the value of the liquidation preference is $250 per share, or approximately $2.6 million at March 31, 2013).

 

We also have a class of convertible preferred stock, Series D, for which 7,000 shares are authorized and 250 shares were issued and outstanding as of March 31, 2013. The shares, which were granted in January 2012, do not vest until the tenth anniversary of the grant date. Such shares were issued in exchange for the cancelation of 120 previously granted warrants to purchase Series D shares. Once vested, a Series D preferred share will be convertible at any time into 100,000 shares of common stock, subject to adjustment in the event of any common stock dividend, split, combination thereof or other similar recapitalization, without additional consideration. Prior to vesting and thereafter, each Series D convertible preferred share is entitled to all voting, dividend, liquidation and other rights accorded a share of Series D convertible preferred stock. As to dividends, the Series D stock is noncumulative. If a dividend is declared on the common stock, each share of Series D stock is entitled to receive a dividend equal to 50% of the dividend declared for the common stock as if the Series D stock had been converted. Despite their nonvested status, voting rights of each share nevertheless consist of the right to cast the number of votes equal to those of 500,000 shares of common stock. Unless otherwise required by applicable law, holders of shares of Series D have the right to vote together with holders of common stock as a single class on all matters submitted to a vote of our stockholders. At March 31, 3013, approximately $3.3 million of compensation expense remained to be recognized over the next 8.8 years related to the Series D shares.

We may periodically issue shares of common stock as payment for services, interest and debt. During the three months ended March 31, 2013, we issued 325,000 shares of common stock to consultants in lieu of cash payment.

STOCK INCENTIVE COMPENSATION PLANS

WARRANTS:

We periodically issue warrants to purchase shares of our common and preferred stock for the services of employees and non-employee directors.

During the quarter ended March 31, 2013, we issued to note holders and consultants warrants to purchase an aggregate of 1.7 million shares of our common stock. The warrants were immediately exercisable at prices ranging from $0.15 to $0.25 and had terms of from two to three years. We recognized approximately $56,000 of compensation costs related to warrants during the three months ended March 31, 2013. Total unrecognized compensation costs related to warrants as of March 31, 2013 was approximately $1,000 which is expected to be recognized over a weighted-average period of nine months. The total fair value of warrants vested during the three months ended March 31, 2013 was approximately $59,000.

A summary of our warrant activity for the three months ended March 31, 2013 and 2012 follows:

 

                             

Warrants

  Shares     Weighted-
Average
Exercise
Price
    Weighted-Average
Remaining
Contractual Term
  Aggregate
Intrinsic Value
 

Outstanding at January 1, 2013

    35,957,583     $ 0.33     4.26 years        

Granted

    1,700,000     $ 0.25              

Forfeited or expired

    (325,000   $ 0.37              
   

 

 

                     

Outstanding at March 31, 2013

    37,332,583     $ 0.33     4.00 years        
   

 

 

                     

Exercisable at March 31, 2013

    37,298,583     $ 0.33     4.00 years     —    
         

Outstanding at January 1, 2012

    41,057,583     $ 0.35     4.86 years        

Granted

    25,000     $ 0.25              

Forfeited or expired

    (100,000   $ 0.53              
   

 

 

                     

Outstanding at March 31, 2012

    40,982,583     $ 0.35     4.61 years        
   

 

 

                     

Exercisable at March 31, 2012

    39,315,583     $ 0.33     4.67 years     —    

 

OPTIONS:

From time-to-time, we grant stock options as compensation for services to our employees, non-employee directors and certain consultants (“grantees”) allowing grantees to purchase our common stock pursuant to stockholder-approved stock option plans. We currently have three active incentive qualified option plans, the 1995 Incentive Plan, the 2002 Incentive Plan and the 2009 Equity Compensation Plan (collectively, the “Plans”), that provide for the granting of stock options, stock appreciation rights, limited stock appreciation rights, restricted preferred stock, and common stock grants to grantees. Grants issued under the Plans may qualify as incentive stock options (“ISOs”) under Section 422A of the Internal Revenue Code of 1986, as amended. Options for ISOs may be granted for terms of up to ten years. The vesting of options issued under the 1995 and 2002 plans generally occurs after six months for one-half of the options and after 12 months for the remaining options. For the 2009 Equity Compensation Plan, the vesting period is determined by the Compensation Committee. The exercise price for ISOs must equal or exceed the fair market value of the shares on the date of grant. The Plans also provide for the full vesting of all outstanding options under certain change of control events. The maximum number of common shares authorized for issuance of options totals 52,000,000 under the Plans. As of March 31, 2013, there were a total of 44,668,000 options available for grant and 6,328,000 options outstanding, 6,011,334 of which were exercisable, under the Plans.

In addition, under our Non-employee Directors’ Stock Option Plan, we are authorized to issue non-qualified stock options to our non-employee directors for up to 1,000,000 common shares. Each non-qualified stock option is exercisable at a price equal to the average of the closing bid and asked prices of the common stock in the over-the-counter market for the most recent preceding day there was a sale of the stock prior to the grant date. Grants of options vest in accordance with vesting schedules established by our Board of Directors’ Compensation and Stock Option Committee. Upon joining our Board of Directors, directors receive an initial grant of 25,000 options. Annually, directors are granted 15,000 options on the date of our annual meeting. As of March 31, 2013, there were 801,668 shares available for option grants and 100,000 options outstanding under the non-qualified directors’ plan, 80,000 of which were exercisable.

A summary of our option activity for the three months ended March 31, 2013 and 2012 follows:

 

                             

Options

  Shares     Weighted-
Average
Exercise
Price
    Weighted-Average
Remaining
Contractual Term
  Aggregate
Intrinsic Value
 

Outstanding at January 1, 2013

    6,618,000     $ 0.32     8.29 years        

Forfeited or expired

    (190,000   $ 0.79              
   

 

 

                     

Outstanding at March 31, 2013

    6,428,000     $ 0.31     8.15 years     —    
   

 

 

                     

Exercisable at March 31, 2013

    6,091,334     $ 0.31     8.11 years     —    
         

Outstanding at January 1, 2012

    8,795,400     $ 0.33     7.74 years        

Forfeited or expired

    (40,000   $ 0.38              
   

 

 

                     

Outstanding at March 31, 2012

    8,755,400     $ 0.33     7.49 years     —    
   

 

 

                     

Exercisable at March 31, 20112

    8,004,400     $ 0.33     7.40 years     —    

Total recognized compensation costs during the three months ended March 31, 2013 were approximately $15,000. As of March 31, 2013, there was approximately $35,000 of unrecognized compensation cost related to options expected to be recognized over a weighted-average period of 8 months. We might have recognized approximately $3,000 of tax benefits attributable to stock-based compensation expense recorded during the quarter ended March 31, 2013. However, this potential benefit was fully offset by our valuation allowance due to the aforementioned significant uncertainty of future realization. The total fair value of options vested during the three months ended March 31, 2013 was approximately $10,000.

 

XML 42 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes
3 Months Ended
Mar. 31, 2013
Income Taxes [Abstract]  
INCOME TAXES

NOTE 8 – INCOME TAXES

We are subject to the income tax jurisdictions of the U.S. and multiple state tax jurisdictions. Our provision for income taxes for the three months ended March 31, 2013 and 2012 was attributable to certain states. The effective income tax rate for the three months ended March 31, 2013 and 2012 was 0.2% and 3.6%, respectively.

At March 31, 2013, we have federal net operating loss carryforwards of approximately $34.4 million, the deductibility of $29.2 million of which is presently limited under Section 382 of the Internal Revenue Code. Approximately $361,000 of any net operating losses prior to the January 2009 ownership change (“the earlier change”) can be used to offset taxable income annually. In addition, we can offset our taxable income each year by approximately $274,000 of the net operating losses which incurred between the earlier change and the August 2011 ownership change. We estimate that 59.3% of the $29.2 million pre-change losses will expire and be unavailable to offset our future taxable income.

Management has evaluated our tax positions taken or to be taken on income tax returns that remain subject to examination (i.e., tax years 2009 and thereafter federally, earlier for certain other jurisdictions), and has concluded that there are no uncertain tax positions, as defined in generally accepted accounting principles, that require recognition or disclosure in the consolidated financial statements.

XML 43 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Subsequent Events
3 Months Ended
Mar. 31, 2013
Subsequent Events [Abstract]  
SUBSEQUENT EVENT

NOTE 10 – SUBSEQUENT EVENTS

Other than the changes in our outstanding debt instruments described in Notes 3 and 4, no events were identified that in our opinion require accounting recognition or disclosure in these financial statements, with the exception of the following:

Senior Secured Revolving Credit Facility

On May 3, 2013, we entered into a Senior Secured Revolving Credit Facility Agreement that will allow us to borrow up to $5,000,000 to fund our general working capital needs. Our initial draw on the credit facility occurred May 3, 2013 in the amount of approximately $884,000, which represents an initial draw of $1 million less transaction expenses. The credit facility is guaranteed by the current and future assets of CompCare and its subsidiaries, with the exception of our Puerto Rico subsidiary. Borrowings under the credit facility will bear interest at an annual rate of 12%, payable weekly. The credit facility will mature on November 3, 2013, at which time we may request an extension of the maturity date for an additional six month period provided that we are not in default in any respect, which may be accepted or rejected by the lender in its sole discretion.

The Agreement contains financial covenants such as, but not limited to, minimum revenues, positive earnings before interest, tax, depreciation and amortization expenses, and loan-to-value ratio. The Agreement also specifies events of default and related remedies, including acceleration and increased interest rates following an event of default. Loans under the credit facility will be evidenced by a Revolving Convertible Promissory Note. At any time while the Note remains outstanding, subject to certain limitations, the lender may convert all or any portion of the outstanding principal, accrued but unpaid interest and other sums payable under the Note into shares of our common stock at a price equal to (i) the amount to be converted, divided by (ii) 85% of the lowest daily volume weighted average price of our common stock during the five business days immediately prior to the conversion date.

As consideration for investment banking and advisory services provided to us by the lender, we paid a fee to the lender in the form of 1,470,588 shares of our common stock, issued on May 8, 2013. The shares and the Note were issued by the Company upon reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended, provided in Section 4(2) thereof.

Warrant issuance

On April 11, 2013, we issued warrants to purchase 2,000,000 shares of our common stock to a company in lieu of cash compensation for consulting and pharmacy analytical services. The warrants, which expire in April 2016, were vested in full at issuance and can be exercised at a price of $0.20 per share.

XML 44 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accounts Receivable (Details Textual) (USD $)
3 Months Ended
Mar. 31, 2013
Dec. 31, 2012
Accounts Receivable (Textual) [Abstract]    
Accounts receivable collected from Puerto Rico client $ 2,300,000  
Accounts receivable balance decrease 1,000,000  
Accounts receivable balance assigned to two creditors 1,000,000  
Accounts receivable $ 1,336,000 $ 4,546,000
XML 45 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value of Financial Instruments (Details Textual) (USD $)
Mar. 31, 2013
Fair Value of Financial Instruments (Textual) [Abstract]  
Promissory notes payable to related party at carrying value $ 3,000,000
XML 46 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations (Parenthetical) (Unaudited) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Consolidated Statements of Operations [Abstract]    
Amortization of debt discount $ 48 $ 195
XML 47 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Long Term Debt
3 Months Ended
Mar. 31, 2013
Long Term Debt [Abstract]  
LONG TERM DEBT

NOTE 4 LONG TERM DEBT

On May 13, 2013, we executed an agreement with a holder of approximately $1.3 million of our senior promissory notes to extend the maturity date of the notes from April 15, 2013 to April 15, 2014. We also agreed to extend the term of approximately 5.2 million warrants that had been issued at the time the notes were issued in April 2010 for an additional two years, such that the warrants will now expire in 2017. In conjunction with the renewal, we will issue 774,391 shares of our common stock to the lender relating to 50% of the interest and fees owed as of April 15, 2013.

XML 48 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
Equity Instruments (Details) (Common Stock [Member], Warrants [Member], USD $)
3 Months Ended 10 Months Ended 12 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Dec. 31, 2012
Dec. 31, 2011
Common Stock [Member] | Warrants [Member]
       
Schedule of warrant activity        
Warrants outstanding shares beginning balance 35,957,583 41,057,583    
Weighted average exercise price beginning balance $ 0.33 $ 0.35    
Weighted-average remaining contractual term outstanding beginning balance 4 years 4 years 7 months 10 days 4 years 3 months 4 days 4 years 10 months 10 days
Shares granted 1,700,000 25,000    
Weighted-average exercise price granted $ 0.25 $ 0.25    
Forfeited or expired shares (325,000) (100,000)    
Weighted-average exercise price forfeited or expired $ 0.37 $ 0.53    
Warrants outstanding shares ending balance 37,332,583 40,982,583 35,957,583 41,057,583
Weighted average exercise price ending balance $ 0.33 $ 0.35 $ 0.33 $ 0.35
Weighted-average remaining contractual term outstanding ending balance 4 years 4 years 7 months 10 days 4 years 3 months 4 days 4 years 10 months 10 days
Warrants exercisable shares 37,298,583 39,315,583    
Weighted average exercise, exercisable price $ 0.33 $ 0.33    
Weighted average remaining contractual term exercisable 4 years 4 years 8 months 1 day    
Aggregate intrinsic value exercisable $ 0       
XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 90 206 1 false 35 0 false 7 false false R1.htm 00 - Document - Document and Entity Information Sheet http://compcare.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0110 - Statement - Consolidated Balance Sheets Sheet http://compcare.com/role/BalanceSheets Consolidated Balance Sheets false false R3.htm 0111 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://compcare.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 0120 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://compcare.com/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) false false R5.htm 0121 - Statement - Consolidated Statements of Operations (Parenthetical) (Unaudited) Sheet http://compcare.com/role/StatementsOfOperationsParenthetical Consolidated Statements of Operations (Parenthetical) (Unaudited) false false R6.htm 0130 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://compcare.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) false false R7.htm 0201 - Disclosure - Description of the Company's Business and Basis of Presentation Sheet http://compcare.com/2011-06-30/role/DisclosureDescriptionOfCompanySBusinessAndBasisOfPresentation Description of the Company's Business and Basis of Presentation false false R8.htm 0202 - Disclosure - Accounts Receivable Sheet http://compcare.com/role/AccountsReceivable Accounts Receivable false false R9.htm 0203 - Disclosure - Notes Payable Notes http://compcare.com/2011-06-30/role/DisclosureNotesPayable Notes Payable false false R10.htm 0204 - Disclosure - Long Term Debt Sheet http://compcare.com/role/LongTermDebt Long Term Debt false false R11.htm 0205 - Disclosure - Contingencies Sheet http://compcare.com/role/Contingencies Contingencies false false R12.htm 0206 - Disclosure - Fair Value of Financial Instruments Sheet http://compcare.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments false false R13.htm 0207 - Disclosure - Equity Instruments Sheet http://compcare.com/2011-06-30/role/DisclosureEquityInstruments Equity Instruments false false R14.htm 0208 - Disclosure - Income Taxes Sheet http://compcare.com/2011-06-30/role/DisclosureIncomeTaxes Income Taxes false false R15.htm 0209 - Disclosure - Per Share Data Sheet http://compcare.com/role/PerShareData Per Share Data false false R16.htm 0210 - Disclosure - Subsequent Events Sheet http://compcare.com/role/SubsequentEvent Subsequent Events false false R17.htm 0506 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://compcare.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) false false R18.htm 0507 - Disclosure - Equity Instruments (Tables) Sheet http://compcare.com/role/EquityInstrumentsTables Equity Instruments (Tables) false false R19.htm 0509 - Disclosure - Per Share Data (Tables) Sheet http://compcare.com/role/PerShareDataTables Per Share Data (Tables) false false R20.htm 0601 - Disclosure - Description of the Company's Business and Basis of Presentation (Details Textual) Sheet http://compcare.com/role/DescriptionOfCompanysBusinessAndBasisOfPresentationDetailsTextual Description of the Company's Business and Basis of Presentation (Details Textual) false false R21.htm 0602 - Disclosure - Accounts Receivable (Details Textual) Sheet http://compcare.com/role/AccountsReceivableDetails Accounts Receivable (Details Textual) false false R22.htm 0603 - Disclosure - Notes Payable (Details Textual) Notes http://compcare.com/role/NotesPayableDetailsTextual Notes Payable (Details Textual) false false R23.htm 0604 - Disclosure - Long Term Debt (Details Textual) Sheet http://compcare.com/role/LongTermDebtDetailsTextual Long Term Debt (Details Textual) false false R24.htm 0605 - Disclosure - Contingencies (Details Textual) Sheet http://compcare.com/role/ContingenciesDetailsTextual Contingencies (Details Textual) false false R25.htm 0606 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://compcare.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) false false R26.htm 06061 - Disclosure - Fair Value of Financial Instruments (Details Textual) Sheet http://compcare.com/role/FairValueOfFinancialInstrumentsDetailsTextual Fair Value of Financial Instruments (Details Textual) false false R27.htm 0607 - Disclosure - Equity Instruments (Details) Sheet http://compcare.com/role/EquityInstruments Equity Instruments (Details) false false R28.htm 06071 - Disclosure - Equity Instruments (Details 1) Sheet http://compcare.com/role/EquityInstrumentsDetails1 Equity Instruments (Details 1) false false R29.htm 06072 - Disclosure - Equity Instruments (Details Textual) Sheet http://compcare.com/role/EquityInstrumentsDetailsTextual Equity Instruments (Details Textual) false false R30.htm 0608 - Disclosure - Income Taxes (Details Textual) Sheet http://compcare.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) false false R31.htm 0609 - Disclosure - Per Share Data (Details) Sheet http://compcare.com/role/PerShareDataDetails Per Share Data (Details) false false R32.htm 0610 - Disclosure - Subsequent Events (Details Textual) Sheet http://compcare.com/role/SubsequentEventsDetailsTextual Subsequent Events (Details Textual) false false All Reports Book All Reports Element us-gaap_DebtDefaultLongtermDebtAmount had a mix of decimals attribute values: -6 -5 0. Element us-gaap_DebtInstrumentFaceAmount had a mix of decimals attribute values: -5 0. 'Monetary' elements on report '0602 - Disclosure - Accounts Receivable (Details Textual)' had a mix of different decimal attribute values. 'Monetary' elements on report '0605 - Disclosure - Contingencies (Details Textual)' had a mix of different decimal attribute values. 'Monetary' elements on report '0608 - Disclosure - Income Taxes (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 0110 - Statement - Consolidated Balance Sheets Process Flow-Through: 0111 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 0120 - Statement - Consolidated Statements of Operations (Unaudited) Process Flow-Through: 0121 - Statement - Consolidated Statements of Operations (Parenthetical) (Unaudited) Process Flow-Through: 0130 - Statement - Consolidated Statements of Cash Flows (Unaudited) chcr-20130331.xml chcr-20130331.xsd chcr-20130331_cal.xml chcr-20130331_def.xml chcr-20130331_lab.xml chcr-20130331_pre.xml true true XML 50 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Description of the Company's Business and Basis of Presentation (Details Textual)
3 Months Ended
Mar. 31, 2013
Maximum [Member]
 
Description of Company's Business and Basis of Presentation (Textual) [Abstract]  
Health care contracts initial term 2 years
Health care contracts cancellation written notice period 90 days
Minimum [Member]
 
Description of Company's Business and Basis of Presentation (Textual) [Abstract]  
Health care contracts initial term 1 year
Health care contracts cancellation written notice period 60 days